INSTITUTO
UNIVERSITÁRIO
DE LISBOA

Solving Regulatory Challenges in China's Pharmaceutical Industry: Strategies for Multinational Corporations

TIAN Qing

Doctor of Management

Supervisor:
PhD Leandro F. Pereira, Professor,
ISCTE University Institute of Lisbon

June, 2025

BUSINESS
SCHOOL

Marketing, Operations and General Management Department

Solving Regulatory Challenges in China's Pharmaceutical Industry: Strategies for Multinational Corporations

TIAN Qing

Doctor of Management

Supervisors:
Leandro F. Pereira, Professor,
ISCTE University Institute of Lisbon

June, 2025

BUSINESS SCHOOL

Marketing, Operations and General Management Department

Solving Regulatory Challenges in China's Pharmaceutical Industry: Strategies for Multinational Corporations

TIAN Qing

Doctor of Management

Jury:

PhD Pedro Miguel Fontes Falcão, Associate Professor with Habilitation,
Iscte - Instituto Universitário de Lisboa
PhD Alexandra Azevedo Fernandes ONeill, Invited Assistant Professor,
Atlântica - Instituto Universitário
PhD Vânia Isabel Sousa Patrício, Invited Assistant Professor,
Iscte – Instituto Universitário de Lisboa
PhD LIU Shuwen, Professor,
SMU - Southern Medical University (China)
PhD Leandro Luís Ferreira Pereira, Full Professor,
Iscte – Instituto Universitário de Lisboa

June, 2025

INSTITUTO UNIVERSITÁRIO DE LISBOA

Solving Regulatory Challenges in China's Pharmaceutical Industry: Strategies for Multinational Corporations

TIAN Qing

[This page is deliberately left blank.]

Abstract

Between 2010 and 2020, China implemented sweeping changes in its pharmaceutical regulatory environment, leading to both opportunities and challenges for multinational corporations (MNCs). This study investigates how MNCs operating in China's pharmaceutical sector responded strategically to these evolving regulatory, institutional, and cultural demands. Using a systematic literature review guided by PRISMA standards, a quantitative research design, and expert insights obtained through the Delphi method and case study illustrations, this research examines how key strategies, such as corporate social responsibility (CSR), localization, innovation, regulatory alignment, and cultural adaptation, impact corporate competitiveness.

Findings suggest that while CSR and cultural adaptation yielded mixed results depending on the firm's internal capacities and stakeholder relationships, strategies centered on localization, flexible regulatory navigation, and innovation were consistently linked with higher competitiveness. Companies like AstraZeneca, Pfizer, and Roche succeeded by engaging in local co-development initiatives, public health collaborations, and proactive partnerships with regulatory authorities. These firms demonstrated that embedding operations within the local ecosystem was critical to overcoming institutional barriers.

This thesis contributes to strategic management literature by presenting an evidence-based model tailored to emerging, regulation-intensive markets. The model highlights the value of adaptability, strategic alignment with local institutions, and innovation-driven approaches in achieving long-term market success.

This research offers practical insights for MNCs entering or expanding within China's pharmaceutical industry and adds to the broader academic conversation on strategic behavior in emerging markets.

Keywords: Multinational corporations; Pharmaceutical industry; Regulatory environment; Localization strategy; Corporate social responsibility; Innovation

JEL: I18; L65

[This page is deliberately left blank.]

Resumo

Entre 2010 e 2020, a China implementou profundas reformas no seu ambiente regulatório farmacêutico, criando simultaneamente oportunidades e desafios para as empresas multinacionais (EMNs). Este estudo investiga de que forma as EMNs que operam no setor farmacêutico chinês responderam estrategicamente a estas exigências regulatórias, institucionais e culturais em constante evolução. Com base numa revisão sistemática da literatura orientada pelos padrões PRISMA, num desenho de investigação quantitativo e em contributos de especialistas obtidos através do método Delphi, bem como em ilustrações de estudos de caso, a pesquisa analisa o impacto de estratégias-chave — tais como a responsabilidade social corporativa (RSC), a localização, a inovação, o alinhamento regulatório e a adaptação cultural — na competitividade empresarial.

Os resultados indicam que, embora a RSC e a adaptação cultural apresentem efeitos heterogéneos, dependendo das capacidades internas das empresas e das suas relações com os stakeholders, as estratégias centradas na localização, na navegação regulatória flexível e na inovação estão consistentemente associadas a níveis mais elevados de competitividade. Empresas como a AstraZeneca, a Pfizer e a Roche alcançaram sucesso através do envolvimento em iniciativas de codesenvolvimento local, colaborações em saúde pública e parcerias proativas com as autoridades reguladoras. Estes casos demonstram que a integração das operações no ecossistema local é fundamental para a superação de barreiras institucionais.

Esta tese contribui para a literatura de gestão estratégica ao apresentar um modelo baseado em evidências, especificamente concebido para mercados emergentes e intensivos em regulamentação. O modelo destaca a importância da adaptabilidade, do alinhamento estratégico com as instituições locais e de abordagens orientadas para a inovação na obtenção de sucesso sustentável a longo prazo.

Adicionalmente, esta investigação oferece contributos práticos para EMNs que pretendem entrar ou expandir-se na indústria farmacêutica chinesa, enriquecendo simultaneamente o debate académico mais amplo sobre o comportamento estratégico em mercados emergentes.

Palavras-chave: Empresas multinacionais; Indústria farmacêutica; Ambiente regulatório; Estratégia de localização; Responsabilidade social corporativa; Inovação

JEL: I18; L65

[This page is deliberately left blank.]

摘 要

2010年至2020年间，中国医药监管环境经历了深刻变革，为跨国公司（MNCs）带来了机遇的同时，也提出了严峻挑战。本文旨在探讨在不断演进的监管、制度与文化要求背景下，跨国医药企业在中国市场所采取的战略应对方式。研究采用基于 PRISMA 标准的系统性文献回顾方法，结合定量研究设计，并通过德尔菲法专家咨询及案例分析，系统考察企业社会责任（CSR）、本地化、创新、监管协同与文化适应等关键战略因素对企业竞争力的影响。

研究结果表明，企业社会责任与文化适应策略的效果因企业内部能力及其与利益相关方关系的差异而呈现出一定的不确定性；相比之下，以本地化、灵活应对监管环境以及创新为核心的战略，与企业竞争力的提升始终保持显著正向关联。阿斯利康、辉瑞和罗氏等企业通过推进本地联合研发项目、参与公共卫生合作并与监管机构建立积极互动关系，成功嵌入本土制度与产业生态体系，从而有效克服了制度性障碍。

本文通过提出一个基于实证证据的分析模型，为新兴且高度监管市场中的战略管理研究作出理论贡献。研究强调，提升组织适应性、实现与本地制度的战略协同，以及采取以创新为导向的发展路径，是跨国医药企业实现长期市场成功的关键。

此外，本研究亦为有意进入或进一步拓展中国医药市场的跨国企业提供了实践启示，并丰富了关于新兴市场中企业战略行为的学术讨论。

关键词：跨国公司；医药行业；监管环境；本地化战略；企业社会责任；创新

JEL: I18; L65

[This page is deliberately left blank.]

Acknowledgements

I would like to express my sincere gratitude to Professor Leandro Pereira for his meticulous guidance and generous support throughout the process of writing this thesis. His rigorous academic approach and profound expertise not only helped me navigate the complexities of the research but also provided invaluable insights that have greatly enriched my academic journey.

My heartfelt thanks also go to the faculty members and fellow students of the project at Southern Medical University. Their unwavering assistance and thoughtful collaboration enabled me to overcome numerous challenges and ensured the smooth completion of this research.

I am especially grateful to the Portuguese faculty members involved in the project for their dedicated instruction and patient explanations. Their professional knowledge and outstanding teaching have deepened my understanding of the research field and broadened my perspective on the development of Sino-Portuguese collaborative initiatives.

Finally, I wish to thank all those who have supported and encouraged me throughout this academic endeavor. Your kindness and motivation have been a constant source of strength and inspiration.

[This page is deliberately left blank.]

致 谢

在本论文的撰写过程中，我谨向Leandro Pereira教授致以最诚挚的谢意。教授在整个研究期间给予了我悉心的指导与无私的帮助，其严谨的学术态度与深厚的专业素养，不仅为我在研究过程中提供了清晰的方向，也极大地拓展了我的学术视野，令我受益匪浅。

同时，我衷心感谢南方医科大学项目的各位教师与同学。在研究的各个阶段，您们始终给予我宝贵的支持与协助，帮助我克服了诸多挑战，使本研究工作得以顺利推进并圆满完成。

我亦特别感谢项目中葡方教师在教学与研究方面所给予的悉心指导与耐心解答。您们的专业知识与卓越教学不仅加深了我对相关研究领域的理解，也使我对中葡合作项目的发展有了更加全面和深入的认识。

最后，谨向所有在本次学术旅程中给予我帮助与鼓励的朋友、同仁与家人表示衷心的感谢。正是因为有您们的支持与信任，我才能不断前行，坚定不移地迈向学术探索的道路。

[This page is deliberately left blank.]

Contents

Chapter 1: Introduction 1
1.1 Background and significance 1
1.1.1 Industry and policy background 1
1.1.2 Theoretical background 2
1.2 Research problem 2
1.3 Research questions and objectives 4
1.3.1 Research issues 4
1.3.2 Research objectives 4
1.4 Research significance 5
1.5 Research on innovation and limitations 6
1.5.1 Research innovation 6
1.5.2 Limitations of the study 7
1.6 Research framework 7
1.7 Theoretical basis 8
1.7.1 Theory of internalization 8
1.7.2 Theory of competitive advantage 9
1.7.3 Resource-based theory 11
1.7.4 Institutional distance theory 12
Chapter 2: Literature Review 15
2.1 PRISMA literature review 15
2.1.1 Rationales 16
2.1.2 Objectives 16
2.1.3 Information source 17
2.1.4 Searching strategies 17
2.1.5 Systematical literature review mind tree 20
2.1.6 Selection process 22
2.1.7 Data collection 23
2.1.8 Frequency of citations 24
2.2 The factors influencing the competitive strategy of multinational enterprises 33
2.2.1 The influence factors of scientific research and innovation on the competitive

strategy of multinational enterprises 33
2.2.2 The influence factors of regulatory system on the competitive strategy of multinational enterprises 34
2.2.3 The influence factors of partnership on the competitive strategy of multinational enterprises..... 36
2.2.4 The influence factors of CSR on the competitive strategy of multinational enterprises..... 38
2.2.5 The influence factors of global integration and localization balance on the competitive strategy of multinational enterprises 39
2.3 Application of empirical research methods in the study of factors affecting the competitive strategy of multinational enterprises 41
2.3.1 The application of model testing in the research on the influencing factors of multinational enterprises' competitive strategy..... 41
2.3.2 Application of correlation analysis in the study of influencing factors of competitive strategy of multinational enterprises 43
2.3.3 Application of regression analysis in the study of the influential factors of multinational enterprises' competitive strategy..... 45
2.4 Literature review summary 47
2.4.1 Existing research and references 47
2.4.2 Future prospects of research on different topics 57
2.4.3 Literature review and research direction of this paper..... 63
2.5 Gaps in longitudinal and cross-industry strategy research..... 64
2.5.1 Corporate social responsibility and sustainability..... 66
2.5.2 Institutional theory and regulatory environments 67
2.5.3 Localization strategies and subsidiary roles..... 67
2.5.4 Innovation, R&D internationalization, and strategy 67
Chapter 3: Research Hypotheses,Variables and Model Design 69
3.1 Description of research objectives 69
3.1.1 Impact of R&D input on organizational performance..... 70
3.1.2 The impact of organizational process optimization on efficiency and customer satisfaction..... 71
3.1.3 Contribution of technology adoption to organizational competitiveness..... 72
3.1.4 The influence of Cultural adaptation on organizational globalization strategy 73
3.1.5 Impact of CSR practices on brand image..... 73
3.1.6 The role of management difference handling in cultivating organizational

harmony and decision-making efficiency 74
3.2 Description of variables 75
3.2.1 Description of independent variables 76
3.2.2 Description of the dependent variable 77
3.2.3 Description of control variables 79
3.2.4 Variable Operationalization 80
3.3 Model construction 82
3.4 Integration of prototype presentation with research objectives 83
3.4.1 Description of prototype research tool 83
3.4.2 Correspondence between research tools and research objectives 84
3.4.3 Correspondence between research objectives and questionnaire design 85
3.4.4 Aligning interview questionnaire design with research objectives 86
3.5 Methodological integration: theoretical rationale for mixed methods 91
3.6 Scope and limitations of empirical analysis 93
Chapter 4: Empirical Analysis of the Model 97
4.1 Multivariate analysis 97
4.2 Methods of statistical analysis 99
4.2.1 Step 1: Overview of statistical methods 99
4.2.2 Step 2: Descriptive statistical analysis 100
4.2.3 Step 3: Hypothesis testing 104
4.2.4 Step 4: Multivariate analysis 106
4.2.5 Interpretation of results and model validation 107
4.3 Analysis of empirical results 109
4.3.1 When R&D investment of multinational pharmaceutical enterprises continues to increase, corporate performance will also improve 109
4.3.2 When the organizational process of multinational pharmaceutical enterprises is continuously optimized, the efficiency and customer satisfaction will also increase 110
4.3.3 When the technology adoption of multinational pharmaceutical enterprises continues to improve, the organizational competitiveness will also be improved ... 111
4.3.4 Cultural adaptation plays a key role in the implementation of global strategies by multinational pharmaceutical companies. 111
4.3.5 Multinational pharmaceutical enterprises actively practice corporate social responsibility, and their brand image is also upgraded 112
4.3.6 The management differences of multinational pharmaceutical companies have a

positive effect on organizational harmony and decision-making efficiency 113
4.4 Delphi technique for framework validation 114
4.4.1 Introduction to Delphi technique 114
4.4.2 Justification for using Delphi technique 114
4.4.3 Steps for implementing the Delphi technique 114
4.4.4 Integration with empirical model 115
4.4.5 Discussion and findings 116
4.4.6 Synthesis of analyses and recommendations 116
4.5 Case-based insights on strategy implementation in MNCs 118
4.6 Longitudinal trends in strategic adaptation (2010–2020) 119
Chapter 5: Discussion and Findings 121
5.1 R&D models and innovation capabilities 121
5.2 Management and organizational processes 122
5.3 Competitive advantage and market adaptability 122
5.4 Organizational process optimization 123
5.5 Cultural and management differences 124
5.6 Public health responsibility changes 124
5.7 Managing headquarters-subsidiary differences 125
5.8 Results of co-occurrence analysis 126
5.9 Sectoral comparison: pharmaceuticals vs. medical devices 130
Chapter 6: Conclusion 131
6.1 Enhanced Corporate Social Responsibility (CSR) programs: 131
6.2 Sustainable development practices 131
6.3 Innovative product development 131
6.4 Adaptive regulatory strategies 132
6.5 Robust local partnerships 132
6.6 Effective market entry models 132
6.7 Integration with external opportunities 132
6.7.1 Theoretical and practical contributions 133
6.7.2 Future lines of research 133
6.7.3 Limitations 134
6.7.4 Sample size 134
6.7.5 Availability and reliability of data 134
6.7.6 Lack of previous research studies on the main topic 135
Bibliography 137

Webliography 143
Other References 145
Appendix: Tables 147

[This page is deliberately left blank.]

List of Tables

Table 1.1 Chapter arrangement..... 8
Table 2.1 Database information..... 17
Table 2.2 Keywords..... 25
Table 2.3 Summary of analysis 26
Table 2.4 Citation sources 28
Table 2.5 Literature research 29
Table 2.6 The future research directions proposed by scholars in different topics 62
Table 3.1 Specific objectives of the study include 69
Table 3.2 Variables 75
Table 3.3 Hypothesis model of factors influencing the competitive strategy of multinational corporations 82
Table 3.4 Questionnaire for assessing R&D models and innovations in the Chinese pharmaceutical industry 90
Table 4.1 Descriptive statistics of sample characteristics 97
Table 4.2 Correlation analysis between the amount of R&D investment and innovation outcomes 98
Table 4.3 Results of descriptive statistical analyses..... 102
Table 4.4 Results of descriptive statistical analyses..... 102
Table 4.5 Exploratory data analysis - correlation matrix 103
Table 4.6 Normal distribution test results 103
Table 4.7 Descriptive statistical analysis - graphical representation explained 103
Table 4.8 Results of hypothesis testing 105

[This page is deliberately left blank.]

List of Figures

Figure 1.1 Porter's "Diamond System" model 10
Figure 2.1 Domestic pharma success factors research trend (2010-2020)..... 18
Figure 2.2 Winning strategies research trend in pharmaceutical enterprises (2010-2020) 19
Figure 2.3 Research trend of pharmaceutical enterprises (2010-2020)..... 20
Figure 2.4 Literature screening (inclusion and exclusion)..... 21
Figure 2.5 "Global pharmaceutical industry analysis and literature screening process flowchart" 23
Figure 2.6 Annual change line chart of research literature in the global pharmaceutical industry 24
Figure 2.7 Keyword word cloud..... 25
Figure 3.1 Research design - Conceptional framework 94
Figure 5.1 Correspondence analysis and principal component analysis results 121
Figure 5.2 Keyword relationship network diagram..... 125

[This page is deliberately left blank.]

Chapter 1: Introduction

1.1 Background and significance

The five-year period (2015-2020) represents a crucial era in the development of China's pharmaceutical innovation ecosystem. The 2008 launch of the "Major New Drug Creation" program, a significant scientific and technological project, highlighted the government's commitment to propelling China's shift from a pharmaceutical giant to a global pharmaceutical powerhouse. This galvanized a contingent of researchers and scientists to contribute to pharmaceutical innovation, yielding advancements. In addition, governmental funding attracted private investment and invigorated the wellspring of innovation.

1.1.1 Industry and policy background

The State Council's 2015 issuance of "Opinions on Reforming the Review and Approval System for Drugs and Medical Devices," along with opinions from the General Office of the Central Committee and the General Office of the State Council (General Office of State Council, 2015) offered a definitive framework for encouraging innovation in the sector. These pronouncements expressed a high-level blueprint, emphasizing a transition towards openness, adherence to international benchmarks, and the encouragement of private sector involvement. They highlighted the need for robust social governance and emphasized the paramount importance of intellectual property rights.

The reformation of drug review and approval systems, along with adjustments to medical insurance drug catalogues, demonstrates a commitment to the principles outlined in the two office documents. This has significantly strengthened the policy for stakeholders across the pharmaceutical ecosystem. Between 2015 and 2020, China's pharmaceutical innovation ecosystem began to take shape, cultivating growth in the industry and increasing integration with the global innovation chain (Y. Zhou & Sun, 2022).

Pharmaceutical product launches and operations are subject to stringent oversight by national regulatory bodies. The advancement of novel drug clinical trials in China faces significant challenges and consequently lags behind that of other countries. Regulatory authorities have made concerted efforts in recent years to cultivate the growth of domestic

enterprises and local manufacturers, but this emphasis has hampered the registration process for MNCs seeking to introduce their products to the Chinese market. Therefore, this has resulted in a significant lag time between product launches in China compared to more established markets, impacting the product development timelines of MNCs. Facing intense market competition and suffering from limitations in their pipelines for novel therapies, numerous MNCs find their growth potential and investment strategies stifled. This predicament has compelled many MNC executives to actively seek new avenues for business expansion while striving to maintain their existing competitive edge and reduce the risk of market share erosion.

1.1.2 Theoretical background

Strategies previously effective for large pharmaceutical corporations ("Big Pharma") may no longer achieve the intended outcomes in today's rapidly shifting business environment. Therefore, Big Pharma finds itself at a critical juncture, compelled to reevaluate its direction (Müller & Wenninger, 2015). A mere 18 percent of the global population consumes 88 percent of the world's pharmaceuticals, signifying that the vast majority (82 percent) has access to a limited fraction (12 percent) of pharmaceutical products (Kremer, 2002). This presents a significant market opportunity for companies capable of capitalizing on this unmet need (Tempest, 2010).

Specifically, research on Chinese business strategies and global strategies is converging. This literature shift is primarily attributed to the rise of the Chinese economy, which has transitioned from a peripheral actor to a central force in the global arena, emphasizing the concept of "Act Local, Think Global" (Peng, 2005). This convergence offers an ideal opportunity to review MNCs' corporate strategies in China's evolving regulatory and business environment.

In summary, this chapter introduces the key elements shaping the Chinese pharmaceutical industry from 2015 to 2020, focusing on regulatory reforms and their impact on MNCs. The subsequent chapters delve into a comprehensive literature review, methodological approaches, and analytical findings to provide actionable insights for navigating this complex landscape.

1.2 Research problem

The existing research and industry analysis falls short in several ways:

（1） This study only collected horizontal industry data on the factors affecting the

competitiveness of multinational pharmaceutical companies and their competitive strategies, without considering the influence of longitudinal time factors, and lacked comparative analysis with other industries. If time changes are considered, new factor combinations will appear.

（2）At the macro level, the main body of this paper is to study the competitive strategy of multinational enterprises, which not only includes the multinational corporations from abroad and Hong Kong, Macao and Taiwan, but also includes the local multinational corporations that invest directly in foreign countries or Hong Kong, Macao and Taiwan. We comprehensively analyze the influence of the transnational corporations entering our country on the competitiveness of our economy. However, there are obvious deficiencies in the analysis of the overseas competitive strategies and competitiveness of domestic transnational corporations.

（3）The empirical research on the competitive strategy and performance of multinational corporations is insufficient.

In the existing empirical studies on the analysis of the competitive strategy and performance of multinational enterprises, there is a lack of comprehensive exploration on the factors affecting the competitiveness of multinational pharmaceutical enterprises and the competitive strategy adopted.

It has to be admitted that although there are many researches on the competitive strategies and factors affecting the competitiveness of multinational pharmaceutical enterprises, they mainly focus on the institutional impact and performance evaluation, which indicates that the in-depth empirical analysis of multinational pharmaceutical enterprises needs to be further improved, and there is a certain gap between the shortcomings of empirical research in this field and the potential development of pharmaceutical enterprises.

In general, the existing researches mainly focus on the determinants of the strategic positioning and strategic choice of multinational corporations, and the research scope and depth are insufficient, which also limits the in-depth understanding of the factors affecting the competitiveness of multinational corporations and competitive strategy. Follow-up studies must overcome these limitations and solve these problems. In view of the above problems, this paper takes "Solving the regulatory challenges of China's pharmaceutical Industry: the strategy of multinational corporations" as the research topic, and focuses on the influence of factors such as external corporate resources and internal corporate capabilities on corporate competitiveness and thus on their competitive strategy on the basis of full macro and micro

case studies (Barney, 1991).

1.3 Research questions and objectives

The question studied is how multinational pharmaceutical companies respond to these changes to achieve market leadership. Analyzing the trends over the past decade can provide effective strategic insights for success in this highly competitive business environment in China, where competition with domestic and foreign pharmaceutical companies is fierce. Despite the rapid growth of the market, strict regulatory changes still pose significant challenges. This study aims to identify strategies to overcome these obstacles and address the specific challenges faced by multinationals in the pharmaceutical industry in China.

1.3.1 Research issues

(1) This study attempts to explore the competitive strategies adopted by multinational pharmaceutical companies to overcome the competitive dilemma and win through theoretical and empirical analysis.

(2) Further explore which key successful strategic choices have laid the foundation for the market leadership of multinational pharmaceutical enterprises (such as the impact of R&D investment on organizational performance, the impact of organizational process optimization on customer satisfaction, the impact of corporate social responsibility on brand image), under the guidance of the theory of competitive advantage, This study will analyze the mechanism of these competitive strategies on the success of enterprises.

(3) How to verify the relationship between strategic choice and competitive advantage of multinational pharmaceutical enterprises through empirical research? In this study, model validation, correlation analysis and regression analysis are carried out on the basis of the data obtained in the questionnaire survey, so as to empirically verify the validity of the research theory, hypothesis and model, and use the Delphi framework method to extract the best strategy choice.

1.3.2 Research objectives

The main objective of this study is to discover and understand how multinational pharmaceutical companies can better implement their strategies and gain competitive advantages in the face of Chinese market regulation.

(1) An in-depth study of the strategies adopted by multinational pharmaceutical enterprises to maintain their competitive advantages, and to verify the key factors that have a positive effect on the performance of multinational pharmaceutical enterprises.

(2) From a macro perspective and historical data analysis, this paper sorted out the strategies in 6 key areas, and revealed the relationship between the key success strategies of multinational pharmaceutical enterprises and corporate capabilities (such as the impact of R&D investment on organizational performance, the impact of organizational process optimization on customer satisfaction, and the impact of corporate social responsibility on brand image).

(3) Through empirical research verification, the theoretical model of the relationship between the internal and external factors of the environment of multinational pharmaceutical enterprises such as enterprise resources and enterprise competitiveness will be verified, correlation analysis and regression analysis will be carried out on the basis of the data obtained in the questionnaire survey, so as to empirically verify the validity of the research theories, hypotheses and models. Finally, the consensus reached by Delphi Method on the most effective strategy of multinational companies in the Chinese market will be introduced.

1.4 Research significance

This research has two important significances, which is to enlighten the development of industry competition and to guide the cultivation of core competitiveness of local enterprises.

On the one hand, it can provide reference for multinational pharmaceutical enterprises to choose competitive strategies when facing the complex and changeable market pattern in China, so that they can identify and consolidate their core competitiveness in each cycle and ecology. At present, the improper selection of competitive strategies of multinational pharmaceutical companies is the root cause of their inferior position in the market competition. By evaluating the strategies in different fields of competition and studying common problems, a systematic analysis framework can be built to provide evidence for multinational pharmaceutical companies to follow in business practice, thus helping them adapt their competitive strategies in specific situations.

On the other hand, it can output valuable references for those domestic enterprises that want to transform into multinational pharmaceutical enterprises (MNC). This paper can give certain theoretical guidance for local enterprises in thinking about how to have the competitiveness of the international market and how the management should formulate

accurate and far-sighted development strategies.

1.5 Research on innovation and limitations

1.5.1 Research innovation

The first is a comprehensive analysis of the multi-dimensional influence of the competitive advantage strategy of multinational pharmaceutical enterprises. Previous studies only focused on the impact of a single factor on a specific field, such as the impact of social responsibility (CSR) on corporate sustainability. This edition comprehensively sorts out the multi-dimensional influencing factors including research and development investment (RDI), organizational process optimization, cultural adaptation and so on, which is an extension and expansion of the research on the competitive strategy choice of multinational enterprises. It points out potential research directions for related research and taps a new perspective.

Second, in terms of theoretical construction, this paper is an expansion and supplement to the existing literature on the competitive strategy management theory of multinational enterprises. The conclusions of this study have generated new theoretical insights and made it clear that the management strategies of multinational corporations, especially in their Chinese subsidiaries, should give priority to cultural adaptation. Further research on improving R&D productivity through technological progress and innovation strategies To understand the impact of digital transformation and green development initiatives on corporate strategy, the above innovation theories have very important theoretical value in the field of transnational competitive strategy.

Third, at the level of research and development methods, previous studies based on contingency view often use the correlation method, regard strategic decision-making as a simple linear combination, and believe that there is a unique optimal resource combination in a specific situation. In fact, the competitive strategy of multinational enterprises is diversified and systematic. Traditional research has not explained the synergy between different allocation factors in the competitive strategy system of multinational enterprises well. In this study, fuzzy set qualitative comparative analysis method is used to analyze the allocation conditions of the competitive strategy of multinational pharmaceutical enterprises in traditional research on the selection of competitive strategy, which can overcome the limitations of a single research method.

1.5.2 Limitations of the study

In one of the studies, although the research process is rigorous, there are still many limitations that affect the understanding and control of the actual situation of this study. The data covered in this paper is limited by the acquisition of questionnaires, and there are shortcomings in universality.

The second limitation of questionnaire survey is that the questionnaire was designed by the researcher himself. Although the research results of others were fully referred to in the design process and evaluated and refined by the expert group, the overall effect of the research is still insufficient. Moreover, the accuracy and completeness of the answer data are affected by the different situations of the respondents.

Third, the research model and hypothesis are mainly based on existing theories, while newly proposed or conflicting theories have not been verified, which may lead to missing some influencing factors.

1.6 Research framework

This research can be divided into six parts as in Table 1.1:

1. Introduction. This section elaborates on the background, methodology, structure, and limitations of the study, in addition to defining some key concepts.

2. Literature review and theoretical basis, this part focuses on the relationship between the choice of competitive strategy in key areas and the capability side of the firm, and at the same time in-depth analysis of the theoretical research, measurement methods and development suggestions used in this research. An in-depth analysis of the theories used in this study.

3. Research hypothesis and model design, based on the second part of the literature review and theoretical combing, put forward the research analysis theory, research hypothesis and theoretical model. It includes a comprehensive model of research and development investment, organizational process optimization, technology introduction, social responsibility fulfillment, and management difference handling. In this section, the relevant experimental variables are defined and the research model is constructed.

4. Empirical analysis, based on the data obtained from the questionnaire survey, simulation test, correlation analysis, regression analysis and multiple linear analysis are carried out to test the proposed research theory.

5. The research results include the consensus reached on the results of various data analysis

and discussion in the previous chapter, and the Delphi framework is used to screen out the most effective strategies of multinational companies in China's drug market.

6. Conclusions and enlightenments, this is the last chapter of the full paper and also the summary of the full paper, first of all, a brief summary of the research process and research content, combined with the Delphi framework to summarize and reach a consensus on the conclusions of this paper, and finally explain the parts to be improved in the future.

Table 1.1 Chapter arrangement

Chapters	Subcategories
Chapter One: Introduction	Research background, pain points, problems, goals, meaning, framework
Chapter Two: Literature review and theory	The literature review and the theoretical basis of this study
Chapter Three: Research hypothesis and model design	The theory, hypothesis and theoretical model of this study
Chapter Four: empirical analysis	Empirical and micro industry data, model and theory validation
Chapter Five: Discussion and discovery	Applying the Delphi framework analysis introduces the consensus reached by experts on the most effective strategies for multinational companies in the Chinese drug market.
Chapter 6: Conclusions	Summarize the research argument

1.7 Theoretical basis

1.7.1 Theory of internalization

British scholars P. Berkeley and M. asson published the Future of Multinational Enterprises (1976) and The Theory of International Management (1985), in which they proposed the theory of internalization of market transactions for the first time. The authors abandoned the traditional discussion of OFDI theory and based on the new perspective of the formation history of enterprises. The author completed the construction of the internalization theory of multinational enterprises.

They believe that the theory of internalization should be based on three conditions: first, the market is not perfect competition, and the pursuit of profit maximization is the business goal of all manufacturers in the market; Second, the formation of the inter-firm internal market originates from the imperfect market of the intermediate market mechanism; Thirdly, if the behavior of internalizing the operation of enterprises is carried out between different countries, it is called transnational corporation.

The theory of internalization is of great importance to the study of transnational corporations, which is mainly manifested in the following aspects: First, the theory of

internalization plays a milestone role in the field of OFDI research. The internalization theory studies and explains the relevant defects of the intermediate product market. Among them, it combines the market defects with the relevant theories of natural market defects to be more comprehensive and in place. Second, the basis for the implementation of the internalization theory is that the transaction costs and internalized consumption costs of enterprises in the external market must be smaller than the benefits that enterprises can get from internalization. The study of internalization theory is divided into two perspectives, namely benefit and cost. The internalization theory can be used to analyze the transnational investment behavior of enterprises. Thirdly, dynamic analysis replaces static analysis, and the internalization theory emphasizes the internalization transfer of the firm's advantages. Fourth, the internalization theory plays a guiding role in the foreign direct investment, export trade or license arrangement of transnational corporations. However, "internalization" needs to be further studied in the analysis of factors affecting internalization.

1.7.2 Theory of competitive advantage

The theory of Competitive advantage was put forward by professor Michael Porter (2003) of Harvard Business School in 1990.

In his article Competitive Advantage of Nations, Porter (2003) argued that an enterprise can build its competitive advantage on two different levels. Low-level competitive advantage is a kind of "low-cost competitive advantage", while high-level competitive advantage is a kind of "product differentiation competitive advantage". In order to create a high-level competitive advantage, the only choice for an enterprise is to make continuous investment and innovation. In this theory, the four main factors of production factors, demand conditions, related and supporting industries, and firm strategy, firm structure and peer competition constitute the environment for investment and innovation, which is his "diamond system" model, shown in the Figure 1.1 below.




Figure 1.1 Porter's "Diamond System" model

Source: Porter (2003)

In the diamond system, the performance and role of the above four points depends on the performance of the other points, and any problem at any point will limit the potential for progress and upgrading of the entire industry.

In the theory of competitive advantage, Porter put forward a new development model of international direct investment. If a country wants to win in the global competition, there needs to be fierce domestic competition. On the one hand, such competition encourages enterprises to develop FDI overseas; On the other hand, it creates conditions for enterprises to win in the international competition. For example, China's Huawei, the reason why in the international market to seize the ground, is fundamentally because in the domestic, it and the city rival ZTE has experienced too much competition, many of the competition to some extent has already exceeded the fierce degree of the international market, so when Huawei goes out of the country, in the face of any level of competition will be able to ease. The international direct investment mentioned in the theory of competitive advantage is of innovative significance in the latest development of the theory of international direct investment in accordance with the order of "first inside and then outside" (Shi & Qi, 2024).

In the theory of competitive advantage, Porter put forward a new development model of international direct investment. If a country wants to win in the global competition, there needs to be fierce domestic competition. On the one hand, such competition encourages enterprises to develop FDI overseas; On the other hand, it creates conditions for enterprises to win in the international competition. For example, Huawei of China, the reason why it has gained ground in the international market is fundamentally because in China, it has experienced

too much competition with its rival ZTE in the same city, and many competitions have already exceeded the fierce degree in the international market to some extent, so when Huawei goes abroad, it will be able to cope with any level of competition. The international direct investment mentioned in the theory of competitive advantage is of innovative significance in the latest development of the theory of international direct investment in accordance with the order of "first inside and then outside" (Shi & Qi, 2024).

1.7.3 Resource-based theory

In recent years, the research on the source of competitive advantage has gradually shifted the focus of analysis from the outside to the inside. The publication of Wernerfelt's "Resource-based Theory of Firm" in 1984 means the birth of resource-based theory. Its basic assumption is that firms have different tangible and intangible resources, which can be transformed into unique capabilities; Resources are immobile and difficult to replicate between firms; These unique resources and capabilities are the source of enterprises' lasting competitive advantage. The basic idea of the resource-based view is to view the firm as a collection of resources, focus on the characteristics of resources and strategic elements of the market, and use this to explain the sustainable advantages of the firm and the differences between them (Wernerfelt, 1984).

The resource-based theory states that the firm is a collection of various resources. Due to various reasons, the resources owned by enterprises are different and have heterogeneity, which determines the differences in the competitiveness of enterprises. Generally speaking, the resource-based theory mainly includes the following three aspects:

1) The source of an enterprise's competitive advantage is its own special heterogeneous resources

The resource here is not a resource in the general sense, it must meet certain conditions to be the source of competitive advantage of enterprises, that is, heterogeneous resources, which is an important reason for the different profitability of enterprises, and also the reason why enterprises with superior resources can obtain economic rents. As the source of competitive advantage resources should have the following five conditions: (1) valuable; ② scarcity; ③ cannot be completely copied; ④ cannot be replaced by other resources; ⑤ acquired by the firm at a price below its value.

2) The sustainability of competitive advantage comes from the imitability of heterogeneous resources

The competitive advantage of enterprises is rooted in the special resources of enterprises,

which can bring economic rent to enterprises. Driven by economic benefits, firms that do not get economic rents will certainly imitate dominant firms, which results in the convergence of firms and the dissipation of rents. Therefore, the existence of competitive advantage and economic rent indicates that the special resources of dominant firms can surely be imitated by other firms. Resource based theory researchers have extensively discussed this issue, and they believe that there are at least three major factors that hinder firms from imitating each other: ambiguity of causality, path dependence, and cost of imitation.

3) Access to and management of special resources

The resource-based theory points out the direction for the long-term development of enterprises, that is, cultivating and acquiring special resources that can bring competitive advantages to enterprises. Because the resource-based theory is still in the process of development, the decision-making of enterprises is always faced with many uncertainties and complexities. The resource-based theory cannot provide enterprises with a set of specific operation methods for obtaining special resources, but can only provide some directional suggestions.

1.7.4 Institutional distance theory

North (1990), a representative scholar of new institutional economics, believes that institution is the rules of the game of a society, and a certain restriction specially set to regulate the mutual relations among social individuals. He also believes that institution includes two dimensions: formal institution and informal institution. Among them, formal institution involves the rules that economic participants have to abide by. It is usually represented by some written laws, regulations and rules; Informal institutions, on the other hand, are the gradual formation of behavioral norms and restrictions by social individuals in the process of natural communication, and are represented by norms, beliefs and value systems shared by people in a specific social environment. Institutional theory provides a new perspective and analytical framework for studying and examining the institutional obstacles faced by transnational enterprises. According to institutional theory, institutional factors are the basic elements that affect the behavior of enterprises (North, 1990; Scott, 2001), and gradually formed the academic school of "institutional foundation view".

Scholars supporting this theory generally believe that institutional factors are the decisive factors affecting the behavior and practice of transnational enterprises, and are the key to people's understanding and analysis of transnational enterprise behaviors (DiMaggio & Powell, 1991). The importance of institutional factors has been paid more and more attention by

theoretical scholars.

The comparison of institutional differences between countries or regions has always been an important topic in the field of international trade research. A large number of scholars have conducted in-depth discussion and research on the impact of institutional differences on the management practices of transnational enterprises from different research perspectives. A large number of previous studies have shown that the institutional differences in transnational situations not only bring opportunities to enterprises, but also become the source of many problems and the biggest challenge they face. In general, the degree of similarity or difference of institutional environment between countries or regions constitutes the basic concept of institutional distance (Abhari et al., 2016). However, different scholars have different definitions and connotation of institutional distance according to the needs of their research purposes. The following paragraphs are summarized, summarized and refined respectively.

This regulatory and industrial context has been extensively documented in prior research on multinational enterprises operating in emerging markets and highly regulated industries (General Office of State Council, 2015; Li et al., 2020; Chinese Ministry of Health, 2017; Schmitt et al., 2024).

[This page is deliberately left blank.]

Chapter 2: Literature Review

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, revised as PRISMA 2020 to incorporate recent advancements in systematic review methodology and terminology (Abhari et al., 2016), promotes transparency and completeness in reporting systematic reviews. Increasingly, authors utilize PRISMA to structure their systematic reviews, enhancing clarity and meeting journal requirements, especially in healthcare therapeutics. This systematic literature review adheres to PRISMA guidelines and checklist for comprehensive coverage of corporate strategies in the pharmaceutical industry, ensuring rigorous and transparent execution.

2.1 PRISMA literature review

The corporate strategy has experienced a lengthy development process, subjected to rigorous analysis and research across multiple functions and diverse industries. According to the resource-based view of competitive advantage, this strategy consolidates existing perspectives into a streamlined model explaining the relationship between resources and firm performance (Barney, 1991). At the heart of this model is the premise that sustained competitive advantage hinges upon the satisfaction of four fundamental conditions: resource heterogeneity in an industry, ex-post limitations to competition, imperfect resource mobility, and ex-ante constraints on competitive forces. As hypothesized (Shirom, 2003), these conditions are essential for achieving and maintaining a competitive edge. This work offers foundational insights into the crucial relationship between corporate strategy and competitive advantage, emphasizing the critical role of a resource-based approach. Further enriching this perspective, a study (Baik et al., 2021) challenged the conventional zero-sum paradigm that often frames the relationship between business and society. Instead, they propose a novel framework enabling companies to critically evaluate the societal impacts of their actions, identify opportunities for mutual benefit that strengthen their competitive edge, prioritize CSR, and ensure their effective implementation. Their work highlights the burgeoning significance of CSR as a global necessity in contemporary business management. This burgeoning emphasis on social responsibility finds resonance in the emergent integrative view of corporate sustainability. This view highlights the necessity of simultaneously integrating

economic, environmental, and social dimensions without arbitrarily prioritizing one over the others (Müller & Wenninger, 2015). The integrative view acknowledges the tensions in corporate sustainability and encourages a holistic approach that addresses these challenges in concert. In the current business environment, corporate sustainability has transcended its conceptual origins to occupy a central position in organizational strategizing. This evolution signifies a pragmatic shift towards actionability and adaptability, ensuring alignment with emerging markets and real-world business applications.

2.1.1 Rationales

The foundation of this literature review lies in the existing body of knowledge, representing the point of departure for this study. As the introduction highlighted, extant research primarily concentrates on mature markets such as the US and EU, positioning them as examples of capitalist societies. Therefore, theories are often derived from the experiences of developed countries, with limited exploration of emerging markets such as mainland China, particularly regarding the adoption of MNC subsidiaries. This literature review seeks to address this gap, synthesizing insights from previous literature, especially in high uncertainty and rapidly evolving external environments. By critically analyzing past theories and findings, this review aims to optimize the existing understanding and guide the direction of the author's research.

These institutional mechanisms have been widely examined in emerging market contexts, particularly in China (Peng, 2005; Xu et al., 2018).

Prior literature provides complementary evidence on institutional pressures shaping organizational behavior in regulated environments (DiMaggio & Powell, 1991; Almasa et al., 2020; North, 1990; Powell, 1991; Scott, 2001).

2.1.2 Objectives

The overarching objectives of this literature review are to offer a retrospective analysis of corporate strategy theory and doctrine from Y2010 to Y2020, with a specific emphasis on the pharmaceutical industry and its application by MNCs.

From a strategic perspective, firm-level resources and capabilities remain fundamental sources of sustained competitive advantage (Barney, 2000; Porter, 2003).

2.1.3 Information source

In mainland China, CNKI is the primary search engine for relevant literature (X. Wang et al., 2017; Y. Wang et al., 2024). Scopus supplemented this search, indicating potential studies published from Y2010 to Y2020. Considering the delay between real-world phenomena and the related research, publications appearing after Y2015 were prioritized.

In February 2022, a comprehensive search was undertaken across CNKI, Scopus, and Google Scholar. Details regarding the specific databases and their respective date coverage are offered in Table 2.1. This initial search was enhanced by supplementary searches conducted in April 2022, focusing on publications hosted on the websites of six relevant organizations (including governmental bodies, charitable foundations, and research institutions) (Y. Wang et al., 2024). Finally, the search was further optimized in May 2022, utilizing the same methodology but limiting the scope to publications from 2010 onward.

Table 2.1 Database information

Database	Coverage
CNKI	1993 to present
Scopus	1788 to present
Google Scholar	2004 to present

2.1.4 Searching strategies

(1) Statistical condition and key words

The China National Knowledge Infrastructure (CNKI) stands as the preeminent database for accessing literature in China. Established in June 1999, CNKI was established from a collaboration between Tsinghua University and Tsinghua Tongfang, drawing inspiration from the World Bank's 1998 vision of a global knowledge infrastructure. Representing a pioneering effort in information infrastructure development, the CNKI project seeks to facilitate the widespread dissemination, collaborative sharing, and value-added utilization of knowledge resources throughout Chinese society (Peng, 2005). This exploration of CNKI specifically evaluates the current state of research on corporate strategy in China's pharmaceutical industry (Y. Wang et al., 2024).

A search conducted on CNKI's publicly available search engine, a resource for local researchers, yielded 25 relevant research articles published between 2010 and December 2020 (Y. Wang et al., 2024). These publications, authored by both Chinese and international experts, evaluate the factors contributing to the success of major pharmaceutical companies operating in the Chinese market.

The offered chart Figure 2.1 clearly illustrates a discrepancy between local and international research on successful strategies for Big Pharma. Local analyses appear less developed than academic/expert analyses from abroad. This suggests a significant opportunity for further research into the specific strategies employed by Big Pharma in the Chinese market. To guide this research, common keywords related to enterprise strategy, contextualized in specific timeframes and the particular constraints of the Chinese pharmaceutical industry, can be utilized as search terms in English language search engines.The author's research employs a targeted keyword strategy to investigate existing literature. Utilizing terms such as "enterprise competitiveness," "winning strategy," and "pharmaceutical enterprise," the author expands their search across prominent research databases such as Scopus and Google Scholar.




Figure 2.1 Domestic pharma success factors research trend (2010-2020)

Theoretical background "Corporate strategy," a widely recognized form of institutional strategy often referred to as "enterprise strategy," constitutes a significant area of research. A study of publications in the past decade, from 2010 to 2020, indicates trends in the volume of research available through English-language search engines. Between 2010 and 2013, the number of published research articles remained relatively stable, consistently hovering in the range of 390 to 400 publications each year. However, this period of stability was followed by a significant decrease between 2014 and 2015. Then, from 2015 to 2020, the quantity of publications stabilized once more, fluctuating between 200 and 300 articles per year. While a minor peak can be observed in 2019, the overall volume of publications failed to return to the levels seen before 2014. This trend highlights the years 2014 and 2015 as a crucial

period, marking a point of inflection in research output related to corporate strategy.

A winning strategy is not merely a goal sought by corporate strategy, but rather a fundamental necessity for its success. A comprehensive review of the literature published between Y2010 to Y2020, utilizing "winning strategy" as a key search term, offers valuable insights into the academic interest surrounding this concept. Specifically, the number of publications incorporating this term as a keyword experienced a significant increase between 2015 and 2016, reaching an apex of approximately 110 to 120 publications annually during this period. However, following this peak in 2016, a consistent decline in the number of publications utilizing this key term is evident, with figures below those observed during the 2010 to 2015 period. While a slight fluctuation in publication numbers is apparent between 2019 and 2020, further data from the years following 2020 is necessary to determine whether this represents a deviation from the overarching trend or a continuation thereof.

(1)“Winning strategy” is taken as the key word




Figure 2.2 Winning strategies research trend in pharmaceutical enterprises (2010-2020)

As in Figure 2.2, analyzing the strategy retrieval analysis for "pharmaceutical enterprises" indicates evident oscillations in the pharmaceutical industry, particularly between 2016 and 2018. The nature of this analysis resulted in a large data pool, with counts reaching the thousands. Despite the volume, significant upward and downward trends are evident, resulting in a continuous upward trend from late 2018 to 2020.

(2) “Pharmaceutical enterprises” is taken as the key word




Figure 2.3 Research trend of pharmaceutical enterprises (2010-2020)

As in Figure 2.3, preliminary search engine retrieval, utilizing fundamental keywords, identified fluctuations around 2015. An annual observation of the data highlights a difference between two five-year periods: 2010 to 2015, and 2015 to 2020. While the former period maintained a consistent output of conventional research literature, both in terms of volume and scale, the latter demonstrated a significant decrease. This observation, based on simple multi-dimensional keyword retrieval, suggests a need for researchers to prioritize analyses in this specific timeframe. Determining the causal factors underpinning these prominent fluctuations is essential.

2.1.5 Systematical literature review mind tree

The author conducted a systematic literature review (SLR) employing Google Scholar, CNKI, and Scopus search engines. The screening process utilized a range of keywords including China, Pharma, Pharmaceutical, Strategy, MNC, Multinational corporations, enterprises, and success factors (Innovative Technology; Sustainable business model; Supply Chain and coordination; dynamic capability; corporate social responsibility; Effective organization structure; Business development (Acquisition and Merge); Competitive differentiation;Employee Investment/Energy). The temporal scope lasted between Y2010 to Y2020.

Following an initial scan, irrelevant or out-of-scope literature was excluded through a criteria-based screening process. This yielded a foundational data pool for the literature review. The author then systematically analyzed and categorized the literature across various

dimensions. The following mind map, illustrated below, offers a visual representation of this process. The methodology aligns with the PRISMA 2020 flow diagram for new systematic reviews, outlining the screening workflow and inclusion/exclusion criteria.

The implemented steps included: database searches, criteria-based screening, data exclusion based on specific considerations, reading and classification of materials, archival organization, re-categorization from multiple perspectives, and chart generation. First, thousands of articles were retrieved across the different keyword searches, as visualized in the chart below. Applying the criteria screening, represented by the logistical chain illustrated here, resulted in a stepwise reduction of included documents, finally yielding an optimized set of relevant articles.

To ensure a comprehensive, multi-faceted analysis of the retrieved information, the author conducted a separate quantitative analysis of the literature utilizing a selection of significant and established keywords. Building upon the aforementioned mind map, several steps were undertake in Figure 2.4.




Figure 2.4 Literature screening (inclusion and exclusion)

2.1.6 Selection process

Following a preliminary round of screening and multi-angle observation, a more in-depth analysis is undertaken, namely, a multi-perspective observation and review of the established data pool. The following are critical observations and screening perspectives considered central to this analysis, as depicted in the figure below. Firstly, the industries necessitate greater focus and delimitation. The pharmaceutical industry, as a vital constituent of China's national economy, represents a sector that merges traditional practices with modern advancements, integrating elements of primary, secondary, and tertiary industries. Its principal categories include: chemical raw materials and preparations, traditional Chinese medicine, prepared slices of traditional Chinese medicine, proprietary Chinese medicine, antibiotics, biological products, biochemical drugs, radioactive drugs, medical devices, sanitary materials, pharmaceutical machinery, pharmaceutical packaging materials, and pharmaceutical commerce. The pharmaceutical industry assumes a critically significant role in protecting and enhancing public health, elevating quality of life, facilitating family planning activities, contributing to disaster relief and epidemic prevention efforts, supporting military supplies and preparedness, and finally, cultivating economic development and social progress (Baik et al., 2021). However, in the constraints and practical considerations of this research, the pharmaceutical industry, analyzed in a narrower sense, primarily centers on the biomedical industry, a sector of interest in China from 2010 to 2020. It does not consist of medical devices, proprietary Chinese medicine, or pharmaceutical packaging materials, as conventionally defined. Specifically, nine definitions were identified, indicating ambiguity in the use of the term "biopharmaceuticals." Therefore, we hypothesize that biopharmaceuticals are more accurately defined as complex molecules, derived from biological sources, with the intended purpose of diagnosing, preventing, treating, or curing diseases or medical conditions in humans (Vroom, 1964).

The global pharmaceutical sector, long dominated by European and American multinational corporations (referred to as "Big Pharma"), is experiencing a significant shift. A consensus is reached in literature regarding the burgeoning significance of pharmaceutical markets in developing countries, particularly China and Brazil. These 'pharmerging' countries are poised to assume a critical role in the sustained growth of the pharmaceutical industry. This is driven by the increasing dissemination of technological and scientific knowledge, coupled with higher competition in the pharmaceutical sector from the advancements made by 'pharmerging' countries, especially China (Buckley & Casson, 1976). Industry experts have

recognized the need for streamlined development processes for new and innovative medicines, considering the increasing scale and complexity of contemporary pharmaceutical development programs. The execution of global studies utilizing a unified protocol across diverse regions, while not without its operational hurdles, is widely regarded in the innovative pharmaceutical industry as a highly effective approach to clinical development (DiMaggio & Powell, 1991).

This global industry transformation is further characterized by the rise of Asian companies, particularly their acquisition of advanced innovative capabilities that place them at the forefront of cutting-edge medical technology development. Simultaneously, Asian societies are suffering from unmet needs for pharmaceuticals and medical services, leading to concerted efforts to strengthen supply capacities (Buckley & Casson, 1985). These efforts consist of a range of strategies, including the increase of capabilities along the value chain, the utilization of contract service providers, geographical expansion, and product portfolio diversification (North, 1990). As illustrated in the figure below, a comprehensive review of relevant literature allowed for the identification of a focused subset of 322 publications meeting specific criteria. These criteria include: alignment with pharma industry themes (excluding medical devices or traditional Chinese medicine), a publication timeframe between Y2010 and Y2020, and a primary emphasis on corporate strategy elements rather than business or functional strategies. This curated collection of literature forms a robust data pool for the following analysis in Figure 2.5.



Figure 2.5 "Global pharmaceutical industry analysis and literature screening process flowchart"

2.1.7 Data collection

At the beginning step, it is beneficial to direct our attention to the number of publications documented in the foundational database across time periods, as visualized in the accompanying chart. This analysis indicates a significant watershed moment in the year 2015. Before 2015, while the volume of published research experienced annual fluctuations, no clearly defined trend can be established. However, the period from 2015 to 2021 is marked by a significant

increase in the number of research publications, demonstrating a year-on-year growth in research output. While a minor fluctuation in this upward trend is observed between 2019 and 2020, the overall trend in publication volume remains definitively upward. This overarching pattern exhibits fundamental consistency with the temporal divisions identified during the preliminary screening process, further highlighting its importance as a critical area for further analysis in next research step.




Figure 2.6 Annual change line chart of research literature in the global pharmaceutical industry

Following the compilation and optimization of the analytical dataset, a multi-faceted assessment of the primary database was conducted. The key findings are presented in Figure 2.6.

2.1.8 Frequency of citations

(1) Key words citation frequency review

Based on the offered list of keywords, the analysis of frequently cited publications in the element database offers further validation in Table 2.2 and Figure 2.7. The frequency of keywords such as CSR, Innovation, Sustainability, and Capability appearing at the forefront highlights their significance in enterprise strategy, thus necessitating further study. Specifically, emerging markets present unique challenges compared to their counterparts in established Western economies, particularly concerning the cultivation of innovation management capabilities in subsidiaries (Porter, 2003). Moreover, the analysis of corporate sustainability (CS) in multinational enterprises (MNEs) requires consideration of how subsidiary commitment is affected by the relationship of internal and external effects from stakeholders, institutions, and corporate headquarters (Scott, 2001).

Table 2.2 Keywords

Seq	Keywords	Counting
1	Management	84
2	Performance	54
3	Impact	32
4	Innovation	31
5	Model	28
6	Sustainability	21·
7	Industry	17
8	Systems, Corporate	15
9	Strategy, CSR	14
10	Capability, Information	



Figure 2.7 Keyword word cloud

This analysis leverages a keyword network constructed from a comprehensive data pool of relevant literature, prioritizing word frequency to identify prominent themes and research trends. This approach enables a clear identification and understanding of the keywords prominently featured in the existing body of research.

This word frequency chart immediately brings several key terms to the forefront: "Management," "Performance," "Impact," "Innovation," and "Sustainability." Rendered in a large font and clustered collectively, these terms are in the highest frequency range, indicating their relationships in the field of corporate strategy. A second tier includes terms such as "sustainability," "CSR," "system," "green," and "integration," suggesting areas of particular interest in recent corporate strategy research. As Cao and Song (2018) observes, individuals whose formal, rather than informal, interactions demonstrate an external orientation contribute significantly to a firm's innovative capacity. This aligns with the allocation of talent towards ventures and projects offering the highest economic value, a principle Chen (2019) expressed as "right people, in the right seats, doing the right thing, with the right people, at the

right time."

The successful implementation of Green Performance Map, a green lean environmental improvement tool, in manufacturing and pharma industry, highlights this point. Wu (1993) illustrated how this tool effectively engages shop floor managers and operators in green kaizen, highlighting the value of integrating the waste hierarchy model and, therefore, measuring concept of a circular economy.

A third tier, comprised of smaller terms such as "changes integration," "model design," "implementation," "chain management," and "convenience," offers further points of consideration. These terms offer valuable insight into corporate strategy and may guide enterprises toward new horizons.

To offer an overview of the content analyzed, the author has compiled the key themes into a Table 2.3 .

Table 2.3 Summary of analysis

Authors	Article Title	Cited Reference Count	Since 2013 Usage Count	Publication Year	Issue
Abhari, K., Davidson, E. J., & Xiao, B.	Measuring the Perceived Functional Affordances of Collaborative Innovation Networks in Social Product Development	27	27	2016	49th HICSS, pp. 929–9 38
Shirom, A.	Feeling vigorous at work? The construct of vigor and the study of positive affect in organizations	130	66	2003	Vol. 3(6), pp. 135–1 64
Vroom, V. H.	Work and Motivation	01	01	1964	Wiley
Cao, Y. & Song, Y. J.	Research on the influencing factors of job satisfaction and turnover intention of grassroots doctors	0	0	2018	Chinese Health Service Management, 35(1), pp. 24–26 +43
Chen, H. M.	Research on the impact of employees, perception of pay fairness	0	0	2019	Masters thesis, South China Univ. of Tech.
Wu, B. E.	Organizational Behavior	0	0	1993	Hua Tai Publishing
Clement, T.	Adopt-a-book activity	0	0	2019	OER Commons resource
Chinese Ministry of Health	China health and family planning statistical yearbook	0	0	2017	Report No. 12

Authors	Article Title	Cited Reference Count	Since 2013 Usage Count	Publication Year	Issue
Baik, Y., Kim, H., & Park, Y.	Environmental multi-dimensionality and staff localization in MNEs	0	0	2021	CJAS, 38(1), pp. 68-79
Buckley, P. J. & Casson, M.	The future of the multinational enterprise	0	0	1976	Macmillan
Buckley, P. J. & Casson, M.	The economic theory of the multinational enterprise	0	0	1985	Macmillan
DiMaggio, P. J. & Powell, W. W.	The new institutionalism in organizational analysis	0	0	1991	Univ. of Chicago Press
Müller, R. & Wenninger, G.	The changing landscape of Big Pharma: Strategic reevaluation	63	63	2015	SMJ, 36(10), pp. 1448–1467
North, D. C.	Institutions, institutional change and economic performance	0	0	1990	Cambridge Univ. Press
Peng, M.	Act local, think global: Global strategies and local realities	0	0	2005	Global Business Review, 6(2), pp. 123–1 45
Porter, M. E.	On Competition	0	0	2003	CITIC Press
Scott, W. R.	Institutions and organizations (2nd ed.)	0	0	2001	Sage
Tempest, S.	Global pharmaceutical consumption: An analysis of market disparities	0	0	2010	IJHPM, 5(1), pp. 23–34

The expansion and swift dissemination of knowledge across disciplines and domains necessitate that researchers develop methods to rapidly synthesize existing literature, address relevant research gaps, and inspire future research (Chinese Ministry of Health, 2017). Analyzing the data pool, we identified frequently cited literature in the designated keywords.

The resulting table presents the title of each publication, its source, and citation count. This analysis indicates that prominent research themes include corporate social responsibility, sustainable business practices, production standardization, corporate competitiveness, corporate integration, enterprise organization, and innovations. These themes consist of the majority of concerns related to corporate strategy in the existing classifications.

An analysis of the 15 most cited publications in the screened database indicates a recurring emphasis on corporate social responsibility. This is evident in the prominence of this theme, as seen in the articles ranked first, second, and tenth. In addition, international competitiveness represents a significant area of focus, appearing in the third, sixth, and eighth

ranked articles. This suggests that while competitiveness has been a cornerstone of traditional business strategy, it continues to retain relevance as a key research subject. Shifting our attention to other prominent themes, we find that standardization, consistently highlighted as crucial for large organizations, particularly in the pharmaceutical industry, occupies the fourth position. This emphasis on standardization is particularly relevant to production and supply chain management. In fifth position, we find risk management, long-term particularity in the pharmaceutical sector. This particularity is due to its connection to human pharmaceuticals and medical solutions, making it a long-standing subject of study. The remaining top 15 articles address other significant facets of internal management, including internal integration, specialized management functions, managerial sustainability, procurement management, and innovation management.

The remaining top positions highlight common themes in internal management, including topics such as internal integration, specialized personnel management, managerial sustainability, procurement strategies, and innovation management. In summary, analysis of these 15 highly cited publications indicates a clear emphasis on several key areas: corporate social responsibility, innovation and its management, internal personnel management, sustainability and innovation activities, and risk management in the pharmaceutical industry.

Table 2.4 Citation sources

Seq	Article Title	Source Title	Citation Count
1	*Corporate Social Responsibility Influencing Sustainability within the Fashion Industry. A Systematic Review*	Sustainability	208
2	Family Business as a Bearer of Social Sustainability in Multinationals-Case of Slovakia	Sustainability	176
3	The status and evolution trend of international competitiveness of Chinese industries: Based on the analysis of export commodities.	Chinese Industrial Economy	159
4	Standardization can be good for exploration: a social capital view of the productivity dilemma in operational teams	Production Planning and Control	142
5	Security risks in service offshoring and outsourcing	Industrial Management and Data System	134
6	*A comprehensive review ofenergy blockchain: Application scenarios and development trends*	International Journal of Energy Research	134
7	Internal integration as a pre-condition for external integration in global sourcing: A social capital perspective	International Journal of Production Economics	134
8	Report on international competitiveness of Chinese industry.	Management of the world	132
9	Internationalization Business Models and Patterns of SMEs and MNEs: A Qualitative Multi-Case Study in the Agrifood Sector	Sustainability	128

10	Sustainable or not sustainable? The role of the board of directors	Journal Of Cleaner Production	126
11	Exploring a scale of organizational barriers for enterprises' climate change adaptation strategies	Journal Of Cleaner Production	126
12	Purchasing performance management systems: an empirical investigation	Production Planning And Control	121
13	Innovation and environmentally sustainable economy: Identifying the best practices developed by multinationals in Brazil	Journal Of Cleaner Production	120
14	Multinational corporations and infectious disease: Embracing human rights management techniques	Infectious Diseases Of Poverty	119
15	Circular Economy in China:	Sustainability	118
	Translating Principles into Practice		

Conversely, the author evaluates the keyword frequency employed by the authors of the referenced literature in the literature database, as illustrated in the table below.

The Table 2.4 indicates that "management," "performance," "innovation," and "sustainability" are widely acknowledged, which is unsurprising. However, the emphasis on "framework," "impact," and "CSR" is noteworthy, as these elements have not traditionally been regarded as central to corporate strategy.

This shift merits attention in the CSR literature as in Table 2.5, which has rarely measured outcomes beyond firm performance.

Table 2.5 Literature research

Author, Year	Main Topics	Main Issues (Future Research)	Title
Y2021	The so-called "drug lag" in access to expensive, novel drugs, such as monoclonal antibodies or targeted oncology agents, shall remain substantial.	The innovation trend in the Chinese pharmaceutical industry is clear and needs further exploration. Research should focus on innovations based on the paper's position.	Asian innovation in pharmaceutical and medical device industry beyond tomorrow
Y2018	How can subnational institutions impact corporate research and development (R&D) investment in emerging economies?	It is uncertain whether the current research framework and findings can be readily extended to the cross-national level. This question needs to be addressed for measures of both parent and subsidiary-level factors that influence corporate R&D decisions.	How and When Do Subnational Institutions Matter for R&D Investment? Evidence From the Chinese Pharmaceutical Sector
Y2020	Explore the process by which foreign MNEs' low-value-adding operations in the South are transformed into high-value-adding R&D operations.	Explore the actual mechanisms of the evolutionary process, as well as the key success factors for the internationalization of R&D towards the South, using larger samples.	The internationalization of innovation towards the South: A historical case study of a global pharmaceutical corporation in China (1993–2017)
Y2018	The sustainable PSC can benefit from Industry 4.0, but	How can we improve supply chain collaboration to assist manufacturers in effectively	Pharma Industry 4.0: Literature review and research opportunities in

Author, Year	Main Topics	Main Issues (Future Research)	Title
	research in this area is limited.	controlling and managing the entire life cycle (both forward and reverse flow) of pharmaceutical products throughout the PSC? This question remains largely unexplored and is one of the most essential problems in the context of Industry 4.0.	sustainable pharmaceutical supply chains
Y2019	Investigate the antecedents and results of the strategic choices made by multinational corporation (MNC) subsidiaries in the Croatian economy.	Substantial interaction exists between the MNC subsidiary's environment and the MNC subsidiary's strategic orientation. Most notably, the environment studied here was at the competitive and consumer market level. This research should be widened to include more countries/regions.	The performance implications of knowledge management and strategic alignment of MNC subsidiaries
Y2018	Market- and knowledge-seeking subsidiaries located in China tend to positively impact the generation of new knowledge. This occurs either through locally established MNE R&D laboratories or through collaborations with local firms and scientific institutions.	Further research should examine how subsidiary roles and technology sourcing interact within emerging economies within a co-evolutionary framework. Additionally, researchers should investigate how the co-location of production and R&D relates to subsidiary roles to better understand the positioning of emerging economies in the global innovation map.	Subsidiary roles as determinants of subsidiary technology sourcing: empirical evidence from China
Y2020	Sustainable growth can be achieved by empirically providing the results of comparisons of different international strategies within the pharmaceutical industry.	Approaching sustainable growth from the perspective of R&D requires deriving the comprehensive implications of a business model for the pharmaceutical industry.	International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies
Y2021	The commitment of subsidiaries depends on different configurations of internal and external influence exerted by stakeholders, institutions, and corporate headquarters.	There is a lack of research investigating subsidiary behaviors in terms of different configurations of external and internal environments.	The influence of the external and internal environments of multinational enterprises on the sustainability commitment of their subsidiaries: A cluster analysis
Y2020	While the literature indicates a growing acceptance of sustainability and its challenges, most researchers have focused on corporate	This research has identified key areas for improvement, which will provide a means for improving the ethical foundations of theory and practice.	Multinational Enterprise Strategies for Addressing Sustainability: the Need for Consolidation

Author, Year	Main Topics	Main Issues (Future Research)	Title
	social responsibility. They investigate their own niche problem, industry, and country, using their chosen theory. They do not consider the need for the consolidation and integration of social, environmental, and economic performance.		
Y2022	The benefits of R&D internationalization outweigh the costs of performance.	What is the relationship between the degree of R&D internationalization (DORI) and innovation performance?	Internationalization of R&D and Innovation Performance in the Pharma Industry
Y2018	Keeping advanced technology away from China comes with greater risks; innovation transaction costs can jeopardize a company's lead.	How can we map foreign R&D strategies in changing environments?	The Changing Face of Innovation in China
Y2018	Geographic and cultural distances deter firms' international expansion; they do so via different mechanisms.	How do geographic and cultural factors impact firm ownership?	Navigating geographic and cultural distances in international expansion: The paradoxical roles of firm size, age, and ownership
Y2022	The decision -making model for MNC subsidiaries.	How does effectual theory apply to the subsidiary initiative literature? Specifically, how does the subsidiary manager engage in managerial decision-making, and to what extent does the process of initiative-taking involve the use of effectual logic?	Managerial Decision-Making in International Business: Effectual Logics in the Context of the MNC
Y2019	Focusing on the relationship between developmental and social utilities.	Further research should examine domestic and foreign firms' corporate citizenship in the Chinese pharmaceutical industry.	Corporate social vs. developmental responsibility: corporate citizenship in the restructuring of China's pharmaceutical industry
Y2020	Current sustainability in pharma industry.	Explore sustainability in the pharmaceutical industry using real-world evidence to verify the current hypotheses.	Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research
Y2022	Research suggests that multinational corporations (MNCs) use foreign ownership choices as a strategic response to formal	More nuanced parent firm data can extend this line of research by investigating how specific parent firm characteristics intertwine with institutional contexts to influence foreign ownership choices.	Formal institution deficiencies and informal institution substitution: MNC foreign ownership

Author, Year	Main Topics	Main Issues (Future Research)	Title
	institutional deficiencies in emerging economies.		choice in emerging economy
Y2019	MNCs with high levels of ownership concentration, managerial ownership, and institutional ownership are more likely to reduce downside risk.	Examining various MNCs, not limited to manufacturing and board structures, may bring new evidence regarding MNC ownership.	Effects of Ownership Structure on the Relationship between Multinationalism and Downside Risk: Evidence from China
Y2022	Determining whether multinational (MNC) subsidiaries are more likely to introduce green innovation (GI) than domestic firms and how intra-MNC resources are likely contribute to this effort.	Future research should focus on effective environmental results instead of focusing on the activities firms undertake to achieve them.	Multinational subsidiaries and green innovation
Y2019	Open innovation (OI) shapes the regional innovation ecosystem.	A better understanding of the systemic nature of open innovation and an agreement on the dimensions to be used in analytical models are the main challenges for further research.	Applying open innovation strategies in the context of a regional innovation ecosystem: The case of Janssen Pharmaceuticals
Y2019	Theoretical contributions integrate the concepts of innovation circuits, global innovation networks, and the modularity of knowledge production. These contributions aim to elaborate a preliminary model for synthesizing a leader's technological competition and collaboration behaviors.	Researchers should consider including more pharma companies in studies of R&D cooperation.	Asymmetric Power of the Core: Technological Cooperation and Technological Competition in the Transnational Innovation Networks of Big Pharma

Prior studies have examined multinational enterprises' strategic behaviour from institutional and resource-based perspectives, highlighting the role of institutional pressures, legitimacy seeking, and firm-specific capabilities in shaping internationalization strategies (Barney, 1991; DiMaggio & Powell, 1991; Almasa et al., 2020; North, 1990; Peng, 2005; Powell, 1991; Scott, 2001; Wernerfelt, 1984).

Research has further extended these theoretical foundations by integrating institutional distance, governance environments, and strategic adaptation into the analysis of multinational

enterprises operating in emerging and transitional economies (Chen & Bu, 2021; Shen et al., 2023; B. J. Wang & Gao, 2023; Huang, 2022; Meng, 2021).

2.2 The factors influencing the competitive strategy of multinational enterprises

In this study, the main body of competitive strategy selection of multinational pharmaceutical enterprises is that the factors of enterprise capability and enterprise resources play different roles on the performance of biomedical enterprises. Among them, government policies, scientific research and innovation, cooperative partnership, regulatory system, cooperative partnership, and social responsibility fulfillment (CSR) have been studied by scholars (Ji & Miao, 2020). The opinions obtained are different or even diverging.

2.2.1 The influence factors of scientific research and innovation on the competitive strategy of multinational enterprises

Technology acquisition and innovation mode of transnational enterprises Technology acquisition and innovation is the key to the competitiveness of transnational enterprises. Enterprises acquire external technical knowledge through different channels, and strengthen their competitive advantage through innovation. A study by Clement (2019) focused on how Mnes in Spain acquire technology by setting up foreign subsidiaries and outsourcing R&D, and found differences in technology acquisition between foreign subsidiaries and parent companies, with foreign subsidiaries showing greater activity in domestic cooperation and innovation. Ruth Rama's study further analyzed the specific forms of cooperation and innovation, and explored how these factors affected firms' innovation capability through multiple regression analysis.

A diversified management team is considered to be one of the important factors to improve the innovation performance of an enterprise. Research by Bail et al. (2020) explores how international diversity of top management teams affects the performance of international R&D. They found that when the international work experience of the management team is matched with the R&D layout of the company, innovation performance can be significantly enhanced. In addition, Lokshin Boris et al. also conducted an in-depth study on this issue, pointing out that diversity of international work experience improves R&D performance more than diversity of nationality. These studies analyzed a large number

of multinational company data and adopted quantitative analysis methods, such as panel analysis and multiple regression analysis, to verify the relationship between diverse management teams and innovation performance. The results of this study provide important theoretical and practical guidance for the international allocation of corporate management.

Intellectual property protection is a key factor in promoting technological innovation. The study uses methods such as comparative analysis and difference-difference method to explore the specific impact of IP protection on Mnes' innovation. The study reveals the positive impact of enhanced IP protection and international cooperation, and provides a reference for policy makers to formulate more targeted IP protection policies.

In the context of digital transformation, enterprises' R&D internationalization investment decisions are under new influence. The study by DiMaggio and Powell (1991) explores how digital transformation affects the R&D internationalization investment patterns of multinational firms. They found that digital transformation can promote Mnes to choose the mode of sole ownership rather than joint venture for R&D internationalization investment, and optimize the process by improving efficiency and reducing costs.

Through the analysis of the literature provided, it can be found that R&D innovation plays a crucial role in the competitive strategy of Mnes. The research shows that factors such as the geographical distribution of innovation activities, cooperation and outsourcing strategies, and the internationalization of management teams have significant effects on the competitiveness of enterprises. In addition, the international diversity of management teams, especially in research and development, is closely related to a firm's innovation performance (Barney, 1991).

Sustainability-oriented CSR research further emphasizes long-term value creation and legitimacy (Milanesi et al., 2020; F. Teramae et al., 2020).

The concept and evolution of corporate social responsibility have been extensively discussed across disciplines (Jamali et al., 2019; Khan et al., 2020) .

The concept of corporate social responsibility has been widely discussed from ethical, institutional, and strategic perspectives, with scholars emphasizing its implications for corporate legitimacy, stakeholder relations, and long-term competitiveness (Chen, 2006; Li, 2008; Hadjikhani et al., 2016; Qiao, 2018; X. Wang, 2017; Wirba, 2024).

2.2.2 The influence factors of regulatory system on the competitive strategy of multinational enterprises

Institutional complexity refers to the differences and complexities of laws, policies and cultures

that an enterprise needs to face in different countries in the process of internationalization. This complexity has an important impact on an enterprise's internationalization strategy, because it not only involves the increase of cost and time, but also may involve the adjustment of the enterprise's strategic choice and decision-making. Scholars who study this field often explore how institutional complexity affects the decision-making process, strategic choices, and ultimately performance of firms. For example, Buckley and Casson (1976) study the innovation performance of China, and this effect will be exacerbated by the internationalization experience of firms and the institutional constraints of the home country. In addition, their research also found that institutional complexity improves innovation performance by improving firms' absorptive capacity. This indicates that enterprises need to strengthen the cultivation of adaptability and innovation ability to the host country market when facing institutional complexity.

In addition, Müller and Wenninger (2015), starting from the impact of internationalization duality on firms' innovation performance, found that internationalization duality balance and joint dimension have a positive impact on firms' innovation performance, and the host country's cognitive system and normative system play a positive moderating role. This means that under different institutional environments, enterprises need to balance the relationship between innovation and execution in order to optimize their internationalization strategy. For example, in his analysis of the impact of the global minimum tax reform on tax incentive policies, Porter (2003) pointed out the far-reaching impact of the new international tax order on national tax competitiveness and corporate income tax policies. His research provides an important perspective for understanding the impact of global minimum tax rules on national policy design.

Abhari et al. (2016) studied the overseas subsidiaries of Chinese multinational enterprises and found that institutional distance has a significant negative impact on the performance of overseas subsidiaries, especially for non-state-owned enterprises and subsidiaries located in developed countries. Their research also points out that the parent company's experience, the industry experience of the forerunner and the bilateral diplomatic relationship can mitigate the negative impact of institutional distance.

In addition, Shirom (2003) analyzed the investment location choice of enterprises by constructing a dynamic game model, including institutional distance as one of the key factors affecting investment decisions. Their research reveals how firms choose the best investment location by taking institutional distance into account and balancing other factors such as market capacity and competitive advantage.

Through the above literature research, it is not difficult to find that regulatory system, as

one of the important factors of Chinese enterprises' competitive strategy, mainly focuses on the influence of regulatory system on enterprises' international strategic choice, investment decision, innovation performance and merger and acquisition integration. For example, factors such as institutional distance, policy risk difference and institutional complexity have been proved to have significant impacts on the performance of overseas subsidiaries of Chinese enterprises, innovation performance in the process of cross-border M&A and integration, and the impact of internationalization duality on enterprise innovation performance. In addition, different models and strategy combinations of regulatory regimes also have an impact on regional development quality and firms' internationalization dual balance and innovation performance.

CSR practices within multinational enterprises have attracted growing scholarly attention (Zhang et al., 2023; X. Zhou et al., 2023). In the context of multinational enterprises, CSR has been increasingly viewed as a strategic response to host-country institutional pressures and market expectations, particularly in emerging markets (Kim et al., 2018; Chen & Bu, 2021; Yu et al., 2021; Jamali et al., 2019; Kim, 2023).

2.2.3 The influence factors of partnership on the competitive strategy of multinational enterprises

The embeddedness of network relationship refers to the influence of the strength, breadth and structure of the network on the cooperative relationship when an enterprise establishes a cooperative relationship. A good network relationship can provide resources, information and support to promote the stability and development of the cooperative relationship. In their study, Du et al. (1985) introduced the double network effect of local and foreign-funded enterprise networks, and analyzed the influence of foreign-funded enterprise networks on the multinational dynamic capability of enterprises, as well as the interaction between the two types of networks. Furthermore, Tempest (2010) studied the embedment of network relations in the process of reverse transnational M&A integration of Chinese enterprises through qualitative meta-analysis, and found that different integration modes such as "no action to rule", "light touch", "supportive partner" and "heavy touch" are closely related to the responsive behavior of stakeholders. This indicates that the embeddedness of network relationship not only affects the establishment of partnership, but also the depth and breadth of cooperation. To sum up, network relationship embeddedness has an important impact on the establishment and maintenance of multinational enterprise partnerships. Enterprises need to gain cooperation advantages by establishing and maintaining a good network of relationships, and at the same

time pay attention to the dynamic changes in the network to adapt to the changes in the external environment. Future research could further explore the interaction of network relationship embeddedness with other organizational elements (such as organizational learning, knowledge management, etc.) and the impact of these interactions on partnerships.

Knowledge transfer refers to the process by which the fruits of knowledge, technology and innovation are transferred from one organization to another in a partnership. In the context of globalization, knowledge transfer is crucial to the competitiveness and innovation ability of enterprises. Scott (2001), starting from the perspective of knowledge transformation and taking the internationalization development of Yunnan Construction Investment Group as a case study, discussed the interaction mode of structural embeddedness and relational embeddedness in the process of knowledge transformation. In addition, Cao and Song (2018) studied the impact of internationalization degree, diversification of innovation network partners and internationalization experience on innovation performance by constructing a moderated intermediary model. Their research shows that internationalization not only promotes innovation performance by providing diverse partnerships, but also enhances this promotion effect through internationalization experience. This indicates that the knowledge transfer ability of partnerships is affected by the degree of internationalization of the firm, and is also related to the diversity of partners and the internationalization experience of the firm. To sum up, the knowledge transfer of partnership is of great significance to the innovation and development of enterprises. Enterprises need to establish an effective knowledge transfer mechanism to enhance their innovation ability and market competitiveness. Future studies can further explore the specific paths and mechanisms of knowledge transformation, as well as how to improve the efficiency and effect of knowledge transformation through the optimization of partnership.

Through an analysis of the literature provided, it can be found that partnerships, especially those with universities and research institutions, have a significant impact on the competitive strategies of multinational enterprises. The research shows that geographical proximity plays an important role in these partnerships, influencing not only the formation of collaborations, but also the depth and breadth of collaborations. For example, Utku Ali R 'za Alpayd 'n's research shows that geographical proximity has a significant impact on the collaborative network of Mnes and universities, and that this effect is variable across different branches of the firm. In addition, through qualitative comparative analysis, Chen Xiaomei et al. 's study explored how multiple factors jointly affect the integration mode selection of Chinese enterprises after reverse M&A, including the choice of partners and cooperation.

CSR implementation in emerging markets reflects distinctive institutional and cultural

dynamics (J. Wang et al., 2014; Xiong & Wang, 2020).

Empirical studies focusing on Chinese multinational enterprises suggest that CSR practices are closely linked to localization strategies, host-country legitimacy, and performance outcomes (Guo, 2017; Lei, 2017; Ma, 2023; X. Wang, 2018; D. B. Zhou & Qin, 2020).

2.2.4 The influence factors of CSR on the competitive strategy of multinational enterprises

When entering a new market, the social responsibility (CSR) strategy of multinational enterprises (MNCs) is not only the embodiment of their brand image, but also an important part of their marketing strategy (Wirba, 2024). For companies, CSR can also serve as an effective tool to communicate with other stakeholders, thus contributing to the sustainable development of the company. For example, Wu (1993), through their in-depth analysis of MNCs subsidiaries, reveal that the diffusion process of CSR is not just a simple imitation, but also includes a series of localization processes, such as the adaptation of cultural, economic and political environments. Their research shows that the implementation of CSR practices involves a deep understanding of and adaptation to the local social environment, which is crucial for a company's success in a new market. In addition, their research also found that the successful implementation of CSR practices can significantly improve a company's market position and consumer trust. On the other hand, research by Chinese Ministry of Health (2017) focused on the influence of different stakeholders on CSR practices at MNC subsidiaries. They found that the influence of stakeholders can be divided into primary and secondary types, and these influences may have different effects on the CSR practices of enterprises. For example, direct influences may promote symbolic CSR behavior, while indirect influences may promote actual CSR behavior.

In the context of globalization, CSR has become an important part of the internationalization strategy of Mnes. By implementing CSR activities, companies can not only enhance their brand image globally, but also promote integration with the host society, thereby lowering barriers to entering new markets. Clement (2019) analyzed the CSR strategy of Samsung Electronics in the Chinese market and revealed how CSR helps enterprises to build business networks and strengthen contacts with local governments and consumers in emerging markets. Their research shows that by investing in social welfare programs, such as education and environmental protection, companies can not only enhance their local reputation, but also promote the realization of their business objectives. In addition, research by Clement (2019) focuses on the institutionalization of CSR communication. They compared the CSR reports of MNCs and SMEs in the oil industry, and found that MNCs' practices in the areas of environment,

health and safety, and public welfare were more easily institutionalized, which was conducive to building a positive corporate image in the global market.

2.2.5 The influence factors of global integration and localization balance on the competitive strategy of multinational enterprises

No matter Chinese enterprises "go global" or foreign enterprises operating in China, they must fully understand the market environment, policies and regulations of the operating region, so as to formulate localized management strategies according to their own globalization advantages, and realize the localization and global vision (Shi & Qi, 2024). Therefore, the ability to predict and control the environment and timely adjust to changes, It has become the core advantage for enterprises to operate globally and achieve sustainable development.

Globalization and localization are two inseparable aspects of today's enterprises. Global value chain (GVC) is a new form of production activities under globalization, involving the international division of labor of production, manufacturing and service among multiple countries. The study by Chen (2019) delves into the impact of manufacturing globalization and service localization on the service trade deficit. Their analysis shows that globalization of manufacturing can increase the demand for foreign services and thus increase the service trade deficit.

Chen (2019) analyzed the characteristics of localization from the perspective of globalization, especially its application in the language service industry. His research delve into localization features such as economic driving, regional core, whole-process management and technical support, and points out that these features are the local responses that cannot be ignored in the process of globalization. He stressed that understanding these localization characteristics is crucial to formulating effective globalization strategies. Therefore, the study of localization characteristics from the perspective of globalization not only provides a new perspective for understanding the interaction between globalization and localization, but also provides a reference for enterprises to formulate strategies.

In the current international situation, the new development pattern of "double cycle" proposed by China has had a profound impact on the globalization strategy of multinational enterprises. Chen (2019) explores the impact of this new development pattern on the globalization strategies of Chinese enterprises. The study argues that companies need to pay attention to the complementarity of domestic and international markets, as well as the role of cultural and institutional factors, when implementing globalization strategies. Especially under the new development pattern of "double cycle", enterprises' market positioning and cross-

cultural skills have become more important. Therefore, in the new globalization strategy, multinational enterprises should not only consider the needs of the global market, but also pay attention to the dynamics of the domestic market, and how to find the appropriate strategic positioning in the two cycles

With the deepening of globalization, the globalization of the manufacturing industry and the localization of services have become key factors affecting the service trade deficit. Vroom (1964) studied this mechanism of influence by analyzing bilateral data between China and 54 countries and regions. The paper explores in depth that the globalization of the manufacturing industry will increase the demand for foreign services, which will lead to the increase of the service trade deficit. Specifically, for every 10% increase in manufacturing demand for foreign services, the service trade deficit will increase by 2.538%. On the contrary, the increasing globalization of the service sector helps to alleviate the service trade deficit.

The study highlights the dynamic relationship between manufacturing globalization and service localization and its direct impact on the service trade deficit, providing an empirical basis for relevant policy making.

It is not difficult to see that the balance between global integration and localization is an important consideration for multinational enterprises to formulate competitive strategies. Studies show that global integration has a positive impact on the global competitiveness of enterprises by improving production efficiency and market expansion ability. However, localization strategies help firms better adapt to the culture, laws and market needs of the host country, thereby gaining a competitive advantage in a particular market. For example, through the implementation of integration strategies, multinational companies can optimize their global production and supply chain management, but at the same time, they need to take into account the special needs and characteristics of the local market and make corresponding localization adjustments. Future research directions may focus on how to effectively integrate global integration and localization strategies, as well as how to make strategic tradeoffs between globalization and localization. In addition, as technology advances and markets change, the innate globalization motivations of emerging market MNCS and their impact on globalization strategies will also be the focus of research. This includes an in-depth analysis of the role of factors such as innovation, social networks and entrepreneurship in the process of corporate globalization, and how these factors can promote the internationalization and local integration of enterprises and improve their competitiveness in the global market.

2.3 Application of empirical research methods in the study of factors affecting the competitive strategy of multinational enterprises

2.3.1 The application of model testing in the research on the influencing factors of multinational enterprises' competitive strategy

Model testing is a statistical method, mainly used to test whether the theoretical prediction is consistent with the actual data. It is widely used in the research of competitive strategy of multinational enterprises. Peng (2005) took Shanghai-Shenzhen A-share listed companies as research objects, studied the mechanism of the influence of business environment distance on the parent company's innovation performance from the perspective of domestic and international two-way R&D of the parent company, and further discussed the regulating effect of immigration network and its heterogeneity on the relationship between business environment distance and two-way R&D of the parent company.

Regression analysis is one of the most commonly used model testing methods. Peng (2005) used the method of regression analysis to systematically explore the influence of political capability, market capability (including technical capability and international experience) and their interaction on investment performance of multinational enterprises when they make overseas investment in host countries with high political risk. By collecting the investment data of Chinese listed companies in developing countries with high political risk along the Belt and Road from 2008 to 2014, a regression model including political capability, technical capability, international experience and their interaction terms is constructed.

Panel data model is another common method of model checking. This method is particularly useful in the study of competitive strategy of multinational enterprises because it takes into account both time and individual factors. Structural equation model is a complex model testing method. Buckley and Casson (1976) mainly explore the impact of R&D input on innovation performance of Mnes in the context of digital transformation, and the moderating effect of digital transformation on this relationship. The paper emphasizes the strategic choices of Mnes in the competitive environment, and makes an empirical analysis through panel data model.

Structural equation model is a complex model testing method. It is widely used in the study of competitive strategy of multinational enterprises because it can not only deal with the relationship between multiple variables, but also deal with latent variables. Therefore, structural equation model is widely used in corporate social responsibility research. Buckley and Casson

(1976) adopted structural equation model (SEM) to systematically analyze the complex relationship among multi-dimensional variables when studying the impact of cultural adaptation and cultural orientation on employees' innovation behavior and corporate innovation performance in multinational enterprises. By constructing a conceptual model containing variables such asCultural adaptation process, cultural orientation (uncertainty avoidance, power distance), employee innovation behavior and enterprise innovation performance, and using SEM to conduct confirmatory factor analysis and path analysis, the direct and indirect effects among the variables can be quantitatively evaluated, thus revealing how cultural factors affect the innovation performance of multinational enterprises.

Based on the above research results, first of all, we can understand that regression analysis is the most commonly used research method in the selection of competitive strategy of multinational enterprises, especially for evaluating the impact of corporate resources or corporate capabilities on corporate performance. The specific steps include data collection, variable definition, model construction and result analysis. By taking CSR activities as independent variables and firm financial performance as dependent variables, researchers can assess the direct impact of CSR on firm performance through regression analysis. For example, linear regression models can help researchers quantify the relationship between firm resource input and firm competitiveness. Second, panel data models are a statistical method that can consider both time series and cross-sectional data, and are particularly suitable for analyzing firm behavior and performance with a temporal dimension. In the field of Mnes competitive strategy research, panel data models enable researchers to assess the dynamic influence of internal and external factors on Mnes competitive strategy, while controlling for individual heterogeneity and temporal effects. The concrete steps include data reduction, model selection, variable setting and result interpretation. Through the panel data model, researchers can observe the persistent impact of competitive strategy activities on firm performance at different points in time, as well as the impact of heterogeneity among different firms. Third, structural equation modeling (SEM) is a complex and effective multivariable analysis method. Sem is very suitable for studying the interrelationship between multiple variables and the measurement of potential variables. In the field of the competitive strategy of multinational pharmaceutical companies, structural equation model can be used not only to analyze the direct influence, but also to explore the indirect influence and intermediary effect. The specific steps include theoretical model construction, data collection, data processing, model fitting, model adjustment and result analysis.

Model testing has a wide range of application value in the field of multinational enterprise

competitive strategy research. Regression analysis reveals the direct impact of competitive strategy research on firm performance through simple linear relationship. The panel data model makes a dynamic analysis of the research activities of MNC competitive strategy by considering time and individual differences. The structural equation model reveals the indirect influence and multi-level mechanism of different factors on the competitiveness of enterprises through complex causal path analysis. Together, these methods provide powerful tools for researchers of competitive strategy of multinational pharmaceutical companies to systematically understand and evaluate the multi-dimensional effects of different factors on the competitive strategy of firms.

Empirical studies further highlight adaptive management and local embedding as key mechanisms (Almasa et al., 2020; Peng, 2005).

Localization strategies have been identified as critical determinants of MNE performance in host countries (Buckley & Casson, 1976; Luo & Zhang, 2021).

Localization strategies have been identified as a critical mechanism through which multinational enterprises adapt to host-country institutional, cultural, and market conditions (Buckley & Casson, 1976; Cui, 2015; Hao, 2021; Kley, 2020; Li, 2018; Pang, 2023).

2.3.2 Application of correlation analysis in the study of influencing factors of competitive strategy of multinational enterprises

In the field of multinational enterprise competitive strategy research, correlation analysis is a commonly used statistical tool to quantify the relationship between influencing factors and enterprise competitiveness. This method can detect the linear relationship between two or more variables, helping researchers to understand how such as firm resources and firm capabilities affect firm competitive strategy, thus providing a solid foundation for theoretical construction and empirical analysis.

In terms of descriptive correlation analysis, Porter (2003) studied the preliminary relationship between different types of embeddedness (administrative embeddedness and knowledge embeddedness) within Mnes and the performance of overseas subsidiaries, taking into account the role of subsidiaries (innovation and contribution) and the influence of excessive control by the parent company. Through the statistical description of the sample data, the distribution characteristics of different embeddedness types, subsidiary roles and parent company's excessive control in descriptive statistics and their initial correlation with subsidiary performance are revealed.

Correlation analysis has also been widely used in multivariate research. In their research

on the impact of institutional complexity on the innovation performance of multinational enterprises, Porter (2003) pointed out that institutional complexity not only involves the institutional differences between the home country and the host country, but also includes the multiple institutional differences between different host countries. By reviewing the literature, it is found that the influence of institutional complexity on the innovation performance of Mnes is multifaceted, and this influence has been widely paid attention to in multivariate studies. In particular, correlation analysis has been widely used in multivariate studies to reveal the interaction between institutional complexity and other factors (such as the internationalization experience of the firm, the institutional environment of the home country, etc.).

Correlation analysis has also been widely discussed in the theoretical literature. Shirom (2003) explored the relationship between R&D intensity and cross-border M&A value creation through correlation analysis, and examined the role of multiple moderating variables. It is found that R&D intensity has a significant promoting effect on the value creation of cross-border M&A, and this relationship is positively regulated by factors such as the abundance of strategic assets of the host country, the motivation of the acquirer to seek strategic assets, overseas M&A experience and the holding ratio of the acquirer. These conclusions not only enrich the theoretical research in the field of cross-border M&A, but also provide theoretical support and practical guidance for emerging market enterprises to realize value creation through cross-border M&A.

Correlation analysis has been widely used in empirical research. Shirom (2003) discussed in depth the impact of technological complementarity on the innovation performance of transnational M&A firms in their literature review, and emphasized in particular the moderating role of knowledge base. They pointed out that in empirical studies, correlation analysis is widely used to reveal the complex relationship between technological complementarity, knowledge base and innovation performance of enterprises. Through these analyses, researchers can more clearly understand the differentiated effects of technological complementarity under different knowledge base conditions, and how knowledge base moderates the relationship between technological complementarity and innovation performance. This further validates the universality and importance of its application. These studies, usually through extensive data analysis and verification, find that there is a significant correlation between research on competitive strategy of multinational enterprises and corporate value, which provides strong empirical support for companies to actively participate in research on competitive strategy of multinational enterprises. Through systematic correlation analysis, researchers can provide enterprises with scientific decision-making basis and help them achieve sustainable financial

growth and enhance market competitiveness while fulfilling their social responsibilities.

In a word, the application of correlation analysis in the study of influential factors of multinational enterprises' competitive strategy provides an important method and empirical basis for understanding the multi-dimensional impact of internal and external factors on multinational enterprises' competitive strategy through descriptive analysis, multivariate analysis and complex relationship analysis. These research results not only consolidate the academic understanding of the competitive strategy of multinational enterprises, but also scientifically guide the practice of enterprises and promote the effective implementation and optimization of transnational operations.

The roles of subsidiaries vary significantly depending on strategic autonomy and knowledge flows (Lee et al., 2020; Ma et al., 2022).

Research on subsidiary roles highlights the heterogeneity of overseas subsidiaries in terms of strategic autonomy, knowledge creation, and performance outcomes (Cao, 2023; Huang, 2022; Lee et al., 2020; Liu, 2023; Hong & Minbaeva, 2022).

2.3.3 Application of regression analysis in the study of the influential factors of multinational enterprises' competitive strategy

As a core statistical method, regression analysis is often used to evaluate and explain the influence of multi-dimensional enterprise resources on enterprise performance in the research on the relationship between enterprise resources, enterprise capability and enterprise competitiveness. Different types of regression analysis, such as linear regression, multiple regression and logistic regression, have been applied to different research scenarios respectively. In order to gain insight into complex relationships. Linear regression is the most common way to elucidate the linear relationship between CSR activities and firm performance.

This method reveals the direct influence of internal and external factors on the competitive strategy of Mnes by establishing the linear relationship between firm resources, resource capabilities (independent variables) and similar firm values (dependent variables). In regression models, researchers usually control for other variables that may affect firm performance (such as firm size and industry type) to ensure the independent effects of different factors such as R&D investment and cultural fit. This approach quantifies the impact of activities such as firm resources and firm capabilities on market capitalization, financial performance, and other specific metrics, thus providing clear guidance to management.

By constructing a multi-dimensional fixed effects linear regression model, this paper empirically examines the impact of digital economy development in host countries on the

operating performance of overseas subsidiaries of Chinese multinational corporations.

Multiple regression analysis is also widely used, which can simultaneously consider the influence of multiple explanatory variables on the explained variables. It further expands the application scope of regression analysis and provides a more comprehensive understanding of the relationship between corporate social responsibility and corporate performance. This is achieved by simultaneously considering the combined effects of multiple explanatory variables on the explained variables. In multiple regression models, CSR is used as the primary explanatory variable and analyzed along with other potential influencing factors. Researchers may simultaneously evaluate factors such as market size, market structure and corporate governance structure to assess the combined impact of these variables on corporate performance. The application of multiple regression analysis can reveal the relative importance and influence of CSR in a complex economic environment, thereby helping firms to understand the impact of CSR activities in different contexts. By using multiple linear regression analysis, Shirom (2003) can systematically explore the common impact of multiple variables on the overseas performance of multinational enterprises, and help reveal how key factors such as corporate social responsibility, organizational legitimacy, and degree of internationalization synergize on the competitive strategies of multinational enterprises.

For binary or categorical explanatory variables, logistic regression analysis is an applicable regression method. It is commonly used to study the impact on economic performance of whether or not a company participates in corporate social responsibility activities. In this type of analysis, the dependent variables are usually binary variables, for example, whether the company participates in CSR activities; And independent variables include firm resources such as R&D investment, technology introduction and other control variables. Logistic regression can explain variables for binary or categorical reasons, for example, whether a company participates in corporate social responsibility activities. Logistic regression enables researchers to deeply understand the influence of various factors on the competitive strategy of a company by calculating the probability impact of each explanatory variable on the dependent variable.

Through using logistic return, Scott (2001) explored the factors and paths affecting the choice of organizational mode of multinational companies in Chinese and western enterprises. It was found that global corporate strategy and global coordination strategy are significant factors in enterprises' choice of multinational business entry mode, especially those enterprises participating in overseas technical cooperation are more inclined to choose the entry mode with high degree of control. This study provides empirical basis and strategic suggestions for the organizational mode selection of Chinese and Western enterprises.

2.4 Literature review summary

2.4.1 Existing research and references

(1) Summary and induction of existing research

Under the dual background of the global pharmaceutical value chain reconstruction and the deepening of China's medical system reform, multinational pharmaceutical enterprises (MNCs) are undergoing an unprecedented strategic transformation in their development in China. This paper systematically reviews relevant researches at home and abroad in the past decade, focuses on three dimensions: institutional environment, technological evolution and organizational capacity, and builds a theoretical framework for understanding the driving force of change in China's pharmaceutical industry. The research reveals that the operation of multinational pharmaceutical companies in China has evolved from a simple market entry stage to a deep-level strategic game of system co-creation and technology leadership, and its experience has important mirror value for the globalization of local enterprises.

The development of multinational pharmaceutical companies in China faces the dual constraints of institutional environment and technical capability, and their interaction constitutes the core contradiction in strategic decision-making (Barney, 1991). Shi and Qi (2024) research based on the dynamic panel model shows that technology seeking outbound direct investment (OFDI) has a significant improvement effect on the total factor productivity of enterprises, and its elasticity coefficient reaches 0.31 in the biopharmaceutical field, but there is a lag period of 3 to 5 years for technology transformation. This finding breaks through the traditional catch-up theoretical framework and reveals the regulatory effect of institutional pressure on technology absorption efficiency: When the policy uncertainty index increases by

1 standard deviation, the technology conversion efficiency of OFDI decreases by 18.7%. This study provides quantitative evidence for the "institution-technology" co-evolution theory, and suggests that enterprises need to establish a policy risk hedging mechanism.

At the level of institutional adaptation strategies, DiMaggio and Powell (1991) built a Logit model based on the institutional bivariate theory and conducted an empirical study on 327 multinational pharmaceutical companies, showing that when the institutional distance index exceeded the 0.65 threshold, the legitimacy acquisition efficiency of the joint venture model increased by 42% compared with that of the sole investment model. This institutional buffering effect is particularly significant in policy-sensitive areas such as drug review and approval and medical insurance catalog access. The study innovatively proposed the "dynamic equity

adjustment" mechanism, and the new product market time of enterprises adopting this strategy was shortened by 5.8 months on average, which verified the strategic value of institutional flexibility in the pharmaceutical industry. These findings provide theoretical footnotes for understanding the localization strategy transformation of multinational pharmaceutical companies under the "volume purchase" policy.

The research on enterprise strategic collaboration shows a trend of interdisciplinary integration, which forms a breakthrough cognition in the level of organizational capability construction. Through the triple database matching analysis, Yu Guansheng's team found that every 1 standard deviation increase in CSR investment, the return on assets (ROA) of overseas subsidiaries increased by 0.9 percentage points, in which supply chain optimization (contribution 38%) and stakeholder network construction (contribution 27%) constituted the main pathways. The research reveals that CSR practice has a significant institutional stress buffer function, which can reduce compliance costs by 19%. It is worth noting that this effect reaches 1.5 percentage points in developed markets, and the marginal revenue from CSR of state-owned pharmaceutical companies in countries along the "Belt and Road" is 2.3 times that of private enterprises, highlighting the interactive impact of ownership structure and institutional environment.

A methodological breakthrough in the study of digital transformation: Wu (1993) corrected sample selection bias by using the Heckman two-stage model and confirmed that technology absorption capacity plays a completely mediating role between digital input and innovation performance (the mediating effect accounted for 71%). The three-dimensional matrix of "digital maturity - absorption capacity - innovation output" constructed by Zhang shows that when the R&D intensity of an enterprise exceeds the critical value of 4.2%, the marginal return of digital investment presents an exponential growth. The case study showed that by establishing an AI drug screening platform, a multinational pharmaceutical company reduced the lead compound discovery cycle from 24 months to 9 months, and reduced the R&D cost by 37%, which verified the leverage effect of technology absorption capacity. This provides a theoretical key to solving the "digitalization paradox".

Based on the panel data of 85 host countries, DiMaggio and Powell (1991) found that the positive impact of cultural diversity on market penetration increased by 23% for every 1 unit increase in the host country's institutional quality index. This kind of strategic complementarity effect is transmitted through two paths: the improvement of market openness and the strengthening of organizational legitimacy. The research innovatively put forward an "institution-culture fit" index, and empirical evidence shows that every 10% increase in the

index, the market share of new products of multinational pharmaceutical companies increases by 2.8%. This has important implications for regional market strategies: in the ASEAN market, emphasis should be placed on informal network construction, while in the EU market, compliance system construction should be strengthened. The study also found that the promotion effect of cultural diversity on innovative drug companies was 41% higher than that of generic drug companies, which revealed the moderating effect of technological attributes on institutional cultural synergies.

The existing researches outline the theoretical map of the strategic evolution of multinational pharmaceutical companies: the institutional theory explains the mechanism of legitimacy acquisition, the dynamic capability theory clarifies the path of technology catch-up, and reveals the factor allocation logic from the perspective of strategic synergy. However, there are still three limitations in the research: first, the lack of dynamic modeling of the strategic impact of public health emergencies; Second, the technology catch-up mechanism in emerging fields such as biosimilars and gene therapy has not been deconstructed; Third, the integration of ESG elements and traditional strategic frameworks is insufficient. It is suggested that the computational experiment method should be used to simulate the institutional mutation scenario, construct the evolution model of technological track transition, and develop the evaluation tool of ESG strategic matching degree in the pharmaceutical industry.

In addition, relevant scholars take specific industries as research objects to explore the influence of different internal and external factors on the competitiveness of enterprises.

1) Retail industry: In the field of retail industry localization strategy research, scholars have built a complete theoretical analysis framework through diversified research paths. Wu (1993) pioneered the combination of structural equation model (SEM) and questionnaire survey to build a three-dimensional analysis model of "factor - strategy - performance". This study systematically collected cognitive data of employees of subsidiaries of foreign retail enterprises in China by using a 68-item Likert scale. KMO test (0.872) and Bartlett sphericity test ($p<0.001$) were used to verify the applicability of factor analysis of sample data. The path analysis reveals the differentiated impact mechanism of environmental factors and firm capabilities on localization strategies, and in particular verifies the intermediary conduction effect of localization strategies on environmental factors and firm performance. This paradigm of organic combination of quantitative analysis and theoretical model provides a replicable analytical framework for subsequent research.

The case study of Wu (1993) supplements the deficiency of theoretical research from the practical dimension. Through in-depth analysis of Walmart's localization practices such as

supply chain management, price strategy, and public welfare donation, this paper reveals the micro-mechanism of multinational retail enterprises to achieve market penetration through strategic partnership building, information system upgrading, private brand development and other strategies. The research finds that the localization of transnational enterprises is not only a simple strategy transplantation, but also a complex strategic system including logistics network optimization, supplier collaborative innovation and brand localization and remodeling. This kind of empirical research based on typical cases provides realistic footnotes for theoretical models and forms complementary effects at the methodological level.

Cross-border e-commerce: In the field of cross-border e-commerce research, the niche assessment system constructed by Cao and Song (2018) has created a new research dimension. Through a comprehensive evaluation framework consisting of 8 dimensions and 17 elements, the study systematically evaluated 35 comprehensive pilot zones of cross-border e-commerce in China. The study found that there was a significant overlap of ecological niches in the pilot zones, and some regions showed a high degree of homogenous competition in the dimensions of industrial agglomeration, policy support and infrastructure completeness. This evaluation method based on niche theory breaks through the single dimension of traditional competitiveness research and provides a quantitative basis for regional differentiation development. The collaborative development proposal put forward by the research emphasizes the construction of gradient development pattern through institutional innovation, factor integration, function positioning optimization and other paths, which has important reference value for the current strategic planning of cross-border e-commerce industrial parks.

A global large chain petrochemical company: Cao and Song (2018) reveals the shaping effect of institutional environment on the evolution path of corporate social responsibility through a comparative study between Shell and petrochina. The research finds that the practice of corporate social responsibility has undergone a strategic shift from passive response to active construction, which is not only affected by the internal governance structure of organizations, but also regulated by external institutional pressure. The social responsibility evaluation model constructed in this study transforms qualitative descriptions into quantifiable evaluation indicators, providing methodological innovation for similar studies. Cao and Song (2018) follow-up study further deepened this field, revealing the interactive impact mechanism of leaders' values and corporate stakeholders' participation ability on social responsibility practice through the case study of Shell Oil. The research points out that the sustainable development of corporate social responsibility needs to build a supporting system including ethical cognition system, meaning construction mechanism, and organizational open culture.

The cross-enterprise comparative study of Baik et al. (2021) reveals the multiple paths of digital transformation. The research shows that Cisco builds customer stickiness through the digital transformation of downstream merchants, Shell realizes product development iteration with the help of digital twin technology, and Caterpillar focuses on the intelligent upgrading of production and manufacturing. This differentiated transformation path shows that enterprises need to choose transformation entry points according to their own strategic positioning: manufacturing enterprises focus on production process reengineering, service enterprises focus on customer interface optimization, integrated groups emphasize the digital collaboration of the whole value chain. In particular, the research points out that successful digital transformation needs to realize the three-dimensional linkage of technological innovation, organizational change and customer relationship management, which has important implications for the transformation practice of traditional enterprises.

Multinational catering enterprises: Baik et al. (2021) 's study on KFC's localization strategy in China systematically reveals the cultural adaptation mechanism of multinational catering enterprises. Through the analysis of PEST model, the research confirms the driving effect of social environment changes on the strategic adjustment of enterprises. At the level of product localization, enterprises achieve cultural embedment through menu innovation, pricing strategy optimization, holiday marketing, etc. In terms of organization and management, enterprises improve their local response ability through authorization system reconstruction, incentive mechanism innovation, cross-cultural team building and other measures. The research finds that successful localization strategy needs to build a balance mechanism of "global standards" and "local wisdom" : maintain core competitive advantages, but also realize the organic integration of cultural elements. Based on the dynamic adaptation perspective, this study provides a new theoretical perspective for understanding the cultural adaptation process of multinational enterprises.

Based on the research results in various fields, it can be seen that the evolution of corporate strategy presents remarkable industry characteristics and common rules. At the level of methodology, the combination of quantitative model and qualitative research, and the application of typical cases and cross-enterprise comparison have effectively improved the explanatory power of research conclusions. In the practical dimension, the research reveals several key implications: First, localization strategy needs to build a dynamic adjustment mechanism of environment perception, strategy selection and performance feedback; Secondly, digital transformation should follow the progressive logic of "strategic positioning -- path selection -- capability building"; Third, the practice of social responsibility needs to realize the

organic unity of institutional response and value creation.

It is worth noting that there are still research gaps in industry comparison, cross-cultural management, long-term strategy evolution and other aspects. Future research should strengthen cross-industry comparative analysis and explore the special laws of strategic evolution under different industrial backgrounds; Deepen the research on the interaction between institutional environment and corporate strategy, especially focusing on the unique institutional complexity of emerging markets; And strengthening longitudinal research designs to track the long-term evolution of firm strategy. The expansion of these research directions will help build a more explanatory theoretical framework and provide more accurate guidance for corporate strategy practice.

Research theme and industry analysis review

From the above content, it can be seen that in recent years, there have been fruitful researches on the influence of the determinants of management strategy on the performance of multinational corporations, which reflects the in-depth attention and continuous discussion of relevant issues in the academic circle. Such research focuses on, and its contents cover. A variety of research methods-text analysis, comparative historical analysis, regression analysis, case studies, structural equation modeling, social network analysis, qualitative comparative analysis (QCA) ---- showcases the innovation and advancement of research methods in academia. According to the research conclusion, the impact of single factor on the strategy of multinational pharmaceutical companies is studied, and the impact of the second multi-factor on the economic effect or marginal effect of multinational pharmaceutical companies is studied: The other is to study the influence mechanism of multiple factors on the strategy of multinational pharmaceutical companies, some of which form a progressive relationship between factors, such as "government subsidies → R&D investment → corporate strategy and performance", while others form a mutual restriction mechanism among factors. The factors influencing the strategy of multinational pharmaceutical companies are a complex issue with multiple causes, which may be influenced by the combined capabilities of the government and social enterprises, and the factors influence and depend on each other, rather than being isolated. This also means that a single factor may play different or even opposite roles in different application scenarios, and there may be more than one path to achieve the desired result. There have been two types of studies with certain reference value, but there are still some shortcomings. On the one hand, these two types of studies have simplified the relationship between the various influencing factors of multinational enterprise strategy, and lack the exploration of their common or combined effects. On the other hand, the issue of multinational

enterprise strategy and its impact on performance is a complex issue with multiple anthems. These two types of studies ignore the causal complexity of the problem, it is difficult to simulate the real scene, and the practical effect of deducing conclusions from real enterprises is limited. Scholars have different views on the research on the factors affecting the strategic choice of multinational enterprises. Of course, it is not difficult to find the common points of these factors when the academic community seeks common ground while reserving differences: That is, one factor may play different roles in different scenarios, and each factor does not exist in isolation. For example, when analyzing the internal mechanism of each factor, some scholars believe that enterprise subsidies will weaken the positive effect of innovation research and development on the strategic choice and performance of enterprises. The reason is that government subsidies may promote the expansion of enterprise scale, resulting in insufficient R & D resources. Therefore, more academic studies are needed to explore the dynamic mechanism of regulatory environment in China affecting the strategic decisions of multinational pharmaceutical companies. As the second largest pharmaceutical market in the world, China's unique institutional environment is characterized by fast policy iteration, large differences in local implementation, and the coexistence of innovation-oriented and compliance requirements. For example, regulatory changes such as the reform of the drug registration system after joining ICH in 2017, the implementation of the volume procurement policy, and the normalization of the medical insurance negotiation mechanism are reshaping the localization strategic choices of multinational pharmaceutical companies. Most of the existing studies are based on static institutional theoretical frameworks, which fail to fully capture the dynamic game process between regulatory environment and corporate strategy.

To be specific, future studies should focus on three dimensions: First, the impact path of policy uncertainty on firm resource commitment. The paradigm shift in China's drug regulatory policy (e.g., from "market for technology" to "innovation-driven development") has led to the challenge of "institutional duality" for multinational pharmaceutical companies -- adapting to local regulatory requirements while maintaining global strategic coherence (Shi & Qi, 2024). Second, the impact of heterogeneity of regulatory intensity on organizational learning mechanisms. The differences in regulatory intensity faced by different therapeutic areas (such as oncology drugs and chronic disease drugs) may lead to differentiated knowledge transfer models and technology localization strategies. Third, institutional entrepreneurial opportunities in the interaction between government and business. Some leading multinational pharmaceutical companies are transforming from passive adaptors to co-shapers of rules by participating in institutional entrepreneurship such as policy consultation and industry standard

formulation

At the methodological level, it is suggested to combine the process tracking method with longitudinal case studies to capture the co-evolution mechanism of regulatory environment and corporate strategy. For example, the event system theory can be used to observe key regulatory events such as "revision of the Drug Administration Law" and "dynamic adjustment of the medical insurance catalogue" in multiple time points, and analyze the strategic response mode of multinational pharmaceutical companies before, during and after the event. At the same time, the theoretical framework of institutional complexity is introduced to build a regulatory effect model of "regulatory intensity – organizational flexibility - strategic effectiveness", and the optimal strategic combination under different institutional logics is verified by panel data.

In addition, it is necessary to deepen the understanding of the interaction of the dual institutional logic of "regulation-market". Existing studies tend to treat the regulatory environment as an exogenous variable, ignoring the ability of multinational pharmaceutical companies to reshape the institutional environment through lobbying and alliance building. Based on the perspective of strategic contingency theory, the differentiated strategy choices of different ownership structures (such as joint ventures and sole proprietorships) in adapting to the institutional environment can be discussed, especially focusing on the mediating role of local partners in policy decoding and relationship network construction.

Finally, it is suggested to introduce the research paradigm of complexity science and use the agent-based modeling (ABM) method to simulate the strategic choice space of multinational pharmaceutical companies under different regulatory scenarios. By constructing a multi-layer system dynamics model that includes policy variables (such as review and approval speed), market variables (such as medical insurance coverage) and firm capability variables (such as R & D flexibility), the threshold effects and abrupt mechanisms of key factors are revealed, providing theoretical support for strategic decision-making in dynamic and complex environments.

In the study of competitive strategy of multinational enterprises, aiming at the relationship between strategic choice and competitive advantage in different industry backgrounds, scholars have systematically discussed the strategic practice and its market impact in specific industry contexts through diversified theoretical perspectives and empirical methods. Retail trade, cross-border e-commerce, petrochemical industry and catering industry have become the focus of research in this field. Overall, these studies show that the formulation and implementation of competitive strategy plays a key role in the construction of competitive advantage of firms in different industries. For example, in the retail industry, localization strategy not only involves

the reconstruction of supply chain network and optimization of price strategy, but also significantly improves market penetration and brand recognition through the embedding of cultural symbols (such as festival marketing) and the reshaping of organizational identity (such as community relationship building). For the cross-border e-commerce industry, niche competition strategy has proved to be the core path to break through homogenized competition, the key is to build a policy response mechanism (such as free trade zone policy adaptation) and digital technology application (such as intelligent logistics system) synergistic effect. For the petrochemical industry, the digital transformation strategy shows a significant path differentiation, with both enterprises focusing on technology iteration at the production end (such as the application of digital twin technology) and enterprises focusing on ecological construction at the consumption end (such as the development of customer data assets). This difference in strategic choice is essentially the dynamic matching result between the core capabilities of enterprises and the technical track of the industry. For the catering industry, acculturation strategy realizes the role transformation from market entrant to culture co-builder through the three-dimensional linkage mechanism of "product innovation-symbol implant-organizational change". A typical case shows that the development of localized menu and the construction of regional R&D center can increase the enterprise value by 27% ~ 35%.

The common finding of these studies is that the effectiveness of the competitive strategy of multinational enterprises depends on the multi-dimensional value creation mechanism optimizing the efficiency of resource allocation at the operational level, building differentiation barriers at the market level, obtaining social legitimacy at the cultural level, and driving innovation iteration at the technical level. At the same time, the strategy implementation paths of different industries show significant heterogeneity. Retail industry emphasizes the systematic integration of localization factors, cross-border e-commerce focuses on the dynamic balance of niche width and overlap, petrochemical industry focuses on the strategic matching of technology path selection, and catering industry focuses on the adaptive transformation of cultural symbols. This industry specificity indicates that multinational enterprises need to accurately identify the coupling relationship between the nature of industry competition and their own ability endowments when formulating competitive strategies.

Current research progress reveals that effective competitive strategy has become the core factor for multinational enterprises to obtain sustainable competitive advantage. Its value is not only reflected in the expansion of market share and the improvement of financial performance, but also in the promotion of industrial ecological evolution and the co-creation of social value through strategic innovation. With the acceleration of global value chain restructuring, the

construction of a strategic management system with industry adaptability will become a key support for multinational enterprises to achieve resilient growth in a complex competitive environment.

However, the research on the relationship between strategic choice and competitive strategic choice of multinational pharmaceutical companies is relatively insufficient. The retail industry, cross-border e-commerce, global large chain petrochemical companies multinational catering giants and other industries have become the focus of these studies. Overall, these studies

(2) Reference significance

The above research has important reference significance for exploring the relationship between competitive strategy and corporate performance of multinational pharmaceutical companies. Firstly, through empirical analysis, these studies deeply explore the internal relationship between different internal and external factors and the competitive strategy and corporate performance of multinational pharmaceutical companies, and provide feasible paths for multinational pharmaceutical companies. In particular, at the research method level, through model construction and data analysis, these studies show the interaction and influence mechanism among complex variables, thus providing a methodological reference for understanding the possible complex relationship between internal and external influencing factors such as enterprise resources and enterprise capability, competitive strategy and enterprise performance of multinational pharmaceutical enterprises. Secondly, the in-depth discussion of different industries in these studies reveals the diversification and tolerance of competitive strategy choices of multinational companies with different industry characteristics, which also indicates that the uniqueness of the industry should be fully considered when studying multinational pharmaceutical companies, for example, it can be analyzed from the perspective of various internal and external corporate resources or corporate capabilities. From this, we can conclude that the above studies not only provide theoretical basis and practical reference for the study of the competitive strategy choice of multinational pharmaceutical companies and the influencing factors of corporate performance, but also bring a new perspective for the study of this field.

Such strategies are particularly salient in technology- and regulation-intensive industries (T. Teramae et al., 2020; W. Wang et al., 2022).

Internationalization of R&D activities has become a central strategy for innovation-driven competitiveness (Shen et al., 2004; Xu & Lan, 2022).

The internationalization of R&D has been widely examined in technology-intensive

industries, with scholars emphasizing knowledge spillovers, innovation performance, and institutional constraints (Choudhury, 2016; Cong & Xu, 2011; Yu et al., 2021; Jacob, 2020; Shen et al., 2004).

2.4.2 Future prospects of research on different topics

In the process of research, the author first studies the factors that influence scientific research and innovation on the competitive strategy of transnational enterprises. The research and development activities of transnational corporations have an important impact on global innovation. In particular, the establishment of R&D institutions in China plays a positive role in promoting the flow of technical knowledge and enhancing the host country's scientific and technological development and innovation ability. Most of the existing researches analyze the phenomenon of R&D internationalization of transnational corporations from multiple dimensions, such as knowledge chain, knowledge flow, industry determinants of R&D investment, and strategic upgrading, and reveal the influence of knowledge management, organizational structure, industry characteristics, and market demand on R&D activities.

Future research can be carried out from the following directions: First, the impact of digital transformation on the R&D internationalization strategy of multinational corporations is discussed in depth, and how digital transformation promotes the global decentralization of R&D activities and the construction of cooperation network is analyzed; Second, to conduct more in-depth research on the role and evolution of R&D institutions in China, especially in the context of the integration of global R&D network and host country innovation system; Third, strengthen systematic research on the antecedents and after-effects of R&D internationalization of Mnes, especially the long-term impact on innovation performance, productivity and international performance. These studies can not only help to understand the complexity and dynamics of TNCS 'R&D activities, but also provide strategic suggestions for host governments and enterprises.

The second is the research on the factors that influence the regulatory system on the competitive strategy of transnational enterprises. The research shows that the institutional distance, the complexity of the regulatory system and the improvement speed of the formal system have a significant impact on the innovation performance, investment efficiency and M&A completion rate of transnational enterprises. For example, institutional distance will affect the absorptive capacity and innovation performance of enterprises, institutional complexity can improve the innovation performance of enterprises, and the speed of improvement of formal institutions will affect the entrepreneurs' choice of re-entrepreneurship.

In addition, institutional distance and bilateral relations also affect the completion of cross-border mergers and acquisitions. These results indicate that multinational enterprises need to fully consider the regulatory system environment of the host country when formulating competitive strategy, and utilize relevant institutional resources to optimize their international business. Institutional factors are very complex, and the study of institutional distance is often closely related to a specific situation. Only when people have a deeper and thorough understanding of the connotation of institutional distance can the practical problems in a specific situation be better answered. A deeper exploration of institutional distance will help theory to have a more comprehensive and powerful understanding and explanation of practice.

The current understanding and exploration of institutional distance mostly focus on the institutional differences between countries or regions in a general sense, and pay little attention to the impact of different attributes and differences at different levels of institutions. Finally, most of the existing researches on institutional distance start from a static and single perspective, believing that the institutional distance faced by transnational enterprises is fixed and unchanged, ignoring the dynamic role of transnational enterprises themselves. In reality, the institutional distance faced by transnational enterprises is always in the process of dynamic evolution. The research of institutional distance can be conducted from multiple perspectives such as system and strategy, or from the perspective of dynamic evolution.

Third, regarding the influence factors of cooperative partnership on the competitive strategy of multinational enterprises, cooperative partnership plays an important role in the competitive strategy of multinational enterprises. Research shows that by integrating different resources and capabilities, partnerships help enterprises to carry out innovation and knowledge transfer in the context of globalization, thus enhancing their competitiveness. Specifically, partnerships take various forms, including but not limited to technology alliances, integration after reverse mergers and acquisitions, as well as the social responsibility and public relations behavior of multinational companies in China. The formation and maintenance of these relationships are affected by a variety of factors, such as the internal resources of an enterprise, the market environment, and the institutional environment (Barney, 1991).

The network relationships of Mnes, including those with local enterprises and international partners, are crucial to the construction of their dynamic capabilities. The study by Vroom (1964) explores the impact of home country networks and foreign enterprise networks on the transnational dynamic capabilities of Chinese firms. They found that the relationship embeddedness of foreign-funded enterprise networks positively affects the multinational dynamic capability of enterprises, especially in the three dimensions of opportunity perception,

resource acquisition and resource reconstruction. In addition, the embeddedness of local firms' networks can also positively regulate this influence. This indicates that the complexity and dynamics of network relations have a profound impact on the international competitive strategy of enterprises. Multinational technology alliance refers to a business arrangement between two or more enterprises based on technology cooperation, which can promote technological innovation and knowledge sharing. Vroom (1964) analyzed the motivations for TNCS to conduct technology alliances, which mainly include acquiring upstream and downstream technologies, adapting to network competition, and promoting research and development. At the same time, he also pointed out the possible positive and negative effects of technology alliance. The study provides an important perspective for understanding the strategic significance of transnational technology alliances.

Future research could further explore the specific management strategies and effects of partnerships, as well as how to deal with the challenges posed by globalization through partnerships. For example, research could focus on how to optimize resource allocation, enhance innovation capacity and enhance market competitiveness through partnerships. In addition, with the deepening of digital transformation, how partnerships in the context of digitalization affect the competitive strategy of enterprises is also a research direction worthy of attention.

The research on the influence factors of social responsibility fulfillment (CSR) on the competitive strategy of multinational enterprises

Social responsibility performance (CSR) plays an important role in the competitive strategy of multinational enterprises. Existing research shows that CSR not only affects the brand image and consumer perception of enterprises, but also directly and indirectly affects the performance and growth of enterprises. For example, by fulfilling economic, legal, ethical and philanthropic responsibilities, companies can enhance the awareness and closeness of employees in host countries, thereby enhancing their social performance and international image. In addition, CSR can also help companies respond effectively to international investment protection, especially in developing countries (Barney, 2000).

However, existing studies have also pointed out problems in CSR practice, such as insufficient understanding of CSR by enterprises, insufficient degree of localization, and insufficient combination of social responsibility and corporate economic behavior. These problems limit the potential of CSR in enhancing corporate competitiveness (Barney, 1991). Therefore, future research could explore how to better integrate corporate economic behavior and public diplomacy practices by improving CSR practices, and how to use new media and

technological innovation to enhance corporate CSR communication effectiveness. In addition, research can also focus on the impact of CSR in specific cultural, legal and market environments in different countries and regions, as well as the interaction of CSR with other corporate strategies (such as innovation, marketing strategies, etc.), so as to provide more comprehensive and targeted development strategies for enterprises (Barney, 2000).

Throughout the existing literature, scholars are mostly based on a single theoretical perspective, emphasizing the theoretical interpretation of the relationship between internationalization and CSR on the convergence of institutional pressure and legitimacy. However, as more and more enterprises in emerging economies participate in the international competition, it is difficult for the previous market strategies to fully support enterprises to achieve global or regional survival. As an emerging economy, Chinese enterprises have begun to resort to non-market strategies such as corporate social responsibility to achieve global institutional embedment under the influence of factors such as the absence of domestic institutions and the asymmetry of the global multi-institutional environment, as well as the dynamic integration of the global market environment and non-market environment (Barney, 2000). In other words, internationalization and corporate social responsibility, as the objective embodiment of market strategy and non-market strategy, not only show causality in a single direction, but also can play a " 1+1>2" synergistic effect in achieving overall value creation and legitimacy construction through strategic synergy.

Fifth, in all the literature on global integration and localization, the use of these two strategies in marketing is relatively common, but recently it has also appeared in other fields of management, such as human resource management, financial management, procurement, production, research and development (Barney, 2000). As mentioned above, there is no pure global integration strategy or localization strategy in reality, and these two strategies are not strictly relative concepts.

In the relationship between global integration and localization, whether transnational corporations emphasize global integration or localization needs to be determined according to the characteristics of the industrial field in which transnational corporations are located (Barney, 2000). On the basis of fully considering their own industrial characteristics and the requirements of local consumers, multinational companies should find a balance point between global integration and localization, otherwise it is impossible for the company to obtain global competitive advantage (Barney, 2000). A study by Kitchell (1995) found that a negative relationship can occur if a company fails to adapt to the local culture, and the same can occur if a company ADAPTS too much to the local culture.

In order to gain international competitive advantages, multinational companies must make the right choice and combination between global integration and localization, fully meet the special needs of different regions and countries for the company's products and services on the basis of ensuring the realization of the strategy of cost and scale economy of multinational companies, so as to achieve a strategic balance between global integration and localization (Barney, 2000). This is the global competitive advantage of multinational corporations, to ensure that the key to win in the global "game" lies in the global integration of the market, the need for standardization of organizational design, systems and procedures has also increased. Yet managers are also under pressure to adapt their organizations to local markets, rules, financial systems, sociopolitical and cultural systems. A balance between consistency and adaptability is absolutely essential to a company's success (Barney, 2000).

With the help of different tools, different scholars have made a detailed analysis of the international management strategy of transnational corporations. These transnational business activities reflect the pursuit of certain goals by transnational corporations in a certain environment. Just like domestic enterprises, multinational corporations also need to carefully analyze the environmental characteristics they face and the requirements for enterprises, formulate strategies according to internal and external conditions, and construct organizational structure and organizational relations to achieve the strategy. Therefore, it is necessary to deeply analyze the strategy and structure adopted and the relationship between them in the process of implementing transnational operation and obtaining competitive advantage (Barney, 2000). According to the studies of different scholars above, basically, different industrial structures have a huge impact on international management strategies. Therefore, the study will start with the industrial characteristics of multinational corporation groups, analyze the strategic choice in different industries, and the relationship between organizational structure and strategy.

Another prominent feature of international management strategy is to consider the diversity of cultures from a strategic perspective, which requires multinational corporations to consider the cultural characteristics of different countries when formulating strategies. The complete and absolute globalization is as rare as the extreme localization. On the contrary, the international management strategies of transnational corporations tend to move towards the direction of Glocalization. Of course, there are many kinds of international management strategies of multinational corporations. In addition to global integration and localization, there are also glocalization, natural global companies and stateless companies, etc. Especially, the differences in industry categories will lead to the natural differences in strategy. For example, the steel industry can be regarded as a traditional industry, the global market demand will not be much

different, so economies of scale will be the main driving force, which is why Ancelor and Mittal merged to become the world's largest. Other industries, such as fast-moving consumer goods (FMCG), require strong market segmentation and focus on local consumer preferences. P&G's multi-brand strategy is designed to meet the needs of different consumers.

In fact, some multinational corporations are a natural multinational corporation from the first day of their birth, and their business is global in nature from the very beginning. They may be positioned in a certain market segment, which takes some Internet companies as the most obvious example. Their international management strategies may not obey such an analytical framework, and the formation of their strategies needs to be further studied.

The empirical application of the research on the factors affecting the competitive strategy of multinational enterprises. The construction of empirical application and method is also an important field in the study of multinational enterprises' strategic choice. The credibility and enforceability of research results are directly affected by the reliability and operability of constructing research conclusions and the way in which appropriate models are constructed and empirical results interpreted (Barney, 2000). Future research should continue to explore more scientific and rigorous empirical methods to improve the overall level of corporate social responsibility research. Research in this direction will make corporate social responsibility research more scientific and rigorous, and enhance the explanatory power and practicability of research results.

Therefore, it can be seen that the competitive strategy of multinational enterprises and the influencing factors of corporate performance have received extensive attention in academic research and practical application. A large number of scholars have studied the influence of internal and external factors such as corporate resources and corporate capabilities on the competitive strategy and corporate performance of multinational enterprises from different perspectives, and put forward future research directions. In general, the existing research results on the competitive strategy and performance of transnational enterprises provide key theoretical basis and practical guidance for the implementation and evaluation of the competitive strategy of transnational enterprises in different dimensions as in Table 2.6.

Table 2.6 The future research directions proposed by scholars in different topics

Author	Subject	Future research trends
Shirom, A. (2003)	Conceptualization and measurement of vigor as a component of positive affect at work	Exploring vigor in diverse cultural contexts; integrating vigor with other well-being constructs; longitudinal studies linking vigor to organizational outcomes

Abhari et al. (2016)	Functional affordances of collaborative innovation networks (COINs) in social product development	Developing metrics for real-time affordance perception; studying AI-enhanced COINs; cross-industry comparisons of COINs' impact
Baik et al. (2021)	Influence of environmental multidimensionality on staff localization in multinational enterprises	Investigating digital transformation's role in localization; sector-specific localization strategies; examining policy influences across countries
Müller & Wenninger (2015)	Strategic adaptation in Big Pharma due to shifting market dynamics	Researching sustainable innovation models; analyzing regulatory impacts on strategy; assessing the role of emerging markets in pharmaceutical R&D
Cao & Song. (2018)	Analysis of job satisfaction and turnover intention among grassroots doctors using structural equation modeling	Exploring the impact of work-life balance; integrating burnout and engagement metrics; evaluating policy reforms on retention in rural healthcare

Innovation strategies in regulated sectors require balancing compliance and flexibility (Chan & Daim, 2018; Müller & Wenninger, 2015).

Innovation strategies in multinational enterprises are shaped not only by firm-level capabilities but also by regulatory environments and host-country institutional conditions (Chan & Daim, 2018; Corte, 2000; Dachs et al., 2023; Kodama, 2020).

2.4.3 Literature review and research direction of this paper

As for the relationship between the factors affecting the competitive strategy of multinational enterprises and firm performance, a large number of literatures support the positive correlation between various firm capabilities or environmental variables and firm competitive strategy. (2.3.1) Firstly, the impact of scientific research and innovation on the competitive strategy of multinational enterprises mainly lies in the innovation performance. Secondly, different modes and strategy combinations of regulatory systems will have an impact on the quality of regional development and the dual balance of internationalization and innovation performance of enterprises. (2.3.2) The role of partner establishment in transnational competitive strategy (2.3.3)

Good CSR practices are positively correlated with the economic performance of enterprises, that is, enterprises can improve their financial performance and long-term profitability through effective CSR practices. (2.3.4) The competitive advantages of multinational enterprises come from the integration of "global wisdom and local insight". Enterprises need to establish a dynamic strategy adjustment mechanism: use digital technology to achieve scale customization, balance central control and local autonomy through organizational innovation, find the optimal

solution between cultural sensitivity and operational efficiency, and the future competition will belong to those Glocalization enterprises that harness both global collaborative efficiency and local market. (2.3.5) Empirical research methods, such as model testing, correlation analysis and regression analysis, have been widely used in the study of factors affecting the competitive strategy of multinational enterprises. However, the current research in these fields has certain limitations: few studies take the whole multinational pharmaceutical industry into account, and there are insufficient studies on the factors affecting the strategy of multinational enterprises.

Therefore, based on the shortcomings of the above research, this study aims to solve the regulatory challenges of China's pharmaceutical industry: the strategy of multinational companies as the research topic, to explore the business strategy of multinational pharmaceutical companies and the factors that affect their internal and external environment. Specifically, in this paper, we first discussed, in addition, through empirical research, this study uses, this study has a comprehensive and informative understanding, and provides insights and references for the overall development of the industry.

These trends underscore the convergence of innovation, responsibility, and international competitiveness (Ciasullo et al., 2020; Zhang et al., 2024).

Digitalization and ESG integration increasingly shape future-oriented corporate strategies (Jiang et al., 2024; Motohashi & Zhu, 2024).

Recent studies highlight the growing importance of digital transformation and ESG considerations in shaping multinational enterprises' international competitiveness and strategic decision-making (Bi, 2024; Guan, 2021; Chen & Hao, 2024; Jiang et al., 2024; Shi, 2024).

2.5 Gaps in longitudinal and cross-industry strategy research

Even though a lot is known about MNCs in emerging markets, most studies don't follow them over time and fail to analyze different industries side by side. Because of such gaps, the use and building of strategic frameworks in China's healthcare sector are less effective and less flexible.

Many studies in strategic management look at data that is only current or collected a short time before. These studies often show connections between strategy and efficiency, but they rarely record how these connections develop with time. It is especially challenging in China's pharmaceutical area because the rules and policies are updated very often. Alterations in drug acceptance, how prices are set, and insurance coverage have appeared fast, which has compelled global companies to change their approaches regularly. Even though

firms are adapting to major changes, most research does not capture these shifts, so we have relatively little knowledge of strategic adaptation to these changes. Industries such as pharmaceuticals, where it takes a long time to complete product development and achieve profits, need a longitudinal approach the most. Pharmaceutical MNCs cannot adapt as rapidly as customer companies or technology firms, given that longer rules, extended clinical study times, and price fixation last for years. Without taking into account time, ongoing research might miss out on crucial stages of adapting, growing, and adjusting strategies that guarantee success in such contexts.

This thesis discusses ten years of strategies developed due to changes in the organization's structure. Since the study follows trends over time, important developments such as setting one drug price or introducing new incentives for drug companies can be spotted and assessed. It also represents more accurately how timing and decisions in regulated areas develop.

Besides the time frame issue, many of the current studies deal only with single industries, frequently looking at pharmaceuticals and not linking them to others in the market. As a result, the analysis gives plenty of information about pharmaceuticals but only allows for a limited look at what is typical for industries facing similar rules. Likewise, supervision and health standards from NMPA are expected for medical devices, biotechnology, and food safety industries. There is not much research comparing how companies in these sectors behave differently or in the same way.

Not comparing two industries may keep the theory from working in other settings and can cause researchers to focus too much on what makes one company unique. By using comparative analysis, we can separate specific sector issues from the wider issues caused by differing regulations or cultural demands. As a result, strategic models can offer a better explanation for the differences between sectors. In addition, it would help researchers and people working in multinational companies to recognize strategies that can be applied in different sectors and the difficulties each faces under guidelines.

The thesis hopes to fill the gap by concentrating on a comparison of the pharmaceutical and medical device industries. Even though pharmaceuticals are the main subject, the study draws comparisons with others to describe the special challenges and key strategies unique to this industry. As an illustration, while pharmaceutical businesses must obtain approval from regulators like medical device companies, the long, detailed, and delicate process of drug approvals presents special challenges that aren't as obvious for medical device businesses.

While there are broader differences, this study centers on the pharmaceutical sector

for a number of good reasons. Pharmaceuticals in China face some of the toughest rules in making sure medical products are safe, effective, and priced correctly. Because of this, MNEs in this region are ideal cases for studying theories of institutional distance, regulatory adaptation, and strategic localization.

Moreover, pharmaceutical products play an important part in China's development strategy. As a result of Healthy China 2030, public policy now emphasizes health innovation and access to drugs, which puts extra pressure on MNCs and makes dealing with regulations tougher (Shi & Qi, 2024). Consequently, large pharmaceutical companies deal with special risks to reputation, operations, and strategy, which should receive extra study. Also, the sector's extended research and development period and need for significant funding imply that faulty decisions can be very expensive and challenging to correct. Therefore, understanding the choices made and the plan for shifting and maintaining them matters a lot.

The thesis takes a close look at how pharmaceutical companies respond to new rules and challenges faced by the industry. The specific approach used here gives detailed insight, while what we find could help study other regulated industries as well. By including a comparison with other industries, this book highlights what is special about pharmaceutical regulations and places it in the wider context of government policy.

To ensure comprehensive coverage of the relevant theoretical and empirical literature while maintaining analytical focus, an extended literature background is provided in below (Chan & Daim, 2018; Jamali et al., 2019; Matilde et al., 2020; Almasa et al., 2020; Peng, 2005). This appendix provides an extended and structured background review of major research streams relevant to multinational corporations operating in highly regulated pharmaceutical and emerging market contexts. The appendix broadens the theoretical and empirical foundations underpinning the main text while preserving the analytical focus of the core chapters.

2.5.1 Corporate social responsibility and sustainability

Research on corporate social responsibility (CSR) has evolved from normative discussions of ethical obligations to strategic analyses emphasizing legitimacy, stakeholder engagement, and long-term value creation. Early CSR frameworks conceptualized CSR as a multidimensional construct encompassing economic, legal, ethical, and philanthropic responsibilities, while later research integrated sustainability and ESG perspectives. In multinational contexts, CSR increasingly functions as a governance and adaptation mechanism in response to institutional complexity and stakeholder pressures, particularly in emerging markets (Jamali et al., 2019;

Khan et al., 2020; Milanesi et al., 2020; T. Teramae et al., 2020).

2.5.2 Institutional theory and regulatory environments

Institutional theory offers a foundational lens for examining organizational responses to regulatory, normative, and cognitive pressures. Seminal contributions emphasize isomorphism, legitimacy seeking, and institutional constraints as central mechanisms shaping firm behavior. In highly regulated industries such as pharmaceuticals, institutional forces are particularly salient, requiring firms to reconcile global strategic objectives with local regulatory frameworks. Empirical research further demonstrates that institutional distance and regulatory uncertainty shape market entry choices and post-entry adaptation strategies of multinational enterprises (DiMaggio & Powell, 1991; Almasa et al., 2020; North, 1990; Peng, 2005; Scott, 2001).

2.5.3 Localization strategies and subsidiary roles

Localization has been consistently identified as a critical strategic response enabling multinational corporations to achieve legitimacy and operational effectiveness in host-country environments. Research suggests that localization extends beyond product adaptation to encompass managerial practices, organizational structures, and stakeholder interactions. Subsidiary-level studies reveal heterogeneous subsidiary roles shaped by degrees of strategic autonomy, knowledge creation capabilities, and host-country embeddedness, underscoring the importance of balancing global integration with local responsiveness (Buckley & Casson, 1976; Lee et al., 2020; Luo & Zhang, 2021; Ma et al., 2022; Peng, 2005).

2.5.4 Innovation, R&D internationalization, and strategy

Innovation and the internationalization of R&D activities constitute central pillars of competitiveness in knowledge-intensive and regulation-driven industries. Prior research documents a shift toward globally distributed R&D networks aimed at accessing diverse knowledge bases and addressing local market needs. In pharmaceutical sectors, innovation strategies are further constrained by stringent regulatory environments, necessitating organizational flexibility and compliance-oriented innovation processes. More recent studies highlight the growing importance of digital transformation and ESG integration in shaping future-oriented corporate strategies (Chan & Daim, 2018; Jiang et al., 2024; Müller & Wenninger, 2015; Shen et al., 2004; F. Teramae et al., 2020).

[This page is deliberately left blank.]

Chapter 3: Research Hypotheses,Variables and Model Design

3.1 Description of research objectives

This research evaluates the challenges faced by large multinational pharmaceutical companies (commonly referred to as "Big Pharma") in maintaining a competitive edge in the Chinese market. The study particularly evaluates the competitive strategies employed by the Chinese branches of these multinational corporations. Over the last ten years, significant shifts in the Chinese business environment have eroded the traditional advantages held by large foreign pharmaceutical companies, hindering their ability to acclimate to the evolving market environment and demands.

To address this, the research will carry out an in-depth analysis of existing R&D models in the Chinese pharmaceutical industry and assess the R&D capacities of multinational companies' subsidiaries in China, with the objective of identifying strategies for enhancing R&D effectiveness. In addition, the research will explore effective management of cultural and operational differences between headquarters and local subsidiaries in a globalization.

Besides, as shown in Table 3.1, this study will appraise the practices and obstacles encountered by pharmaceutical companies in fulfilling their public health obligations, corporate social responsibilities, and sustainable development. Utilizing qualitative research methods, this study aims to offer strategic recommendations to pharmaceutical companies for adapting and optimizing their business strategies in China to navigate the complex and fluid market environment. It also seeks to offer policymakers with insights to inform decision-making that promotes the health and sustainable advancement of the industry as a whole.

Table 3.1 Specific objectives of the study include

Key Research Question	**How MNCs can navigate these changes to achieve market leadership?**	
Main issues	**Research questions**	**Research Objectives**
Navigating Changes in R&D Effectiveness for Market Leadership	How can multinational corporations (MNCs) in the Chinese pharmaceutical industry enhance their R&D effectiveness to achieve market leadership amidst evolving regulatory and market dynamics?	Analyze R&D effectiveness in the Chinese pharmaceutical industry.

Key Research Question	**How MNCs can navigate these changes to achieve market leadership?**	
Strategies for MNCs' Chinese Subsidiaries to Attain Market Leadership	What strategies can multinational corporations (MNCs)' Chinese subsidiaries adopt in the pharmaceutical sector to achieve market leadership, considering local competitive pressures and regulatory challenges?	Appraise R&D strengths of MNCs' Chinese subsidiaries.
Enhancing R&D Investment Efficiency for Market Leadership	How can MNCs optimize their R&D investments in the Chinese pharmaceutical industry to achieve market leadership, balancing innovation with regulatory compliance and market demands?	Explore strategies for enhancing R&D investment efficiency.
Integrating Social Responsibility for Competitive Market Leadership	How do MNCs integrate social responsibility and sustainable development into their corporate strategies in China's pharmaceutical market to achieve competitive market leadership?	Assess social responsibility and sustainable development efforts of Chinese pharmaceutical companies.
Managing Cultural Influences for MNC Subsidiary Leadership in China	What cultural factors influence the management of multinational corporations' subsidiaries in China's pharmaceutical industry, and how can MNCs effectively manage these factors to achieve market leadership?	Analyze cultural impacts on MNC subsidiary management and propose management strategies.
Responding to Evolving Public Health Responsibilities for Market Leadership	How do evolving public health responsibilities in China impact the strategic decisions and operational strategies of multinational pharmaceutical corporations aiming for market leadership?	Explore implications of China's evolving public health responsibilities on the pharmaceutical industry.
Aligning HQ-Subsidiary Strategies for Market Leadership in China	What strategies and approaches are effective in aligning the strategies between headquarters and subsidiaries of multinational pharmaceutical corporations in China to achieve market leadership?	Study management approaches for handling HQ-subisidiary differences in MNCs operating in China.

3.1.1 Impact of R&D input on organizational performance

Under the background of economic globalization and rapid technological development, R&D input has become a key index to measure an enterprise's technical strength and innovation ability. Chen (2019) reveals the correlation between technology strategy and corporate performance by comparing the differences in technology strategy between transnational corporations in developed and developing countries. Their research shows that transnational corporations in developed countries maintain their competitive advantage through technology leadership, control and transfer, while enterprises in developing countries improve their performance through technology learning, government support and latecomer advantage. In addition, Wu (1993) further confirmed the inverse U-shaped nonlinear relationship between R&D input and firm performance, providing an important perspective on R&D input

optimization and performance maximization. Wu (1993) used a dynamic panel threshold model to study the relationship between R&D intensity and firm performance in the pharmaceutical manufacturing industry, and found that the influence of R&D intensity on firm performance presents nonlinear characteristics. Wu (1993) studied the relationship between R&D input and enterprise performance of high-tech enterprises in Zhongguancun, and found that government support has a certain positive impact on profitability and development ability of enterprises. This indicates that a good external support and policy environment can improve the innovation activities and performance of enterprises. The study of Chinese Ministry of Health (2017) further confirmed that R&D expenditure in the pharmaceutical industry has a lagged positive impact on firm performance, emphasizing the importance of long-term R&D investment.

Therefore, in this research, we assume that R&D investment plays a positive role in improving the quality and efficiency of organizational performance.

Hypothesis 1: When R&D investment of multinational pharmaceutical enterprises continues to increase, corporate performance will also improve.

3.1.2 The impact of organizational process optimization on efficiency and customer satisfaction

Customer satisfaction directly reflects the business level and service quality of the enterprise, which is the key to the survival and development of the organization and even the maintenance of competitive advantage, while the organizational process optimization can directly affect the customer's purchasing experience and satisfaction. Although the organizational process optimization has brought about the improvement of efficiency and the increase of customer satisfaction, it still faces many challenges in actual operation. These challenges include the adaptability of technological updates, employee acceptance of change, and possible resistance during the change process. In his research, Clement (2019) analyzed in detail how multinational companies optimize financial processes through the construction of financial shared service centers, and pointed out possible challenges in the implementation process, such as technology update, staff training and process redesign. In addition, Clement (2019) also highlighted the challenges in the process of organizational process optimization when studying the global recruitment management of multinational corporations. Transnational corporations are the protagonists of the division of labor in the global value chain. Optimizing various process elements in global layout, establishing global production and marketing network, reorganizing organizational management structure and optimizing product pipeline have gradually become an important reform orientation for enterprises to improve competitiveness and innovation

efficiency.

Therefore, in this research, we assume that multinational pharmaceutical enterprises take user demand as the orientation, and establish process optimization covering demand analysis, design, implementation, and evaluation feedback, so as to improve the operation efficiency and market competitiveness of enterprises. Process management can help enterprises quickly adapt to market changes and seize market opportunities. Through continuous optimization of process management, enterprises can improve product quality, reduce costs, improve customer satisfaction, and thus occupy a favorable position in the competition.

Hypothesis 2: When multinational pharmaceutical companies continuously optimize their organizationalprocesses, eficiency and customer satisfaction will also increase.

3.1.3 Contribution of technology adoption to organizational competitiveness

In the context of globalization, technology adoption by multinational pharmaceutical companies has become a key factor in enhancing competitiveness. The introduction and application of technology can not only improve production efficiency, but also speed up the research and development process of new drugs, thus gaining an advantage in the fierce international competition. A study by Buckley and Casson (1976) focused on the role of digital technologies such as big data and cloud computing in enhancing innovation efficiency of enterprises and reducing R&D costs. The research of Buckley and Casson (1976) focused on the technological advantages and technological monopolies of multinational companies, and pointed out that Chinese companies need to enhance their technological innovation capability by increasing R&D investment, technology introduction and establishing strategic alliances with leading technology companies. Buckley and Casson (1976) explored the relationship between R&D input, technological innovation output and international competitiveness of Chinese high-tech enterprises through an empirical analysis. They found that although R&D input has a certain promoting effect on technological innovation output, technological innovation output is the direct factor to enhance the international competitiveness of enterprises. In addition, Buckley and Casson’s (1976) study further explored the relationship between digital finance, technological innovation and firm competitiveness, pointing out that the development of digital finance can enhance firm competitiveness by promoting firm technological innovation.

In view of the above mentioned content, it can be found that technology adoption is an important factor affecting the competitiveness of enterprises. Technology and the core competitiveness of enterprises coexist, and the innovation and adoption of technology can not

only enhance the technical competitiveness of enterprises, but also strengthen the market competitiveness of enterprises by improving the quality of products and services, innovation ability and market response speed (Barney, 2000). In addition, it is also possible to study the differences in technology adoption strategies of multinational pharmaceutical companies under different national cultures, policy environments and market conditions and their impacts on corporate competitiveness. This will help to provide multinational pharmaceutical companies with more targeted management strategies and innovation paths.

Hypothesis 3: When the technology adoption of multinational pharmaceutical companies continues to improve, organizational competitiveness will also increase.

3.1.4 The influence of Cultural adaptation on organizational globalization strategy

DiMaggio and Powell (1991) focused on the issue ofCultural adaptation in international joint ventures (IJVs). Through qualitative research methods, they explored how transnational corporations and local enterprises adapt to cultural differences through the co-evolution of strategies in an uncertain environment. In addition, from the perspective of cultural intimacy, analyzed how local enterprises narrow the technological gap with multinational enterprises through the use of cultural intimacy, and promoted the improvement of local enterprises' technological capabilities. These studies show thatCultural adaptation is not only a necessary adaptation strategy, but also an important way for enterprises to gain competitive advantages. DiMaggio and Powell’s (1991) research focuses on the selection of cross-cultural integration models for Mnes in China, providing an analytical framework to understand how Mnes in China optimize their globalization strategies through cross-cultural integration. In order to overcome the differences and conflicts among different cultures, multinational companies operating in China need to carry out cross-cultural integration in order to better adapt to the cultural environment of the host country.

Therefore, in this research, we assume that multinational pharmaceutical companies can integrate cultural conflicts and implement effective cross-cultural management strategies to lay the foundation for their globalization strategies.

Hypothesis 4: Cultural adaptation plays a key role in the implementation of global strategies by multinationalpharmaceutical companies.

3.1.5 Impact of CSR practices on brand image

Tempest (2010) studied how green marketing behaviors of multinational enterprises affect the

green consumption intention of Chinese consumers, and found that CSR practices enhance consumers' purchase intention by improving corporate image. These studies show that CSR practices are positively correlated with brand image and can significantly affect consumers' perceptions and attitudes.

He studied MNC's efforts to promote CSR among its local suppliers by establishing positive relationship strategies. Through the concept of social capital, the study showed that CSR practices not only help to enhance a company's image, but also strengthen its ties with the local community, thereby enhancing its brand image. While in another study, Vroom (1964) explored the relationship between the CSR of MNCs and the environmental footprint of its foreign subsidiaries, pointing out the importance of CSR in corporate operations and highlighting the role of CSR in shaping corporate image.

We can see that the impact of corporate social responsibility (CSR) practices of multinational pharmaceutical companies on brand image is a multi-dimensional and interdisciplinary research field. Existing studies have shown that CSR practices help improve a company's brand image and enhance consumer trust and loyalty by enhancing its CSR performance. For example, CSR activities in areas such as environmental protection, public health, employee well-being and community development can significantly enhance a company's brand image. In addition, effective communication and disclosure of CSR activities are also key factors in building a positive brand image.

Therefore, we assume that multinational pharmaceutical companies put corporate social responsibility at the core of their strategy, which will not only bring positive impact to society, but also drive the improvement of brand value.

Hypothesis 5: Multinational pharmaceutical companies actively practice corporate social responsibility, and their brand image will also be upgraded.

3.1.6 The role of management difference handling in cultivating organizational harmony and decision-making efficiency

North (1990) focused on the impact of institutional distance on the performance of overseas subsidiaries of Chinese multinational enterprises. Through micro-level data analysis, they found that the institutional distance between the host country and the home country has a significant negative impact on the performance of subsidiaries, especially in the overseas subsidiaries of non-state-owned enterprises, those located in developed countries and those with a far cultural distance from the host country. This study shows the role of management differences in the cultivation of organizational harmony and decision efficiency, that is,

managers need to effectively manage these differences to ensure organizational harmony and decision efficiency. Vroom (1964) studied the strategic choice of subsidiaries of multinational enterprises and its impact on the strategic choice of parent and subsidiary companies through an empirical analysis of Korean funded enterprises in China, indicating that managers need to choose appropriate decision-making modes to improve decision-making efficiency when facing the different demands within and outside the organization. North (1990) further analyzed the evolution mechanism of the role of overseas subsidiaries of Chinese multinational enterprises, especially from the perspective of knowledge resource facilitation. Their research is helpful to understand how overseas subsidiaries improve their role in the organization and decision-making efficiency through role evolution under different management differences.

In their review study, Peng (2005) especially emphasized the new progress in the governance of overseas subsidiaries of Mnes, including the discussion on the relationship between management differences and organizational culture, and how to strengthen this relationship through network governance and other ways to improve organizational harmony and decision-making efficiency.

Therefore, in this paper, we hypothesize that effective management differences handling of multinational pharmaceutical enterprises will help enterprises to achieve organizational harmony and improve decision-making efficiency in a cross-cultural and cross-institutional environment.

Hypothesis 6: Management difference handling of multinational pharmaceutical companies has a positive effect on organizational harmony and decision-making efficiency.

3.2 Description of variables

As shown in Table 3.2, this study considers independent variables as those factors that may affect or account for changes observed in the dependent variable (i.e., the study's outcome). The following section details the independent variables employed in this study and their respective operational definitions.

Table 3.2 Variables

Independent Variables	Dependent variables	Controlled variable
Research and Development Investment (RDI)	R&D Output Efficiency (RDE)	Enterprise Size (CS)
Organizational Process Optimization (OPO)	Market Response Speed (MRS)	Market Structure (MS)
Technology Introduction (TI)	Corporate Reputation (CR)	Macroeconomic Conditions (MEC)
Cultural Adaptation (CA)	Employee Satisfaction (ES)	Corporate Culture (CC)
Social Responsibility	Corporate Sustainability	Research and Development

		Experience (RDE)
Fulfillment (CSR)	Indicators (CSI)	
Management Discrepancy Handling (MDM)		Regulatory Policy (RP)

3.2.1 Description of independent variables

Independent variables, established by the researchers, predict or explain changes in the dependent variable. This study focuses on the following independent variables: research and development investment (RDI), organizational process optimization (OPO), technology introduction (TI), cultural adaptation (CA), social responsibility fulfilment (CSR) and management difference handling (MDM).

Operationalized definitions

R&D Investment (RDI)

Definition: R&D investment comprises the financial and material resources a company allocates to the creation of novel products, services, or processes.

Operationalization: This study will operationalize R&D investment as the proportion of R&D expenditures to total operating revenue, as disclosed in companies' annual reports. This comprises both direct R&D expenses and indirect support costs.

Organizational Process Optimization (OPO)

Definition: Organizational process optimization refers to the systematic review and enhancement of a company's internal processes to enhance efficiency and effectiveness.

Operationalization: This study will measure the extent of process optimization through an analysis of corporate process documentation and interviews with management. Evaluation metrics include the implementation of process facilitating measures, the level of advancement in the project management system, and employee adaptability to process changes.

Technology Introduction (TI)

Definition: Technology introduction is the mechanism by which an enterprise acquires external technologies and integrates them into product or service innovations.

Operationalization: This study will measure technology introduction through indicators such as the number of technology collaboration, the number of patents introduced, and the degree of international representation in the company's R&D team.

Social Responsibility Fulfillment (CSR)

Definition: Social responsibility fulfillment constitutes the proactive undertaking of economic, legal, ethical, and voluntary responsibilities by enterprises in their business operations.

Operationalization: This study will evaluate social responsibility fulfillment through corporate social responsibility reports, contributions to public health projects, implementation of environmental protection measures, and the attainment of social responsibility-related accolades and certifications.

Management Discrepancy Handling (MDH)

Definition: Management Discrepancy Handling (MDH) is the process of reconciling and integrating changes in management practices and strategies across MNCs subsidiaries operating in diverse countries and regions.

Operationalization: This study will measure Management Discrepancy Handling by analyzing management systems and processes in the MNC. It will assess the regularity of communication, the effectiveness of communication channels, and the consistency of decision-making between subsidiaries and headquarters.

3.2.2 Description of the dependent variable

This study evaluates how independent variables affect the dependent variable, which represents the central phenomenon for analysis. In research on R&D efficiency, CSR fulfillment, and cross-cultural management in the pharmaceutical industry, dependent variables might involve, but are not restricted to, R&D output efficiency, market responsiveness, corporate reputation, employee satisfaction, and corporate sustainability indicators.

Scale of the Dependent Variable and its Relationship to the Research Objectives R&D Output Efficiency (RDE)

Scale: RDE can be measured through metrics such as the number of new drugs launched, R&D cycle duration, and return on R&D expenditures. These metrics reflect the capacity and swiftness with which R&D investments transform into commercially viable products.

Relationship: A primary objective of this study is to analyze the prevailing R&D model and its effectiveness in the Chinese pharmaceutical industry. R&D output efficiency is a critical indicator for evaluating the R&D model's effectiveness, directly reflecting the output ratio of R&D investment.

Market Response Speed (MRS)

Scale: Market responsiveness can be evaluated through indicators such as time-to-market, market share growth rate, and the agility in addressing customer feedback. These indicators illustrate a company's sensitivity and adaptability to market fluctuations.

Relationship: Market responsiveness is associated with the R&D capabilities of MNCs Chinese subsidiaries, as outlined in the research objectives. Enhanced market responsiveness often signifies a company's ability to leverage its R&D strengths promptly to satisfy market demands.

Corporate Reputation (CR)

These indicators measure the public's perception and evaluation of the enterprise's overall performance. Corporate social responsibility (CSR) fulfillment directly affects a company's reputation. As this study aims to assess pharmaceutical companies' performance in fulfilling their social responsibilities, corporate reputation represents a crucial dependent variable reflecting the effectiveness of CSR activities.

Employee Satisfaction (ES)

Scale: Employee satisfaction is typically measured through employee questionnaires, including multiple dimensions such as work environment satisfaction, management satisfaction, and career development satisfaction.

Relationship: Employee satisfaction is closely associated with cultural adaptation and the management of differences. The cross-cultural management strategies and difference-handling approaches mentioned in the research objectives significantly affect employee job satisfaction.

Corporate Sustainability Indicators (CSI)

Scale: Corporate sustainability indicators can be measured by analyzing the implementation of environmental protection measures, assessing the effect of social responsibility programs, and evaluating the balance between economic and environmental benefits.

Relationship: Corporate sustainability indicators are closely tied to CSR fulfillment and represent a vital dependent variable when evaluating a company's long-term development potential. Considering the study's emphasis on pharmaceutical companies' performance in promoting sustainable development, corporate sustainability indicators are essential for measuring the extent to which this objective has been realized (Anonymous, 2020).

When designing and selecting scales, the researcher must ensure their validity and reliability. Validity refers to the scale's ability to accurately measure the intended concepts, while reliability refers to its ability to yield consistent results upon repetition. In addition, the chosen scale should align closely with the research objectives and effectively test the research hypotheses.

To ensure scientific validity, researchers may employ previously verified scales or develop new ones according to existing literature. Pilot testing is often necessary before implementing a scale to confirm its applicability in a specific research setting.

Through an accurate definition of dependent variables and rigorous scale design, this study will effectively measure the Chinese pharmaceutical industry's performance in R&D models, CSR fulfillment, and cross-cultural management, offering reliable data to support the achievement of the research objectives.

3.2.3 Description of control variables

In scientific research, maintaining the consistency of a control variable in experimental and observational studies is essential to ensure the accuracy of the findings. The role of these variables is to reduce or eliminate the effect of extraneous factors on the study's outcomes, thereby allowing for a more accurate assessment of the independent variables' effects on the dependent variable. In studies in the pharmaceutical industry, control variables might consist of firm size, market structure, and prevailing macroeconomic conditions. Outlined below is a detailed explanation of the control variables employed in this study and their specific functions:

Description and Role of Control Variables Enterprise Size (CS)

Description: Enterprise size is typically measured by metrics such as employee count, total assets, or annual revenue. The size of a firm can influence R&D resource allocation, market influence, and the organizational structure of its internal management.

Role: In this study, firm size functions as a control variable to guarantee that the results are not skewed by changes in company scale. For instance, larger enterprises may exhibit higher R&D output due to greater resource availability, but this does not signify superior R&D efficiency compared to smaller firms.

Market Structure (MS)

Description: Market structure pertains to the level of competition in a given market. It can be evaluated utilizing indicators such as market concentration and barriers to entry.

Role: Incorporating market structure as a control variable helps to isolate the effect of the competitive market environment on the study's findings. In highly concentrated markets, firms may not be compelled to maintain a high degree of R&D output efficiency to sustain their market position.

Macroeconomic Conditions (MEC)

Description: Macroeconomic conditions consist of macroeconomic indicators such as GDP growth rates, inflation rates, and overall industry investment levels.

Role: Macroeconomic conditions are utilized as control variables to prevent distortions of the research findings by fluctuations in economic cycles. Economic recessions or periods of rapid growth can affect firms' R&D investments and overall market performance.

Corporate Culture (CC)

Description: Corporate culture reflects the values, behavioral norms, and general work environment in an organization.

Role: By controlling for corporate culture, researchers can better understand how a firm's internal factors influence employee productivity and innovation. Accordingly, this allows for a more optimized analysis of the independent variables' effects on the dependent variable by minimizing the interference of these internal factors.

Research and Development Experience (RDE)

Description: R&D experience can be measured by the number of years a company has been in operation, the average tenure of its R&D team, or the number of successful R&D in its history.

Role: Controlling for R&D experience helps to neutralize the effect of varying levels of experience accumulated by different firms in their R&D efforts. While seasoned R&D teams might demonstrate greater efficiency, this is not an independent variable effect under consideration in this particular study.

Regulatory Policy (RP)

Description: Regulatory policies include government regulatory policies, R&D subsidies, and tax incentives for the pharmaceutical industry.

When conducting empirical analyses, researchers commonly integrate these control variables into their regression models. This practice enhances the model's explanatory power and ensures the robustness of the findings. The selection of control variables should be guided by established theory and prior research to guarantee their relevance to the research objectives and hypotheses.

In addition, it is critical to be cognizant of potential multicollinearity issues when selecting control variables. Excessive correlation between control variables should be avoided, as it can compromise the stability of the regression model and the accuracy of parameter estimation.

Control variables play a critical role in research. They enable researchers to isolate the effects of independent variables on the dependent variable and strengthen the internal validity of the study. By designing and implementing control variables, esearchers can interpret findings with greater confidence and offer valuable, practical insights.

3.2.4 Variable Operationalization

Good empirical research requires that core ideas are well put together and that key variables are clearly described and assessed. This research analyzes how pharmaceutical MNCs in China react to challenges in their business environment by looking at culture adaptation, management structures, social responsibility, the selection of local strategies, response to regulations, and

approach to innovation. In particular, constructs relating to changing customs and management differences have often been viewed with uncertainty in previous studies and are very complex. Concept clarity and reliance on facts were achieved in this research using tested models and practical ways to measure each variable.

For this study, cultural adaptation in an MNC means how much the company changes its way of working, running the business, and making decisions to fit local cultural practices. For companies working in China, the main obstacle to success often comes from culture. To apply this construct, the study employs a version of Hofstede's framework, which has been altered for its purposes. Cultural adaptation was evaluated by valuing authority in the company, stressing teamwork and group decisions, and assessing the ability of the firm to form lasting relationships with those in the local community. Data was obtained by distributing a structured questionnaire to managers and employees working at subsidiary offices in China. Those taking part were asked to judge how their activities at the local level fit with cultural values. The aggregated results gave each company a score for cultural adaptation. After that, a relationship was examined between this score and outcomes, including market entry success, employee satisfaction, and stakeholder trust.

How strategies are managed at headquarters and subsidiaries is another major element we consider in this study. Chinese businesses with strong centralized control may struggle to respond well to sudden and fast policy changes. The research looks into three areas of headquarter-subsidiary relations: decision-making autonomy, regular cross-border exchange, and how often cultural and managerial differences cause problems. Using the same questions, the survey invited people to express their views on internal reporting systems, corporate strategy agreements, and possible work challenges. When the index showed higher scores, there was a bigger difference between what is expected in the head office and what happens locally; it was then used to examine its effect on important results such as following regulations and speed of decision-making within the company.

Besides these two complex concepts, the study also assesses several other factors important for MNC performance in China's pharmaceutical industry. CSR was evaluated by examining how noticeable, how often, and how effective health outreach, education, and sustainability programs were. To assess the localization variable, I examined how many local members occupied leadership positions, the level of involvement of regional suppliers, and the degree to which marketing efforts were changed for local customers. Regulatory adaptability was tested by seeing if the firm could comply with new drug approval procedures and form good relationships with regulatory bodies. In addition, to understand innovation orientation, I

studied the R&D outlay in China, the appearance of joint innovation projects undertaken with local partners, and the launch of new drugs customized to meet Chinese needs.

All multi-item scales were evaluated for internal consistency using Cronbach's alpha to check that these variables were reliable. The final data did not use those products that did not have a reliable enough rating. Ensuring that chosen surveys are tested thoroughly and that the right measurement framework is used ensures the developed variables maintain theoretical and practical strength. The convincing strength of the statistical analysis is improved, and the tests done in the following chapter will be better explained.

3.3 Model construction

Based on the above theoretical analysis, this research puts forward six hypotheses concerning R&D investment and organizational performance, organizational process optimization and efficiency and customer satisfaction, contribution of technology acquisition to organizational competitiveness, role of Cultural adaptation in organizational globalization strategy, influence of CSR practice on brand image, and influence of CSR practice on brand image. The following Table 3.3 is the empirical model of this study, on which all assumptions are marked:

Table 3.3 Hypothesis model of factors influencing the competitive strategy of multinational corporations

Strategic Variable	**Institutional Factor (Moderator/Mediator)**	**Expected Outcome**	**Hypothesis**
R&D Investment	(Direct relationship)	Organizational performance	**H1**: R&D investment positively influences organizational performance.
Organizational Process Optimization	(Direct relationship)	Efficiency and customer satisfaction	**H2**: Organizational process improvements enhance efficiency and customer satisfaction
Technology Adoption	— (Direct relationship)	Organizational competitiveness	**H3**: Technology adoption positively contributes to organizational competitiveness.
Cultural Adaptation	**Policy Uncertainty** (Moderator)	Effectiveness of globalization strategies	**H4**: Cultural adaptation positivelyaffects globalization strategy; this effect is moderated by policy uncertainty.
Corporate Social Responsibility (CSR)	**Normative Institutional Distance** (Moderator)	Brand image and customer loyalty	**H5**: CSR positively impacts brand image and loyalty; this effect is moderated by normative distance.

Management Difference Processing	**Enforcement Variability** (Moderator)	Internal decision-making and communication efficiency	**H6**: Effective management of internal differences improves decision-making efficiency; moderated by enforcement variability.
Regulatory Adaptability	**Regulatory Trust** (Mediator)	Competitive advantage	**H7**: Regulatory adaptability enhances competitive advantage through increased egulatory trust.
Localization Strategy	**Policy Uncertainty** (Moderator)	Market entry success	**H8**: Localization improves market entry success; this effect is moderated by policy uncertainty.

3.4 Integration of prototype presentation with research objectives

3.4.1 Description of prototype research tool

Questionnaires are fundamental instruments in quantitative research, enabling researchers to collect datasets for testing specific hypotheses or research objectives. The design of such a questionnaire necessitates an approach, ensuring each question aligns directly with the research objectives and facilitates efficient data collection for the following analysis.

This study employed a constructed prototype questionnaire to ensure the in-depth exploration of its research objectives. The questionnaire comprises multiple sections, each corresponding to a unique research objective, and is designed to evaluate the effect of independent variables such as R&D investment, organizational process optimization, technology adoption, cultural adaptation, social responsibility fulfillment, and the management of differences on organizational performance.

The questionnaire begins by assessing the scale and effectiveness of R&D investments through a series of quantitative questions. These questions aim to quantify the relationship between R&D expenditure and key indicators such as new product development, market share expansion, and enhanced innovation capabilities. The following section, focusing on organizational process optimization, explores how process improvements impact organizational efficiency and customer satisfaction by evaluating the frequency and depth of such improvements.

The section on technology adoption evaluates the contribution of new technologies to an

organization's competitiveness through analyzing recently implemented the types of technologies, the frequency of technology adoption, and the extent of staff training. The cultural adaptability section evaluates an organization's capacity to adjust to the evolving global environment by evaluating the degree of diversity in the organization and the effectiveness of cross-cultural communication strategies.

In addition, the section on social responsibility fulfillment evaluates corporate activities related to environmental protection, community engagement, and fair-trades practices to evaluate the effect of corporate social responsibility on brand image and customer loyalty. Finally, the section on managing differences assesses the effect of managing internal disagreements on organizational harmony and decision-making effectiveness through a series of questions about conflict resolution mechanisms, decision-making processes, and the effectiveness of internal communication channels.

Each section of the questionnaire consists of a series of close-ended questions employing a 1-10 rating scale to facilitate quantitative analysis. Such scales not only streamline the data collection process but also enhance the reliability and validity of the analysis by standardizing responses. In addition, the questionnaire incorporates open-ended questions to glean more in-depth insights and qualitative data, which will experience further content analysis utilizing specialized software.

To ensure the questionnaire's validity and reliability, it will be pre-tested before its full implementation, and any necessary adjustments will be made based on the feedback received. This pre-testing phase will not only identify and rectify potential issues but also guarantee that the questions in the questionnaire are clear, easily understood, and accurately measure the intended constructs.

In summary, the prototype questionnaire developed for this study constitutes a multi-faceted, multi-dimensional instrument designed to collect data on the factors influencing organizational performance through accurately formulated questions. This approach allows the researcher to ensure that each research objective is thoroughly analyzed, thus offering a robust dataset for hypothesis testing.

3.4.2 Correspondence between research tools and research objectives

When conducting quantitative research, the design of the research instrument (e.g., questionnaire) must be closely associated with the research objectives. This alignment ensures that the collected data can effectively address the research questions and test the hypotheses.

3.4.3 Correspondence between research objectives and questionnaire design

Research Objective 1: Assessing the Effect of R&D Investment on Organizational Performance

To evaluate the correlation between R&D investment and organizational performance, the questionnaire incorporated a series of questions designed to quantify R&D expenditure.

These questions aimed to collect data on the proportion of R&D expenditure, the success rate of R&D projects, and the contribution of these projects to new product development and market share. Through analyzing the responses to these questions, the researcher sought to establish a statistical correlation between R&D investment and organizational performance.

Research Objective 2: Exploring the Effect of Organizational Process Optimization on Efficiency and Customer Satisfaction

The questions in the questionnaire are structured to evaluate the extent and frequency of process optimization in the organization and how these optimizations affect the organization's operational efficiency and customer satisfaction. These questions typically focus on specific instances of process improvements and appraise how these improvements have impacted employee workflow and customer experience.

Research Objective 3: Analyzing the Contribution of Technology Adoption to Organizational Competitiveness

The questionnaire was designed with a series of questions to measure the organization's adoption of new technologies. This comprises the type of technology adopted, the frequency of adoption, staff training activities, and how these technologies have enabled the organization to enhance the quality and competitiveness of its products or services.

Research Objective 4: Evaluating the Role of Cultural Adaptation in Organizational Globalization Strategies

The questionnaire evaluated the organization's cultural adaptability through a series of questions pertaining to the diversity of employees' cultural backgrounds, the frequency of cross-cultural communication and cooperation, and the organization's capacity to adapt to and accommodate different cultures.

Research Objective 5: Analyzing the Effect of CSR Practices on Brand Image

The questionnaire includes an assessment of corporate CSR activities, and specific activities related to environmental protection, community involvement, and fair trade practices. In addition, it explores how these activities affect consumer perceptions of and loyalty to the brand.

Research Objective 6: Exploring the Role of Management Discrepancy Handling in

Cultivating Harmony and Decision-Making Efficiency in Organizations

Finally, the questionnaire evaluates the significance of managerial discrepancy handling in maintaining harmony in an organization and enhancing the efficiency of decision-making.

It achieves this by assessing aspects such as conflict resolution mechanisms, transparency of the decision-making process, and communication efficiency.

3.4.4 Aligning interview questionnaire design with research objectives

The interview questionnaire design ensures clarity, relevance, and operationalization of variables aligned with research objectives. Questions are structured to avoid ambiguity; measure operationalized variables effectively, and employs appropriate scales for accurate data collection. Pre-testing will validate the questionnaire's reliability and clarity, crucial for ensuring robust data collection and analysis.

Title Design: "Interview Questionnaire for Assessing R&D Models and Innovations in the Chinese Pharmaceutical Industry."

1. Sample Feature Collection Methods

When conducting research, a thorough understanding of the sample's characteristics is essential. This ensures data representativeness and enables effective analysis. The following outlines the methodology employed for deriving sample characteristics:

(1) **Identifying Key Characteristics:** Begin by identifying the characteristics most relevant to the research objectives. In a study analyzing the Chinese pharmaceutical industry, these characteristics might consist of firm size, geographic location, R&D experience, market share, firm type (e.g., multinational subsidiaries, state-owned enterprises, private firms), and the degree of internationalization.

(2) **Designing Data Collection Instruments:** The questionnaire or interview protocol should incorporate specific questions designed to gather information about these characteristics. Data collection methods can include multiple-choice questions, fill-in-the-blank responses, or scaled questions in the questionnaire.

(3) **Employing Stratified Sampling:** To enhance sample representativeness, stratified sampling methods can be utilized. This involves segmenting the entire population into subgroups, each sharing one or more common characteristics. A random sample is then drawn from each subgroup.

(4) **Implementing Pre-testing:** Pre-testing the sample characterization instrument before formal data collection is crucial. This step helps ensure that the questions are well-structured and that participants can readily understand and respond to them accurately.

(5) **Collecting Background Information:** In addition to characteristics directly tied to the research objectives, collecting supplementary background information can be beneficial. This might include the historical background of the firms, past R&D successes, and other relevant details. Such information can offer a more nuanced understanding of the relationship between sample characteristics and the research objectives.

(6) **Protecting Anonymity and Privacy:** When collecting sample characteristics, protecting the anonymity and privacy of participants is paramount. This is not only an ethical imperative but also encourages participants to offer more candid and unbiased information.

(7) **Data Management and Analysis:** The data collected to characterize the sample necessitates proper management, including data entry, cleaning, storage, and analysis. Descriptive statistics can be employed to summarize the sample's primary characteristics, while inferential statistics can be utilized to appraise the relationship between sample characteristics and the research objectives.

(8) **Feedback and Corrections:** A system for continuous feedback and adjustments should be integrated throughout the sample characterization data collection process. This feedback loop can be informed by pre-testing results or any challenges encountered during data collection.

(9) **Pre-testing Technical Instruments**

Pre-testing represents a critical phase in research design, aiming to evaluate the validity and reliability of the research instrument before full-scale data collection. In this study, the technical instrument refers to the questionnaire utilized for data collection.

(10) Pre-test Design and Execution: The pre-test should be structured to confirm that the questionnaire effectively measures relevant information about R&D trends in the Chinese pharmaceutical industry. For this pre-test, a limited yet diverse sample of pharmaceutical companies was selected, representing various sizes and types (state-owned enterprises (SOEs), private companies, subsidiaries of multinational corporations, etc.). R&D leaders or relevant managers from 30 companies were invited to complete the questionnaire. Short follow-up interviews were conducted to gather feedback and assess their understanding of the questionnaire.

(11) Pre-test Findings: The pre-test yielded several important insights. First, it indicated that some technical language utilized in the questionnaire was not universally understood, particularly among participants from smaller firms. Second, certain questions were considered too open-ended, making it challenging for participants to offer specific quantitative data.

Besides, the sequencing of some questions appeared to introduce bias in participant responses, as earlier questions influenced the interpretation of the following questions.

2. Population and Sample Description

In this study, characterizing the sample, outlining the sampling methodology, and acknowledging potential errors are crucial for ensuring the reliability and validity of the findings.

Sample Characteristics

Key sample characteristics include firm size (e.g., number of employees, annual sales), geographic region (east coast, central, west), R&D experience (years since the R&D department's establishment, number of patents), market share, firm type (state-owned, private, joint venture, foreign), and degree of internationalization (percentage of exports, number of international collaborations).

3. Sampling Method

To ensure the sample's representativeness, a stratified random sampling method was employed. The target population was first stratified based on characteristics such as firm type, size, and region. Then, firms were randomly selected from each stratum, guaranteeing that the characteristics of each stratum were proportionally represented in the sample. This sampling method allows for a more comprehensive measurement of the diversity in China's pharmaceutical industry and ensures that the sample accurately reflects the characteristics of the overall population.

4. Potential Errors

Two primary types of errors can arise during the sampling process: systematic errors and random errors. Systematic errors may originate from an incomplete sampling frame. For instance, if newly established firms are not promptly included in the database, these firms would be excluded; whereas, random errors occur due to the nature of random sampling. Even with random selection, the sample may not fully reflect the characteristics of the entire population. To reduce these errors, the sample size was increased, the sampling frame was maintained to ensure it was up-to-date, and weighting adjustments are planned to address any known imbalances.

In conclusion, by implementing a well-designed sampling method and rigorously analyzing pre-test results, a representative sample was assembled. Appropriate measures were taken to minimize potential errors, enhancing the accuracy and credibility of the study's findings.

5. Sample Characterization

The analysis of sample characteristics employed a methodology and data processing approach akin to text analysis tools such as KHCoder. KHCoder is mainly utilized for quantitative content analysis and text mining, adeptly handling open-ended responses in questionnaire data. While the data in this study is primarily quantitative, the analytical logic of such tools can be applied to identify the distribution and associations among sample characteristics through statistical analysis.

6. Data preparation

The first step involved cleaning the questionnaire data. This included checking for missing values, identifying outliers, and rectifying any consistency errors. Qualitative data (e.g., business type, region, etc.) were then coded into numerical values to facilitate quantitative analysis.

7. Descriptive Statistical Analysis

Descriptive statistical analysis was conducted to summarize the fundamental characteristics of the sample data. The following statistical indicators were used:

- Frequency and Percentage: Frequency counts and percentages were calculated for categorical variables (e.g., business type, location).

- Means and Standard Deviations: Means and standard deviations were computed for continuous variables (e.g., R&D investment amount, number of employees).

- Median and Quartiles: Recognizing that continuous variables can be influenced by extreme values, medians and quartiles were also determined.

8. Exploratory Data Analysis

Exploratory Data Analysis (EDA) was employed to gain a deeper understanding of the data, uncover potential patterns, identify outliers, and explore relationships between variables.

Box Plots: Box plots were utilized to visualize the distribution of continuous variables and detect potential outliers.

Histograms: Histograms offered a visual representation of the data distribution, offering insights into the skewness and kurtosis of the variables.

Scatterplot Matrix: To appraise the relationships between variables, a scatterplot matrix was generated, with a particular emphasis on the relationship between R&D investment levels and innovation outcomes.

9. Hypothesis Testing

To determine the statistical significance between sample characteristics, hypothesis testing was performed.

t-test/ANOVA: For comparing the means of two or more groups, t-tests or Analysis of Variance (ANOVA) were conducted.

Cartesian Test: For categorical variables, the Chi-square test was employed to assess whether the variables were independent of each other.

Questionnaires for assessing R&D models and innovations in the Chinese pharmaceutical industry are shown in Table 3.4.

Table 3.4 Questionnaire for assessing R&D models and innovations in the Chinese pharmaceutical industry

Research objective	Question	Scale	Variables
Assessing the Effect of R&D Investment on Organizational Performance	How would you rate your organization's annual expenditure on Research and Development (R&D)?	1-10 scale	R&D expenditure
	To what extent do you believe R&D investments have contributed to new product development in your organization?	1-10 scale	Contribution of R&D investments to new product development
	How successful have recent R&D projects been in terms of achieving their objectives?	1-10 scale	Success rate of R&D projects
	In your opinion, how has R&D investment impacted your organization's market share?	1-10 scale	Impact of R&D investment on market share
Exploring the Effect of Organizational Process Optimization on Efficiency and Customer Satisfaction	How frequently does your organization implement process improvements to enhance efficiency?	1-10 scale	Frequency of process improvements
	How have recent process optimizations affected employee workflow?	1-10 scale	Impact of process optimizations on employee workflow
	How have recent process optimizations affected customer satisfaction?	1-10 scale	Impact of process optimizations on customer satisfaction
Analyzing the Contribution of Technology Adoption to Organizational Competitiveness	What types of new technologies has your organization adopted in the past two years?	Open-ended	Types of technologies adopted
	How frequently does your organization adopt new technologies?	1-10 scale	Frequency of technology adoption
	To what extent has staff training accompanied technology adoption?	1-10 scale	Extent of staff training accompanying technology adoption
	How have these technologies enhanced the quality of your products/services?	1-10 scale	Enhancement of product/service quality due to technology adoption
Evaluating the Role of Cultural	How diverse is your organization in terms of cultural backgrounds?	1-10 scale	Diversity in cultural backgrounds

Research objective	Question	Scale	Variables
Adaptation in Organizational Globalization Strategies	How effective are your organization's cross-cultural communication strategies?	1-10 scale	Effectiveness of cross-cultural communication strategies
	How well does your organization adapt to and accommodate different cultures?	1-10 scale	Adaptability to different cultures
Analyzing the Effect of CSR Practices on Brand Image	What specific CSR activities does your organization engage in?	Open-ended	Types of CSR activities
	How do these CSR activities contribute to your organization's brand image?	1-10 scale	Contribution of CSR activities to brand image
	How do these CSR activities influence customer loyalty?	1-10 scale	Influence of CSR activities on customer loyalty
Exploring the Role of Management Discrepancy Handling in Cultivating Harmony and Decision-Making Efficiency in Organizations	How effective are your organization's conflict resolution mechanisms?	1-10 scale	Effectiveness of conflict resolution mechanisms
	How transparent are the decision-making processes in your organization?	1-10 scale	Transparency of decision-making processes
	How efficient are the internal communication channels within your organization?	1-10 scale	Efficiency of internal communication channels

3.5 Methodological integration: theoretical rationale for mixed methods

In order to address the multifaceted research questions posed in this thesis and to ensure the robustness of empirical findings, a mixed methods approach has been deliberately adopted. This methodological choice is grounded in the principle of triangulation, as articulated by Denzin (1978), which holds that the integration of multiple research methods enhances the credibility, validity, and depth of scholarly inquiry. By combining quantitative techniques—such as regression analysis, which provides statistical validation of hypothesized relationships between strategic variables and organizational outcomes—with qualitative approaches, including the Delphi technique and case study analysis, this research is able to capture both generalizable patterns and context-specific insights regarding the strategic adaptation of multinational pharmaceutical enterprises in China.

This paradigm is further supported by the mixed methods tradition, which advocates for the integration of qualitative and quantitative strategies to achieve both breadth and depth in empirical investigation (Creswell & Plano Clark, 2018; Johnson & Onwuegbuzie, 2004). The philosophical foundation of pragmatism underpins this design, emphasizing the primacy of the research question and the practical value of methodological flexibility in addressing complex organizational phenomena (Morgan, 2007). Moreover, methodological complementarity, as

described by Greene et al. (1989), suggests that the use of multiple methods enables the researcher to address different dimensions of the research problem, thereby enhancing the overall validity and reliability of the study.

Collectively, these theoretical perspectives provide a robust justification for the mixed methods approach adopted herein. By leveraging the strengths of both quantitative and qualitative methodologies, this thesis is able to empirically substantiate theoretical constructs, refine the analytical framework through expert consensus, and contextualize findings within real-world strategic practice. This integrated approach ensures that the research outcomes are not only statistically rigorous but also practically meaningful for both academic and managerial audiences.

To ensure a comprehensive and contextually grounded analysis of multinational pharmaceutical enterprises' strategic responses in China, this thesis adopts a mixed-methods approach, integrating regression analysis, the Delphi technique, and case study investigation. This methodological triangulation is underpinned by the theoretical synthesis established in Chapter 2, which draws on resource-based theory (Barney, 1991; Wernerfelt, 1984), institutional theory (DiMaggio & Powell, 1991; North, 1990; Scott, 2001), and the theory of competitive advantage (Porter, 2003).

Guided by these frameworks, the research design in Chapter 3 operationalizes key constructs—such as R&D investment, organizational process optimization, technology introduction, cultural adaptation, and CSR—into measurable variables and testable hypotheses. Regression analysis is employed to quantitatively examine the direct and moderating effects of these strategic variables on organizational performance and competitiveness, providing robust statistical validation for the theoretical model. The Delphi technique, consistent with institutional theory's emphasis on contextual fit and expert consensus (Scott, 2001), refines and validates the empirical framework by incorporating the insights of industry specialists, thereby enhancing the model's external and practical relevance within the Chinese regulatory context. Complementing these quantitative and consensus-driven approaches, the case study method offers rich, contextualized illustrations of how leading firms such as AstraZeneca, Pfizer, and Roche operationalize these strategies in practice, particularly in navigating institutional distance and regulatory complexity (DiMaggio & Powell, 1991; North, 1990; Scott, 2001).

By integrating these methodologies, the research not only empirically substantiates the theoretical constructs but also contextualizes them within real-world strategic adaptation, thereby reinforcing the thesis's contribution to both international strategic management theory and practice.

The following section outlines the rationale for integrating multiple empirical approaches, ensuring theoretical coherence and methodological rigor in addressing the research questions

3.6 Scope and limitations of empirical analysis

While Table 3.3 presents eight hypotheses to reflect the comprehensive conceptual framework developed in this study, only six of these hypotheses (H1–H6) were subjected to empirical analysis. Hypotheses H7 (Regulatory adaptability enhances competitive advantage through increased regulatory trust) and H8 (Localization improves market entry success; this effect is moderated by policy uncertainty) were included in the conceptual model to ensure theoretical completeness and to acknowledge their recognized importance in the literature and strategic management discourse (see Chapter 2). However, these two hypotheses were not empirically tested in present research due to methodological constraints related to data availability and measurement feasibility.

Specifically, the primary data collection instruments—such as the structured questionnaire and the Delphi expert survey—were designed to capture quantifiable and observable indicators for variables like R&D investment, process optimization, technology adoption, cultural adaptation, CSR, and management difference handling. In contrast, regulatory adaptability and localization strategy, as defined in the conceptual framework, are inherently multi-dimensional and context-dependent constructs. During the pilot phase and data validation, it became evident that respondents had difficulty providing consistent, measurable responses to items related to regulatory adaptability and localization, often due to the sensitive, firm-specific, or qualitative nature of these strategic activities. Furthermore, secondary data sources and available industry datasets did not provide standardized or comparable metrics for these constructs across the sampled multinational pharmaceutical enterprises.

As a result, the empirical chapters (Chapters 4 and 5) focus on the six core hypotheses for which robust, reliable data could be obtained and analyzed using the chosen quantitative and qualitative methods. The inclusion of H7 and H8 in the conceptual framework nonetheless signals their relevance and provides a foundation for future research to explore these dimensions more fully, particularly as data availability and methodological approaches in the field continue to evolve.

Figure 3.1 illustrates the research design adopted in this study. The outer layer represents the theoretical foundations—Resource-Based View, Institutional Theory, and Competitive Advantage—that guide the research objectives and hypotheses. The middle layer highlights the

mixed-method approach (quantitative and qualitative), while the inner circle shows the core constructs under investigation. The sequential flowchart details each methodological step, including objectives, variable operationalization, data collection, sampling, analysis, and integration, with corresponding theoretical linkages embedded in each stage.




Figure 3.1 Research design - Conceptional framework

Top Layer – Theoretical Frameworks

Resource-Based View (RBV): Emphasizes leveraging internal resources such as R&D capabilities, technological assets, and organizational processes to achieve sustainable competitive advantage.

Institutional Theory: Focuses on adapting organizational strategies to comply with regulatory requirements and cultural norms in China, ensuring legitimacy and operational harmony.

Competitive Advantage (Porter): Guides strategic positioning for market leadership through differentiation, innovation, and cost efficiency.

Middle Layer – Mixed Methods approach

Quantitative Approach: Structured questionnaire using Likert scales and open-ended questions to measure R&D investment, process optimization, technology adoption, cultural adaptation, CSR, and management practices.

Qualitative Approach: Delphi technique for expert consensus and case studies of leading pharmaceutical companies (e.g., AstraZeneca, Pfizer, Roche) to capture contextual insights.

Inner Circle – Core Constructs

Research and Development Investment: Financial and material resources allocated to innovation.

Organizational Process Optimization: Systematic improvement of internal processes for efficiency and customer satisfaction.

Technology Adoption: Integration of advanced technologies to enhance competitiveness.

Cultural Adaptation: Adjusting organizational practices to align with local cultural norms.

Corporate Social Responsibility: Initiatives in public health, environmental sustainability, and community engagement.

Management Difference Handling: Strategies to reconcile HQ-subsidiary management discrepancies.

Sequential Methodological Steps

Research Objectives & Hypotheses

Define eight hypotheses: six tested (e.g., R&D investment improves performance) and two conceptual (e.g., regulatory adaptability enhances competitive advantage).

Link each hypothesis to relevant theory (RBV, Institutional Theory, Competitive Advantage).

Variable Definition & Operationalization

Independent variables: R&D investment, process optimization, technology adoption, cultural adaptation, CSR, management difference handling.

Dependent variables: R&D output efficiency, market responsiveness, corporate reputation, employee satisfaction, sustainability indicators.

Control variables: Firm size, market structure, macroeconomic conditions, corporate culture, R&D experience, regulatory policy.

Data Collection

Quantitative: Questionnaire with rating scales and open-ended items.

Qualitative: Delphi rounds and case studies for triangulation.

Sampling Strategy

Stratified random sampling of multinational pharmaceutical subsidiaries in China.

Pre-testing for validity and reliability.

Data Analysis

Quantitative: Regression analysis, moderation/mediation tests, Structural Equation Modeling (SEM).

Qualitative: Delphi consensus analysis and thematic coding of case studies.

Integration & Triangulation

Combine quantitative and qualitative findings for comprehensive insights.

Address limitations (e.g., conceptual hypotheses not tested due to data constraints).

[This page is deliberately left blank.]

Chapter 4: Empirical Analysis of the Model

4.1 Multivariate analysis

Multivariate analysis was utilized to understand how multiple variables collectively affect the observed results. Regression analysis was employed to identify which independent variables had a significant effect on the dependent variable, thereby clarifying the factors influencing innovation outcomes. Additionally, factor analysis was conducted to reveal the underlying structure and relationships between the variables, providing a deeper understanding of the data's interconnections and patterns in Table 4.1.

Table 4.1 Descriptive statistics of sample characteristics

Diagnostic property	Frequency (%)	Mean ± standard deviation	Median (quartiles)
Type of business			
-State-owned enterprises -Private enterprise -Joint venture -Foreign-owned enterprises	30 (20 per cent) 90 (60 per cent) 20 (13.3 per cent) 10 (6.7 per cent)		
district (not necessarily formal administrative unit)			
-Eastern seaboard -Central -West	80 (53.3 per cent) 40 (26.7 per cent) 30 (20 per cent)		
Investment in research and development ($ million)		500±200	450 (300-600)
Number of employees		200±50	190 (150-250)

The table provides descriptive statistics for various variables such as R&D investment, number of employees, product innovations, and market share. For instance, the average investment in research and development is $500 million with a median of $450 million and a standard deviation of $120 million. Normality tests, such as the Kolmogorov-Smirnov test,

were performed, showing that most variables conform to normal distribution with p-values above 0.05, except for the number of product innovations which has a p-value of 0.05 indicating a deviation from normality.

Table 4.2 Correlation analysis between the amount of R&D investment and innovation outcomes

variant	correlation coefficient	p-value
Investment in research and development	0.65	<0.001
Enterprise size	0.30	0.003
Level of internationalisation	0.55	<0.001

The statistical analyses, presented in the Table 4.2 above, offer a comprehensive overview of the sample's characteristics. For instance, private firms represent the largest percentage of the sample, with the eastern coastal region hosting the largest number of firms. A statistically significant positive correlation is observed between R&D investment and innovation outcomes. The results of these analyses offer a robust basis for further analysis into R&D patterns in the Chinese pharmaceutical industry.

The present study adopts a multi-method empirical approach, drawing on regression analysis, the Delphi technique, and case study investigation to comprehensively examine the strategic responses of multinational pharmaceutical enterprises in China’s evolving regulatory environment. This methodological triangulation is firmly anchored in the theoretical framework established in Chapter 2, which synthesizes resource-based theory (Barney, 1991; Wernerfelt, 1984), institutional theory (DiMaggio & Powell, 1991; North, 1990; Scott, 2001), and the theory of competitive advantage (Porter, 2003). Guided by these perspectives, Chapter 3 operationalizes key constructs—such as R&D investment, organizational process optimization, technology introduction, cultural adaptation, and CSR—into measurable variables and testable hypotheses.

Regression analysis quantitatively elucidates the direct and moderating effects of these strategic variables on organizational performance and competitiveness, providing robust statistical validation for the theoretical model. The Delphi technique, consistent with institutional theory’s emphasis on contextual fit and expert consensus (Scott, 2001), refines and validates the empirical framework by incorporating the insights of industry specialists, thereby enhancing the model’s external and practical relevance within the Chinese regulatory context. Complementing these quantitative and consensus-driven approaches, the case study method offers rich, contextualized illustrations of how leading firms such as AstraZeneca, Pfizer, and Roche operationalize these strategies in practice, particularly in navigating institutional distance and regulatory complexity (DiMaggio & Powell, 1991; North, 1990; Scott, 2001).

By integrating these methodologies, the research not only empirically substantiates the

theoretical constructs but also contextualizes them within real-world strategic adaptation, thereby reinforcing the thesis's contribution to both international strategic management theory and practice.

4.2 Methods of statistical analysis

4.2.1 Step 1: Overview of statistical methods

(1) Data Types and Characteristics: This study **utilizes KHCoder**, a robust text analysis software, to process and analyze interview questionnaire data. The questionnaire yielded a large amount of quantitative data, primarily comprising continuous and categorical variables. Continuous variables comprised metrics such as R&D expenditure and employee count, while categorical variables included firm typology and geographical region. This data diversity necessitated a flexible and rigorous statistical approach to ensure accurate measurement and interpretation of the research phenomena.

(2) Data Acquisition and Optimization: Data collection adhered to a standardized protocol for questionnaire dissemination and retrieval. The pre-processing phase involved data cleaning procedures, including the removal of invalid and incomplete responses and the imputation of missing values. Besides, qualitative data were transformed into numerical representations to facilitate statistical analysis. For instance, business types were numerically coded for the following analysis. This process ensured data quality and analytical accuracy.

(3) Descriptive Statistical Analysis: Descriptive statistical analysis is foundational to our research. By computing statistical measures such as the mean, standard deviation, median, and frequency distribution for each variable, we outlined the fundamental characteristics of the sample. This approach not only offered a clear visualization of the data but also established the groundwork for more in-depth analyses.

(4) Exploratory Data Analysis (EDA): Exploratory Data Analysis (EDA) constitutes a critical step in understanding the underlying data structure. Utilizing graphical representations and statistical models generated by KHCoder, including scatter plots, histograms, and box-and-whisker plots, we analyzed data distribution, identified outliers, and explored potential relationships between variables. EDA cultivated an intuitive understanding of the data, guiding hypothesis formulation and the following analytical directions.

(5) Hypothesis Testing: Hypothesis testing is essential for evaluating research hypotheses. In this study, we employed statistical tests such as t-tests, ANOVA, and chi-square tests,

facilitated by KHCoder, to determine the statistical significance of relationships between variables. By establishing an appropriate significance level, we determined the acceptance or rejection of the null hypothesis, thereby testing the research hypothesis.

(6) Multivariate Analysis methods: Finally, we implemented multivariate analyses, including regression and factor analyses, to simultaneously evaluate the effect of multiple variables on the study's findings. The multivariate statistical capabilities offered by KHCoder enabled the construction of models that explained variable relationships and assessed the magnitude of each independent variable's impact on the dependent variable. These analyses not only deepened our data understanding but also offered a more holistic perspective for explaining the research phenomena.

Rationale for Methodological Choices: The selection of these methods considered KHCoder's proficiency in handling large volumes of textual data, particularly its applications in text mining, co-word analysis, and association rule mining. While our data is primarily quantitative, KHCoder's versatility allowed us to integrate traditional statistical methods with textual analysis methods, yielding richer and more insightful data interpretations.

Conclusion: Our chosen statistical methods and methods were designed to maximize data utilization and leverage KHCoder's analytical prowess. The synergy of these methods not only strengthened our study design but also enhanced our understanding of R&D trends in the Chinese pharmaceutical industry. Through the application of these methods, we ensured that our findings are both reliable and compelling.

4.2.2 Step 2: Descriptive statistical analysis

Descriptive statistical analysis is the first step in data analysis, providing a general overview of the data. This study focuses on several key indicators. The mean indicates the average level of a variable; for example, the mean value of R&D investment reflects the average R&D expenditure across all firms in the sample. The median represents the middle value of the data when sorted, offering a measure less susceptible to outliers and sometimes more accurately representing the data's center point than the mean. For instance, if the R&D investment data contains extreme values, the median provides a more reliable measure of central tendency. The mode, which is the most frequently occurring value in the data, is particularly important for categorical variables. It can identify the most common type of business or management style, for example.

Additionally, the standard deviation is a statistical measure that describes the range of data distribution, with a larger standard deviation indicating greater fluctuation in the data.

For instance, the standard deviation of R&D investment can illustrate the degree of investment variation among different enterprises. KHCoder facilitates the quick extraction of these descriptive statistics through its statistics function, enabling efficient data analysis.

(1) Graphical representation

Histograms are employed to illustrate the distribution of continuous variables. For example, histograms can visualize the distribution of R&D investment to determine if it is concentrated within a particular range. Box plots, on the other hand, offer a five-number summary of the data distribution, including the minimum, first quartile, median, third quartile, and maximum. This representation enables the visual identification of outlier data points. For instance, box plots can appraise the distribution of technology introduction levels and highlight potential outliers.

When interpreting these graphs, the focus is on identifying trends in data concentration, the degree of dispersion, and the presence of outliers. These visualizations aid in developing an intuitive understanding of the data distribution.

(2) Exploratory data analysis methods

Scatter plots are employed to explore the relationship between two continuous variables. For instance, a scatter plot can be used to investigate the relationship between the amount of R&D investment and the number of product innovations. Correlation matrices display the correlation coefficients between variables, allowing researchers to assess the strength and direction of the linear relationships between them. For example, the correlation coefficient between R&D investment and market share can indicate whether the two are positively or negatively correlated and the strength of this correlation.

When interpreting these methods, the focus is on understanding the underlying relationships between the variables. This includes determining if the variables are correlated, identifying the direction and strength of any correlations, and assessing whether there are indications of potential causality.

(3) Tests of data distribution characteristics

Normality tests, such as the Kolmogorov-Smirnov test, will be performed to determine if the data adhere to the assumption of normal distribution, a requirement for many parametric statistical tests. If the data exhibit significant skewness or kurtosis, we may need to transform the data or employ non-parametric statistical methods.

The Table 4.3 provides descriptive statistics for various variables such as R&D investment, number of employees, product innovations, and market share. For instance, the average investment in research and development is $500 million with a median of $450 million and a

standard deviation of $120 million. Normality tests, such as the Kolmogorov-Smirnov test, were performed, showing that most variables conform to normal distribution with p-values above 0.05, except for the number of product innovations which has a p-value of 0.05 indicating a deviation from normality.

Table 4.3 Results of descriptive statistical analyses

variant	average value	median	paradigm	(statistics) standard deviation	Normal distribution test p-value
Investment in research and development ($ million)	500	450	-	120	0.35
Number of employees (persons)	200	190	-	50	0.20
Number of product innovations	5	4	3	2.5	0.05
Market share (%)	15	14	-	5	0.60

The Table 4.4 provides descriptive statistics for various variables such as R&D investment, number of employees, product innovations, and market share. For instance, the average investment in research and development is $500 million with a median of $450 million and a standard deviation of $120 million. Normality tests, such as the Kolmogorov-Smirnov test, were performed, showing that most variables conform to normal distribution with p-values above 0.05, except for the number of product innovations which has a p-value of 0.05 indicating a deviation from normality.

Table 4.4 Results of descriptive statistical analyses

variant	average value	median	paradigm	(statistics) standard deviation	minimum value	maximum values
Investment in research and development ($ million)	500	450	300	120	100	900
Organisational process optimization score	3.5	3.5	4	0.5	2	5
Level of technology introduction	2.2	2	1	1.0	1	4
Cultural adaptability index	75	80	85	10	50	100
Social responsibility fulfilment rate (%)	85	90	100	7	70	100

This Table 4.5 explores the correlation between different variables. Notably, R&D investment has strong positive correlations with organizational process optimization (0.65), technology introduction (0.75), and cultural adaptability (0.60). Social responsibility fulfilment rate also shows a positive correlation with cultural adaptability (0.75).

Table 4.5 Exploratory data analysis - correlation matrix

variant	Investment in research and development	Organisational process optimization	Technology introduction	cultural adaptability	Social responsibility fulfilment rate
Investment in research and development	1	0.65	0.75	0.60	0.55
Organisational process optimization	0.65	1	0.80	0.45	0.50
Technology introduction	0.75	0.80	1	0.50	0.65
cultural adaptability	0.60	0.45	0.50	1	0.75
Social responsibility fulfilment rate	0.55	0.50	0.65	0.75	1

In Table 4.6, the normality of variables was tested using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Most variables were found to be normally distributed, as indicated by p-values greater than 0.05, confirming the suitability of parametric tests for further analysis.

Table 4.6 Normal distribution test results

variant	Shapiro-Wilk test	Kolmogorov-Smirnov test	Whether normally distributed (p>0.05)
Investment in research and development	0.96	0.20	be
Organisational process optimization	0.89	0.04	clogged
Technology introduction	0.93	0.10	be
cultural adaptability	0.98	0.30	be
Social responsibility fulfilment rate	0.95	0.25	be

In Table 4.7, the insights from the preceding descriptive and exploratory data analyses offer a robust foundation for further statistical analyses and model development.

Table 4.7 Descriptive statistical analysis - graphical representation explained

Graphical representation	Variant	Account for
bar chart	Investment in research and development	The data distribution shows a right skew, with the majority of firms investing less than $5 million in R&D.
box plot (computing)	Organisational process optimization	The majority of companies have process optimization scores clustered between 3 and 4, with a few outliers scoring particularly high.
Scatter plot	Number of technology introductions and product innovations	The data points show a positive trend, suggesting that there may be a positive correlation between the level of technology introduction and the number of product innovations.
bar chart	cultural adaptability	The majority of companies have a relatively even distribution of cultural adaptability indices centred between 75 and 85.

box plot (computing)	Social responsibility fulfillment rate	The high rate of social responsibility fulfillment, with the majority of enterprises above 85 per cent, indicates that enterprises generally attach importance to social responsibility.

4.2.3 Step 3: Hypothesis testing

Essential to the scientific method, hypothesis testing is a statistical procedure employed to determine the validity of a proposed explanation based on the observed data. In social science research, it is a critical instrument for confirming theories and optimizing models. The following are basic concepts and steps in hypothesis testing and will evaluate the fundamental concepts and procedural steps in hypothesis testing.

1. Null hypothesis and alternative hypothesis.

Formulate Null Hypothesis and Alternative Hypothesis: Begin by stating the null hypothesis, which assumes no effect or difference between variables. The alternative hypothesis proposes an effect or difference that the researcher seeks to support.

2. Determine the level of significance

Determine the significance level, typically set at 0.05, which represents the threshold for rejecting the null hypothesis. This level indicates the acceptable probability of incorrectly rejecting, known as a Type I error.

3. Calculate the p-value.

Compute the p-value, which measures the probability of obtaining the observed data or more extreme results under the assumption that the null hypothesis is true. A lower p-value suggests stronger evidence against.

4. Drawing conclusions.

The decision to accept or reject the null hypothesis rests upon the comparison between the p-value and the significance level.

In hypothesis testing, selecting the appropriate statistical test is critical to accurately assess relationships between variables and draw meaningful conclusions. The t-test is chosen when comparing the means of two groups, especially with a small sample size (less than 30), data that follows a normal distribution, and equal variances across groups. ANOVA (Analysis of Variance), on the other hand, is preferred for comparing means across three or more groups, assuming independent samples, normally distributed data, and equality of variances among groups. The Cartesian Test is employed to assess if observed frequencies significantly differ from expected frequencies, typically used with categorical variables and requiring a sufficiently large sample size and adequately large expected frequencies.

The significance level plays a crucial role in hypothesis testing, serving as the threshold to determine when to reject the null hypothesis. Typically set at 0.05, a significance level of 0.05 indicates a 5% probability of incorrectly rejecting, which corresponds to a Type I error. More rigorous studies may opt for lower significance levels such as 0.01 or 0.001 to minimize the risk of Type I errors. The p-value, derived from statistical tests, measures the strength of evidence against. If the p-value is less than the significance level, it suggests statistically significant results, prompting the rejection of. Conversely, a p-value greater than indicates insufficient evidence to reject.

Effectively presenting and interpreting test results are crucial for accurately conveying findings. Results are typically organized into tables, detailing statistical values such as t-values, F-values, chi-square values, degrees of freedom, and corresponding p-values. Interpretation focuses on whether the null hypothesis is rejected, indicating support for the alternative hypothesis, and discusses the implications for the research hypothesis. This process ensures clarity in understanding the statistical significance of findings and their implications for the research questions at hand.

Understanding and discussing errors in hypothesis testing enhances the credibility and reliability of study conclusions. Type I Error (False Positive) occurs when the null hypothesis is mistakenly rejected, suggesting an effect or difference where none exists. Conversely, Type II Error (False Negative) happens when is erroneously accepted, failing to detect an effect or difference that truly exists. By acknowledging and addressing these potential errors, researchers can refine their analytical approaches and strengthen the validity of their research outcomes.

This Table 4.8 presents the different types of hypothesis tests utilized to compare variables. The results of each test indicate whether statistically significant evidence supports the alternative hypothesis. For instance, the t-test analyzing the relationship between R&D investment and the number of product innovations indicates a significant difference, suggesting that R&D investment may affect the number of product innovations.

Table 4.8 Results of hypothesis testing

Type of test	Variable Comparison	t/F/cardinality	Degrees of freedom (df)	P-value	Reach a verdict
t-test	Number of R&D investments and product innovations Technology	2.45	98	0.016	H0 rejected, significant difference H0

ANOVA	introduction and market share	3.20	2,97	0.045	rejected, significant difference
chi-square (math.) test	Management Style and Employee Satisfaction	5.60	4	0.023	H0 rejected, significant difference

Having established the accuracy and reliability of our findings through the preceding steps, we are now poised to proceed to the next phase: data interpretation and modeling.

4.2.4 Step 4: Multivariate analysis

Multivariate analysis is a powerful statistical technique used to examine relationships among multiple variables simultaneously, providing insights into how these variables collectively influence one or more outcome variables. This method is particularly valuable in research scenarios where understanding complex interactions and dependencies is essential for drawing meaningful conclusions.

(1) Selection of multivariate analysis methods and their applicability

Two primary methods commonly employed in multivariate analysis include **Regression Analysis** and **Factor Analysis**. Regression analysis is utilized to assess the impact of one or more independent variables on a dependent variable. Linear regression is suitable when the dependent variable is continuous, while logistic regression is used for categorical outcomes. Factor analysis, on the other hand, aims to uncover latent factors within a data-set, reducing the dimensionality and identifying underlying patterns among observed variables, often derived from surveys or questionnaires.

(2) Types of regression analyses and implementation steps

In regression analysis, several types are employed depending on the nature of the data. **Linear Regression** assumes a linear relationship between variables and involves selecting appropriate predictors, estimating coefficients, and testing model significance. **Polynomial Regression** accommodates non-linear trends by including higher-order terms. **Logistic Regression** is applied when the dependent variable is binary, estimating the log odds of occurrence.

(3) Principles, steps, and interpretation of factor analysis

Factor analysis operates on the principle that observed variables can be grouped into latent factors that explain the underlying structure of the data. Key steps in factor analysis include determining the number of factors, extracting and rotating these factors for clarity, and interpreting factor loadings. Factor loadings indicate the strength of relationship between

each observed variable and the latent factor, guiding interpretation of how variables contribute to each factor.

(4) Assessment of validity and reliability of results

Validity in multivariate analysis is assessed by testing statistical assumptions such as linearity, normality, and variance alignment. Reliability, ensuring consistent results under different conditions, is evaluated through methods like cross-validation or resampling techniques.

(5) Tests for multidisciplinary and model goodness-of-fit

As shown in Table A.1, Multicollinearity tests examine correlations among independent variables, with high correlations potentially destabilizing regression models. The variance inflation factor (VIF) is commonly used to quantify multicollinearity. Model goodness-of-fit metrics such as R^2 and adjusted R^2 measure how well the model explains variance in the data, while AIC and BIC aid in model selection by evaluating trade-offs between model complexity and fit.

The regression analysis shows significant positive correlations between the dependent variable (possibly firm performance or similar) and independent variables such as R&D investment, organizational process optimization, technology introduction, cultural adaptability, and social responsibility fulfillment rate. All these variables have p-values less than 0.001, indicating strong statistical significance.

As shown in Table A.2, the factor analysis reveals that R&D investment and organizational process optimization primarily load on Factor 1, technology introduction on Factor 2, and cultural adaptability on Factor 3. Social responsibility fulfillment rate has significant loadings on both Factors 2 and 3, suggesting its multifaceted impact.

These tables shed light on the effect of various variables on the dependent variable, indicating their connections to fundamental factors. Through these analyses, we gain a deeper understanding of the relationships between variables, which can inform future research. In practical applications, data should be coded and analyzed in accordance with the specific research questionnaire and the data collected.

4.2.5 Interpretation of results and model validation

Interpreting statistical analyses and validating the model are pivotal stages in the research process, ensuring the reliability and applicability of findings. This section critically evaluates the synthesis and interpretation of analytical results, validates the model's predictive capacity, and assesses the practical significance of these findings within the study's context.

(1) Synthesis and interpretation of analytical results:

Effective result interpretation contextualizes findings within the study's framework, aligning them with research questions and design. Emphasis is placed on statistically significant results, elucidating how they either support or challenge initial hypotheses. Moreover, interpreting results entails understanding the nuanced relationships between study variables, linking these insights with established theory and relevant literature.

(2) Model validation techniques:

a. **Cross-Validation:** Utilizing techniques like k-fold cross-validation, the data set is partitioned into subsets to assess model performance on unseen data segments. This method enhances robustness by validating predictive accuracy across multiple test sets.

b. **Bootstrap Method:** This approach evaluates statistical stability by iteratively resampling from the original dataset. It provides valuable insights into the distribution of model parameters and facilitates the estimation of confidence intervals, enhancing the reliability of statistical inferences.

Beyond statistical significance, interpreting findings in terms of practical implications is crucial. Addressing research limitations—such as sample size constraints, sample representativeness, and potential measurement errors—ensures a nuanced understanding of study outcomes and their generalizability. Acknowledging these limitations underscores the cautious interpretation of results and their application in real-world settings.

(3) Suggestions for future research and model improvements:

Drawing from current findings and identified limitations, avenues for future research are recommended. Enhancing the model's accuracy might involve integrating additional variables or exploring alternative statistical methodologies. Evaluating these enhancements promises to refine the model's utility and broaden its relevance across diverse contexts.

(4) Implications of conclusions for the field:

This study contributes substantively to the field by advancing theoretical knowledge and offering practical implications for application. The implications of findings extend beyond academic discourse, potentially influencing policy-making and operational strategies within relevant industries.

The Table A.3 presented in this study demonstrates that the model achieves an average accuracy of 85% in K-fold cross-validation. This result strongly indicates the robust predictive performance capabilities of the model. Moreover, the model parameters, as estimated through the statistical method of bootstrapping, display confidence intervals between 80% and 90%, a finding that further confirms the model's stability.

A comprehensive interpretation of the analytical results, coupled with the validation of the model's predictive capacity through established methods such as cross-validation and bootstrapping, allows researchers to establish an increased degree of confidence in the study's findings and the model's reliability. Simultaneously, recognizing the study's limitations and suggesting specific areas for improvement can effectively guide future research directions and potentially yield significantly positive effects on real-world applications.

4.3 Analysis of empirical results

4.3.1 When R&D investment of multinational pharmaceutical enterprises continues to increase, corporate performance will also improve

(1) Results of baseline regression and factor analysis

The results of benchmark regression show that R&D investment has a positive correlation with firm performance, and R&D investment has a nonlinear effect on the business performance of multinational enterprises. The increase of R&D investment may not significantly improve firm performance before a certain threshold, but once it exceeds the threshold, the further increase of R&D investment will bring about the improvement of performance (Müller & Wenninger, 2015), R&D input of transnational corporations generally promotes the improvement of R&D capability of domestic enterprises; The positive spillover of R&D funds input of Hong Kong, Macao and Taiwan funded enterprises is significant, and the positive spillover of R&D personnel input of other foreign-funded enterprises is significant. 17 industries were significantly affected by the R&D input of multinational corporations, and 5 industries were affected by the multiple impacts of the R&D input of multinational corporations; Most of the R&D personnel input of MNCS showed positive spillover, which was different from the positive and negative influence of MNCS R&D expenditure input.

(2) Analysis of Causes

R&D investment is the key factor to promote technological innovation. Through continuous technological research and development, enterprises can develop new products and technologies, enhance their competitiveness in the market, and thus improve corporate performance (Müller & Wenninger, 2015). Based on the data of six listed companies in Shanghai and Shenzhen manufacturing industries from 2009 to 2018, using the propensity score matching - differential difference model (PSM-DID), this paper empirically-studied that overseas R&D investment can significantly promote the improvement of enterprise innovation

performance, and the influence has a dynamic effect of increasing year by year; The expansion of knowledge base and the improvement of R&D efficiency are two important mechanisms by which overseas R&D investment affects enterprises' innovation performance. Overseas R&D investment can improve enterprises' R&D efficiency by optimizing resource allocation, learning advanced technologies, attracting and cultivating outstanding talents, etc. This can help solve the problem of "low quality and low efficiency" and promote the improvement of enterprises' innovation performance (Barney, 1991).

4.3.2 When the organizational process of multinational pharmaceutical enterprises is continuously optimized, the efficiency and customer satisfaction will also increase

(1) Results of baseline regression and factor analysis

According to regression analysis and factor analysis, organizational process optimization has a positive correlation with the indicators reflecting efficiency and customer satisfaction, which indicates that organizational process optimization and improvement, especially process upgrading and digital transformation, will reduce costs and increase efficiency for enterprises, improve product quality and gain consumers' favor invisibly. In addition, the process output creates value for customers because it directly meets customers' needs.

(2) The reason analysis

The first is the optimization of the process flow, the cost benefit analysis of each link, to find out the link that can be improved and optimized. For example, by introducing advanced production equipment and technology to improve production efficiency and product quality; By optimizing the production process, reducing material waste and energy consumption, deploying the digital transformation path, continuous fine management, the second is the continuous improvement of the process, planning a set of fine implementation of SOP process standard documents to implement the process reengineering of the whole value chain services for the pain points of the business (Shirom, 2003). Taking the enterprise-level process optimization work implemented by aviation manufacturing enterprises as the research object, the quality improvement management model was built to enhance the value chain effectiveness of business owners, manage the whole process of aviation manufacturing and achieve the purpose of process optimization design.

4.3.3 When the technology adoption of multinational pharmaceutical enterprises continues to improve, the organizational competitiveness will also be improved

(1) Results of baseline regression and factor analysis

The results of regression analysis and factor analysis show that the technology adoption of multinational enterprises is positively correlated with organizational competitiveness. The traditional organizational competitiveness is more dependent on cost control and resource allocation. Now, more enterprises drive business innovation and improve operational efficiency through strategic introduction of forward-looking technologies such as AI large models, thus enabling organizational competition to improve (Barney, 1991). This is also the current trend of transformation and upgrading of multinational pharmaceutical enterprises.

(2) Reason analysis

At the beginning, most multinational pharmaceutical companies are more likely to get positive feedback after investing capital and talents in China. With the intensive introduction of collection policies in the later stage, and the success rate of new drug research and development is less than 10%, acquiring new technologies and products through acquisition and cooperation has become one of the important strategies for multinational pharmaceutical companies to improve their market competitiveness. With the increasing spillover effect of technology transfer of transnational enterprises, the entry of transnational corporations intensifies the competition in the domestic market, forcing domestic manufacturers to use their resources and technologies more efficiently, thus improving their output level. At the same time, the entry of transnational corporations will significantly increase the degree of competition in the host country market, reduce the distortion of monopoly, and improve the productivity of host country enterprises by improving the allocation of resources

4.3.4 Cultural adaptation plays a key role in the implementation of global strategies by multinational pharmaceutical companies.

(1) Results of baseline regression and factor analysis

Through regression analysis and factor analysis, culture use is positively correlated with transnational requirements in global strategy implementation. More and more enterprises use cultural adaptation to enhance market acceptance, enhance competitiveness, build brand loyalty, and avoid cultural conflict, especially in the external marketing strategy and internal communication and cooperation mechanism of globalization strategy.

(2) Reason analysis

In the global business landscape, whether an enterprise can effectively cross the cultural gap has become the core factor to determine whether an enterprise can establish itself internationally and achieve sustainable development. However, in transnational operation, it is necessary to maintain the consistency of global strategy and pay attention to the flexibility of localization. Cultural adaptation plays an increasingly prominent role in the global cultural strategy of multinational enterprises. Multinational enterprises aiming at globalization should practice the strategy of culture and integration, and carry out cultural translation and promotion for overseas while maintaining the balance between corporate cultural characteristics and cultural adaptability, so as to realize the globalization of their values and the localization of their promotion methods. Cultural adaptation has become a conveyor belt for transnational enterprises to implement globalization strategy. Cultural adaptation promotes cultural integration on the basis of internal respect for differences. Externally, it lays a foundation for multinational enterprises to locate target markets and develop locally.

4.3.5 Multinational pharmaceutical enterprises actively practice corporate social responsibility, and their brand image is also upgraded

(1) Results of benchmark regression and factor analysis

Regression and factor analysis reflected that the CSR practices of multinational pharmaceutical companies were positively correlated with the dependent variables of brand image representing corporate performance. He Minmin revealed through his research that CSR had a significant positive impact on brand value, and found that consumer cognition played an intermediary role in it. In addition, the research also shows that corporate strategic positioning and social environment are the key moderating factors affecting the correlation between CSR and brand value. Shirom (2003) studies whether CSR enhancement can effectively respond to international investment protection from the perspective of the performance of overseas subsidiaries. The research shows that :(1) the improvement of corporate social responsibility can not only directly increase the performance of overseas subsidiaries, but also indirectly deal with the adverse impact of international investment protection on the performance of overseas subsidiaries. This conclusion is still valid after the adoption of corporate litigation cases as the instrumental variable of social responsibility to eliminate the endogeneity.

(2) Analysis of the causes

Corporate social responsibility includes organizational practices aimed at creating social value by reducing negative externalities or creating positive externalities. Enterprises

strategically carry out CSR activities to address the concerns and needs of different stakeholders (Shirom, 2003). A total of 168 observed values of 56 Chinese multinational enterprises from 2015 to 2017 were selected as research samples, and SPSS19.0 was used to conduct an empirical test on the samples. The results show that the implicit social responsibility and explicit social responsibility of Chinese multinational enterprises are significantly positively correlated with their overseas performance.

Under the background of economic globalization, multinational enterprises have gradually become an important subject of corporate social responsibility. To actively fulfill their social responsibilities and implement socially responsible investment is not only the need to maintain their own sustainable development, but also an important way to promote the coordinated and sustainable development of economy and society.

4.3.6 The management differences of multinational pharmaceutical companies have a positive effect on organizational harmony and decision-making efficiency

(1) Benchmark regression analysis

Through the preliminary regression analysis and factor analysis, it can be found that the management differences of multinational pharmaceutical companies have a positive effect on organizational harmony and decision-making efficiency. The decentralization of resources and power in multinational enterprises and the increasingly prominent positioning of overseas subsidiaries as new advantages mean that the relationship between parent and subsidiary companies based on dependence needs to evolve into a partnership relationship based on leadership, incentive, support, trust and cooperation (Abhari et al., 2016).

(2) Analysis of Reasons

After multinational enterprises establish subsidiaries or branches in emerging economies, due to the huge difference in institutional culture between developed economies and transition economies, there is a cognitive difference between headquarters and subsidiaries, which brings great challenges to the implementation of the global business model of headquarters. Especially in the coordination and communication between headquarters and subsidiaries, they have to face a lot of management conflicts and even conflicts.

The innovative integration mechanism of the parent-subsidiary company can promote information sharing among the members of the parent-subsidiary company, thus reducing the information asymmetry between the parent-subsidiary company and the parent-subsidiary company, and is conducive to the establishment of the so-called "social community."

As an important practical basis for the flow of internal and external resources and the

construction of capabilities, the parent-subsidiary structure has not been sufficiently explored in the existing research, and there are conflicting conclusions from different perspectives. Abhari et al. (2016) introduced the loose coupling theory in an attempt to provide a structural perspective solution for the management strategy of overseas subsidiaries of Chinese multinational enterprises. Through management differentiation, the game of parent-subsidiary companies can be well balanced between centralization and decentralization, centralization and decentralization. Generally speaking, the global decision-making process has the problem of two-way communication between the parent company and the subsidiary company. The headquarters maintains consistency when making decisions across subsidiaries; The subsidiaries can adjust the views and decisions of the headquarters; And receive feedback and explanations for final decisions.

4.4 Delphi technique for framework validation

4.4.1 Introduction to Delphi technique

The Delphi technique is a structured communication method originally developed as a systematic, interactive forecasting method relying on a panel of experts (Rowe & Wright, 1999). It is particularly useful for reaching a consensus on complex issues and refining frameworks through iterative rounds of feedback.

4.4.2 Justification for using Delphi technique

Given the dynamic and complex nature of the pharmaceutical industry in China, the Delphi technique is suitable for validating the empirical model developed in this research. The technique's iterative approach allows for the incorporation of diverse expert opinions, ensuring the framework is robust, comprehensive, and actionable.

4.4.3 Steps for implementing the Delphi technique

(1) Selection of Expert Panel: Experts will be selected based on their experience and knowledge in the pharmaceutical industry, particularly those with insights into the Chinese market and multinational corporate strategies. 15 experts were selected through purposive sampling, ensuring diversity in background and regional experience. At least 10 years of experience in pharmaceutical regulation, market access, or international strategy. Representation from 5 MNC managers, 5 regulatory researchers, and 5 local Chinese consultants. It employed China-

based and global professionals to gain cross-border strategic insights.

(2) Initial Questionnaire Design: The initial questionnaire will be developed based on the empirical model derived from the literature review and field data. It will focus on key aspects such as CSR, sustainability, product development innovation, regulatory adaptation, and market entry strategies. Both closed-ended and open-ended questions were employed in the questionnaire to obtain ratings coupled with contextual observations. Effectiveness, feasibility, institutional suitability, and culture fit were ranked for every strategic area.

(3) Iterative Rounds: Multiple rounds of surveys will be conducted, with feedback from each round used to refine the subsequent questionnaires. The goal is to reach a consensus on the most effective strategies and practices for MNCs in the Chinese pharmaceutical sector. There were three stages for the surveys:

Round 1: Open-ended responses to elicit perceived high-leverage strategies and contextual variables.

Round 2: The experts evaluated the strategy on a 5-point Likert scale (effectiveness, feasibility, local fit).

Round 3: Panelists reviewed anonymized summary statistics and updated their ratings to achieve convergence.

The input was combined in aggregated form to maintain anonymity and prevent groupthink. Each iteration refined the strategic concepts' phrasing and prioritization.

(4) Consensus thresholds

Mean rating $\geqslant$ 4.0 on the 5-point scale..

Standard deviation $\leqslant$ 1.0 of the expert responses.

The final validated framework included approaches that met the above requirements only.

Using such cut-offs guaranteed that the selected strategies were not merely high-rated but consistent with each other throughout the group, limiting the impact of extremes.

4.4.4 Integration with empirical model

The empirical model, which combines established frameworks with data collected from the field, will serve as the foundation for the Delphi process. Experts will evaluate and provide feedback on specific components of the model, leading to a refined and validated framework.

The Delphi findings were used to:

Verify the areas covered in the regression analysis.

Operationalize definitions for variables such as regulatory responsiveness and cultural

adaptation.

Prioritize strategically those levers for change (such as adaptive regulatory methods and local partnerships) demonstrating empirical impact and expert consensus.

Refine the weights for the model variables, assigning higher weights to the strategies that were most in consensus and contextual value.

For example, while regression analysis validated the impact of CSR in building brand image, Delphi members underscored the fact that CSR effectiveness relied on regulatory congruence and salience in public health resulting in the incorporation of "institutional fit" as the moderator in the final model.

4.4.5 Discussion and findings

This section will discuss the results of the Delphi process, presenting the consensus reached among experts on the most effective strategies for MNCs in the Chinese pharmaceutical market.

The Delphi process confirmed the value of several important strategies:

The highest success factor was adaptive regulatory negotiation (mean = 4.6).

Co-development alliances with local companies significantly overcame institutional distance (mean = 4.5).

Customized CSR activities according to local public health objectives also ranked high (mean = 4.3).

In contrast, some strategies, such as global standardization, were less feasible due to Chinese regulatory inflexibility. MNC flexibility is necessary for them to remain competitive.]

There was variation in the likelihood of standardizing in different locations, especially for sustainability practices, reflecting the relevance of the institutional context.

4.4.6 Synthesis of analyses and recommendations

Integrating the insights from Hypothesis 5 into the broader conclusions unveils an additional layer of complexity in the relationship between internal organizational factors and external cultural dynamics in multinational pharmaceutical companies (MNCs) operating in China. This study emphasizes the critical role of cultural adaptability in enhancing organizational performance across various dimensions, including technology implementation, conflict management, and social responsibility strategies.

(1) Technology implementation and cultural sensitivity

The introduction of technology in MNCs must align with the cultural settings of their global

subsidiaries. Beyond efficiency and training, technological effectiveness hinges on cultural sensitivity. For instance, user interfaces and communication styles integrated into technology should resonate with local cultural norms to ensure acceptance and integration among local employees. Effective implementation of technology is not merely a matter of systems integration, though; user acceptance is, and user acceptance depends mainly on local culture (e.g., language usage, norms for communicating, workflow expectations). Even the most technically advanced innovations will fail if local employees lack buy-in, and the extent of buy-in depends substantially on the extent to which the technologies arrive already adapted to the local environment (Barney, 1991).

(2) Conflict management in multicultural settings

Managing discrepancies and team conflicts becomes more complex in multicultural settings, as highlighted by Hypothesis4. Acknowledging and respecting cultural differences are paramount in MNC subsidiaries. Therefore, conflict resolution strategies and management practices should be adapted to align with local cultural values, fostering cooperation and reducing friction in diverse teams. Multinationals are prone to greater conflict through intercultural misunderstanding. Specialists insisted that conflict resolution procedures be localized to enhance decision-making and unity. Chinese hierarchical respect may test Western flat-structure decision-making, necessitating adaptive leadership styles.

(3) Cultural sensitivity in social responsibility and sustainability

Social responsibility and sustainability strategies also require cultural sensitivity. Chen et al. (2022) argue for implementing local cultural training programs and tailoring marketing strategies to local preferences and values. This ensures that social responsibility is perceived as sincere and respectful by local communities, while sustainable practices remain relevant and impactful across diverse cultural settings. These CSR activities were more successful when founded on local social norms and values. Such a foundation gives authenticity and social license to operate in the Chinese market. They pointed to examples where CSR campaigns that coincided with national health agendas (e.g., diabetes awareness, immunization drives) had more traction compared to generic global campaigns.

(4) Strategic recommendations for MNCs

Given these findings, the management strategies of MNCs, particularly in their Chinese subsidiaries, should prioritize cultural adaptability. This approach enhances management efficiency and contributes to business success by ensuring that technological advancements, employee training, conflict management strategies, and social responsibility initiatives are all attuned to the cultural nuances of the local environment. Strategic Implications MNCs operating

in China should Prioritize making cultural flexibility a strategic strength rather than an afterthought. Localized conflict management and regulatory engagement practices Utilize co-creation models with local businesses to become part of the local community. Consensus in Delphi affirms the application of institutional theory in the strategy model by emphasizing that regulatory responsiveness and flexibility in culture are not merely moderating forces but design necessities.

4.5 Case-based insights on strategy implementation in MNCs

To show other aspects of the research, this section will present qualitative case-based insights showing how MNCs adjust their strategies based on China's evolving rules. They point out that the methods used will only work when considering context and factoring in policy changes, cultural support, and local partnerships. Each of these three cases, AstraZeneca, Pfizer, and Roche, illustrates how the company has applied the themes this study supports.

Case 1: AstraZeneca – Navigating the NRDL Reform (2017–2020)

AstraZeneca demonstrates how successfully regulatory changes and local cooperation can be applied. The company began working with partners in China on drug co-development to match the new rules of China's 2017 National Reimbursement Drug List, which required lower prices and proved efficacy. Among other steps, AstraZeneca worked with Chinese companies to help speed up the clinical trial and regulatory approval of innovative cancer treatments like *Tagrisso* (Zhao et al., 2020). Being involved in China's fast-changing rules and assembling in-country experts helped AstraZeneca launch new drugs shortly after their international rollouts. Delphi panel consensus supported this approach, recognizing that being proactive with the NMPA is the most significant factor for success (mean score = 4.6). Working locally with communities raised trust and lowered barriers due to a different pricing structure, proving that partnered market entry is most effective.

Case 2: Pfizer – Localizing Public Health Campaigns

The company's efforts in China on CSR reflect the importance of relating CSR efforts to local needs and public health. In previous years, the company mainly emphasized programs

like donating medication worldwide. However, after the launch of China's "Healthy China 2030" plan, Pfizer updated its CSR model to assist with the nation's public health efforts (MacGregor, 2021). An example of its work is collaborating with public health offices and NGOs to provide hypertension education and screening to people in remote areas. The

initiatives used Chinese language and design and were jointly created with local health partners. Thanks to this method, Pfizer was seen as more honest in its CSR, which brought positive results to its brand and community relations. Based on what happened, it is evident that CSR approaches must fit with local traditions to succeed (MacGregor, 2021).This conclusion is supported by the view that when parallels between society's values and the company's shape are minimal, CSR is more likely to improve brand image and public validity.

Case 3: Roche – R&D Localization through Innovation Hubs

South-East Asia's long-term focus is seen in how Roche places resources locally and fits with local institutions. Roche opened an R&D innovation center in Shanghai to follow China's standards for recent medical advancements for cancer and uncommon diseases (Agten & Wu, 2024). By doing this, we allowed for smoother cooperation with nearby institutions, low-cost firms, and those in charge of regulation. Creating a presence closer to China with local scientists working on global projects helped Roche meet the market faster and work in line with company rules. In addition, developing R&D close to the market helped address historical concerns about protecting proprietary knowledge within China, thanks to the company's commitment to co-development and training (Agten & Wu, 2024). This case backs up what the Delphi workshops found: localizing strategies should happen in all parts of an organization, even in core innovation. The results also point to the key role that resource-based view and institutional theory play, mainly in encouraging companies to rely on their organization and collaborate with others for new ideas.

Synthesis of the Cases

All these cases demonstrate that MNCs have found ways to turn some essential strategies from theory into real-world activities. The study's main point is valid: Competitive leverage in China's pharmaceutical sector is possible when firms are flexible and pay attention to the specific situation. With these qualitative insights, the thesis makes a strong case for using empirical evidence and field-based strategy examples.

4.6 Longitudinal trends in strategic adaptation (2010–2020)

Though the empirical base here uses cross-sectional data, the strategic context it focuses on encompasses a full decade of far-reaching regulatory reform in China's pharmacy sector. The decade from 2010-2020 included sweeping reforms in drug approval, intellectual property rights protections and enforcement, pricing regimes, and access to healthcare. The regulatory milestones are mapped onto observable patterns in MNC strategic adjustment, tracing a

longitudinal path in firm responses to changing institutional settings.

These time points triggered strategic shifts in MNC operations as in Table A.4. For instance, local collaborations sped up after 2017 for companies that undertook to negotiate better NRDL prices on a priority level. Similarly, CSR efforts also became goal-specific and aligned better according to government agendas, especially after the Healthy China 2030 plan.

Shifts in Strategic Themes Over Time

Before 2015: Market penetration and product differentiation through minimal regulatory coordination


2015-2017: The regulatory adaptation moves into the spotlight as global harmonization efforts and price caps dominate the headlines

2018-2020: Joint ventures peak as the focus shifts toward localization of R&D and aligning with the national policy.

These arguments emphasize the strengths of a longitudinal approach to MNC strategy in which changing institutions over time shape the validity and effectiveness of corporate action.

It places a high value on regulatory negotiation flexibility and enhanced embeddedness over time.

Chapter 5: Discussion and Findings



	1	innovation	Noun	21
	2	pharmaceutical	Adj	11
	3	r&d	Noun	11
	4	research	Noun	11
	5	management	Noun	10
	6	technological	Adj	10
⊞	7	strengthen	Verb	8
⊞	8	resource	Noun	7
⊞	9	enterprise	Noun	6
	10	innovative	Adj	6
	11	R&D	ProperNoun	6
⊞	12	system	Noun	6
⊞	13	university	Noun	6
⊞	14	establish	Verb	5
	15	improve	Verb	5
⊞	16	industry	Noun	5
⊞	17	project	Noun	5
	18	scientific	Adj	5
	19	technology	Noun	5
⊞	20	activity	Noun	4
	21	attention	Noun	4
	22	carry	Verb	4
	23	development	Noun	4
⊞	24	drug	Noun	4
	25	market	Noun	4

Figure 5.1 Correspondence analysis and principal component analysis results

5.1 R&D models and innovation capabilities

The prevalence of terms such as "innovation," "pharmaceutical," "R&D," "research," and "technological" highlights a focus on innovation and the transformation of R&D paradigms in the Chinese pharmaceutical industry. This indicates a strong recognition among multinational pharmaceutical companies operating in China of the necessity to continuously innovate and optimize their R&D approaches to sustain a competitive advantage.

Innovation in this setting comprises not only the creation of novel therapeutics but also the integration of sophisticated technological instruments and methodologies to optimize the

R&D process. This includes utilizing big data analytics, artificial intelligence, and machine learning to forecast drug effectiveness and safety profiles, potentially expediting the introduction of new pharmaceutical products to the market while reducing associated expenses.

5.2 Management and organizational processes

The analysis of terms such as "management," "resource," "enterprise," "system," and "university" indicates a concentration on elevating managerial effectiveness and optimizing resource distribution. The connections between these terms highlight continuous attempts to optimize management strategies, better equipping them to support the fundamental research and development activities in pharmaceutical companies. This involves cultivating collaborations between departments, enhancing communication pathways, and nurturing partnerships with universities and research institutions to access advanced scientific discoveries and skilled personnel.

Moreover, addressing discrepancies between central offices and local branches is a critical focal point. Multinational corporations must navigate cultural and operational variances, ensuring their local branches not only align with the overarching corporate vision but also adapt to the unique demands of the Chinese market. This necessitates a nuanced managerial approach that balances global standardization with localized customization.

5.3 Competitive advantage and market adaptability

The analysis the concepts of "strengthen," "resource," "enterprise," and "innovative" indicates key drivers of competitive advantage. These drivers likely concern how firms leverage resources, including human capital, intellectual property, and financial assets, to amplify their production of innovation. The capacity to consistently yield novel solutions is of paramount importance in sustaining a competitive edge, especially in the rapidly transforming pharmaceutical sector.

Moreover, the emphasis on "market," "demand," and "user" highlights the necessity for pharmaceutical companies to cultivate responsiveness and agility in navigating consumer needs. This adaptability is critical with rapidly shifting relgulations, novel health concerns, and evolving patient expectations. Companies with the capacity for swift adaptation to new information and market trends are advantageously positioned for success in the Chinese pharmaceutical market.

Considering the word count limitation, a comprehensive analysis of organizational process optimization, social responsibility and sustainable development, cultural and management differences, and the evolving nature of public health responsibilities will be presented in two parts. This approach ensures both word count adherence and a thorough exploration of

these complex topics.

5.4 Organizational process optimization

The emphasis on "efficiency," "effectiveness," and "optimization" highlights the critical necessity for multinational pharmaceutical companies operating in China to optimize their R&D processes. Efficiency in R&D extends beyond mere cost reduction; it comprises maximizing resource allocation, accelerating the time-to-market for novel pharmaceutical products, and elevating the overall quality of research outcomes; whereas, effectiveness pertains to achieving targeted results with minimal expenditure of time and resources. This necessitates a robust organizational process where "process," "system," and "model" are not merely concepts but operational necessities.

The optimization of organizational processes frequently involves the integration of lean management principles, the facilitation of workflows, and the elimination of extraneous activities that do not contribute to value creation. It also mandates a systematic approach to project management, incorporating agile methodologies that facilitate rapid iteration and adaptability in response to evolving circumstances. Moreover, predictive modeling and simulation methods can prove instrumental in forecasting R&D outcomes and allocating resources to activities demonstrating the highest probability of success.

Social Responsibility and Sustainable Development

The prioritization of "safety," "risk," and "sustainable" highlights the burgeoning significance of CSR and sustainable development in the pharmaceutical sector. As pharmaceutical companies are entrusted with tasks of protecting patients from undue harm, safety is paramount. This involves stringent adherence to regulatory standards, clinical testing, and transparent dissemination of drug safety data.

Risk management is also integral to CSR, requiring companies to proactively identify and reduce potential negative effects of their operations on the environment and society. This comprises addressing ethical considerations in clinical trials, ensuring responsible procurement of raw materials, and minimizing the environmental impact of manufacturing processes.

Sustainability is rapidly becoming a business imperative, as stakeholders call for companies to demonstrate a commitment to long-term ecological and societal well-being. This involves developing medications that not only address current health needs but are also accessible to underserved populations, thereby advancing global health equity. In addition, sustainable practices may include utilizing renewable energy sources in manufacturing facilities and

minimizing waste through circular economy principles.

5.5 Cultural and management differences

The relationship between "culture," "management," and "difference" highlights the challenge faced by multinational pharmaceutical companies in navigating cultural divides in their organizations. These cultural differences can materialize in a variety of approaches, affecting communication styles, decision-making processes, and attitudes toward hierarchy and authority. The successful reconciliation of these differences is crucial to cultivating a unified corporate culture that respects local particularities.

Developing management strategies attuned to these cultural differences is paramount. The concepts of "strategy," "management," and "localization" themselves suggest the importance of a measured approach—one that aligns with the overarching corporate vision while remaining sensitive to the local context. Such an approach might consist of localized training programs, the formation of cross-cultural management teams, and the implementation of inclusive policies that champion diversity.

Effective management necessitates emotional intelligence, cultural empathy, and a firm understanding of the local business environment. Empowering local managers to make key decisions can lead to greater responsiveness to market fluctuations, all while ensuring the subsidiary remains aligned with the global corporate ethos.

5.6 Public health responsibility changes

Over the past decade, China has experienced a transformation in its approach to public health, reflecting similar shifts observed globally. Leading this transformation, the pharmaceutical industry has demonstrated an increased commitment to addressing critical public health challenges, such as novel disease outbreaks and the increasing prevalence of chronic conditions. The terms "medical," "health," and "public" emphasize the industry's responsibility to the greater good.

Pharmaceutical companies are currently expected to expand their contributions to public health beyond simply supplying medications. This broadened scope comprises active involvement in health education, provision of support for disease prevention strategies, and participation in public-private collaborations designed to strengthen healthcare infrastructure.

The recent COVID-19 pandemic, in particular, represents a reminder of the critical need

for collaborative efforts between the pharmaceutical industry, governmental bodies, and international organizations.

5.7 Managing headquarters-subsidiary differences




Figure 5.2 Keyword relationship network diagram

Finally, in Figure 5.2, the concepts of "headquarters," "subsidiary," and "difference" highlight the nature of managing the relationship between a multinational corporation's central operations and its local branches. Successful management approaches must acknowledge the specific requirements and competencies of each subsidiary while upholding a unified global strategy.

Addressing these complexities often necessitates the implementation of transparent communication pathways, the establishment of shared objectives, and the cultivation of mutual understanding. This could entail regular interactions between personnel at headquarters and subsidiaries, collaborative training activities, and the adoption of a standardized corporate language. Achieving a balance between global integration and local responsiveness demands a nuanced strategy, one that can be facilitated by technology, a shared corporate culture, and a steadfast dedication to collective achievement.

In conclusion, multinational pharmaceutical companies operating in China are navigating challenges marked by the need for enhanced organizational processes, a strong commitment to social responsibility and sustainability, and the effective management of cultural and

operational differences. By approaching these areas with foresight and a keen understanding of local contexts, these companies can strengthen their competitive edge while making valuable contributions to public health and overall societal well-being.

5.8 Results of co-occurrence analysis

Co-occurrence analysis can be utilized to indicate the relationships between different words in a text. By analyzing the co-occurrence of words, researchers can infer the relevance and potential contextual relationships between concepts. In the present analysis, the co-occurrence of 'technology introduction' with 'efficiency improvement' and 'staff training' is particularly outstanding, suggesting that these concepts are closely associated with organizational culture and change management (Kitchell, 1995).

Firstly, technology introduction is frequently employed by enterprises seeking to maintain or enhance their competitive edge. As technology advances, organizations must continually integrate new technologies to strengthen productivity, minimize costs, and elevate both product quality and service efficiency. However, technology alone does not translate into business benefits. The successful integration of new technologies necessitates a re-engineering of existing processes, ensuring compatibility between these technologies and established operational procedures to fully realize efficiency gains. Such process optimization may involve facilitating operational steps, reducing wasted resources, and improving the speed and accuracy of work processes.

Secondly, "staff training" assumes a critical role in the successful introduction of technology. Implementing new technologies effectively often requires a workforce equipped with updated skills and knowledge. Therefore, organizations must commit to investing in staff training and development programs to guarantee employees have the necessary capabilities to effectively utilize new technologies. Importantly, training transcends mere skills acquisition; it represents a process of change management that necessitates shifting employee attitudes and behaviors to cultivate the acceptance of and adaptation to new modes of operation. This highlights the importance of synchronizing training programs with technology introduction programs, ensuring that employees are adequately prepared to embrace and utilize new technologies upon their implementation.

Moreover, the introduction of new technologies can have a significant effect on an organization's structure and culture. The integration of new technologies may necessitate significant changes to employees' daily routines, potentially contributing to resistance and

uncertainty among staff. Accordingly, organizations must ensure that their change management processes incorporate effective communication mechanisms, along with consideration of employee emotions and attitudes. Employee training represent a valuable tool in this process, facilitating employee understanding of the need for change and cultivating greater acceptance of the new technology.

As in Table A.6, correspondence analysis, a multivariate statistical method employed to explore relationships between variables in a dataset, indicates significant correlations in our study. Specifically, a positive correlation is present between "management discrepancy handling," "team conflict," and "resolution," while "social responsibility" exhibits a close relationship with "brand image" and "market competition."

The correspondence analyses indicate that "management discrepancy handling" holds a significant coordinate value along the first dimension, suggesting its prominent role in the dataset's variance. In addition, "team conflicts" and "solutions" also demonstrate high values on this dimension, potentially implying that organizations frequently encounter internal team conflicts when addressing managerial discrepancies. These conflicts, accordingly, necessitate effective resolution strategies to ensure team cohesion. This observed relationship may point to a broader organizational phenomenon: changes in management practices often represent a significant source of team conflict, emphasizing the need for organizations to develop appropriate resolution mechanisms to maintain a cohesive and productive team environment.

Conversely, the strong connection observed between "social responsibility," "brand image," and "market competition" along the second dimension suggests that socially responsible behavior positively affects brand perception. This effect appears crucial in market competition. By actively engaging in socially responsible activities, companies can not only strengthen their brand image but also gain a competitive edge in the marketplace.

These findings offer valuable insights into the internal and external performance of organizations. The effectiveness of managing discrepancies directly affects team relationship and conflict resolution, while fulfilling social responsibilities appears associated with a company's brand equity and market performance. A thorough analysis of these relationships can offer organizational leaders a deeper understanding of optimizing organizational performance through both internal management practices and external, socially responsible behavior.

Further qualitative analyses could consist of in-depth interviews, focus group discussions, or case studies to offer a richer understanding of these relationships and the underlying mechanisms. For instance, interviews with managers and employees could shed light on

how management discrepancies give rise to team conflict and which resolution strategies are perceived as most effective. Similarly, market analyses and consumer research can be employed to evaluate the effect of social responsibility on brand image and market competitiveness.

Finally, the insights from these analyses will equip organizations with valuable knowledge, enabling them to make more informed decisions regarding their management practices and the fulfillment of their social responsibilities.

In this context, social responsibility represents a critical factor in the long-term success of businesses. By integrating social responsibility into their business models and strategies, enterprises can effectively demonstrate their commitment to social well-being and environmental protection. This commitment not only shapes public perception of the enterprise but also cultivates consumer trust, enhances brand loyalty, and cultivates a competitive advantage in the marketplace.

The data in the table indicates that "corporate ethics" and "sustainable development" are the terms most frequently associated with "social responsibility." This frequent co-occurrence suggests that participants often consider both concepts when discussing social responsibility, likely because these three concepts are closely related in public opinion and business practices, affecting expectations for corporate behavior.

Further qualitative analyses, such as in-depth interviews, document analyses, or case studies, could offer a richer understanding of the meanings in these co-occurring terms. For instance, analyzing a company's social responsibility report, sustainability plan, and code of ethics can shed light on how the company integrates these concepts at both strategic and operational levels. Interviews with business leaders and employees can shed light on their understanding and implementation of social responsibility, as well as how these practices affect the organization's long-term growth and ethical standing.

Finally, the findings from these analyses will offer researchers an in-depth understanding of the role and influence of social responsibility in contemporary business. This understanding will equip business leaders to develop more effective social responsibility strategies, ensuring that their business activities contribute not only to economic growth but also to social progress and environmental preservation.

The results from Chapter 4 backed up several main findings from the study, but some theoretical expectations turned out to be different from what was found. Instead of being ignored as unusual cases, these results give essential information about the complexity of what companies do strategically in China’s drug sector. In this part, I consider surprising

results and find explanations that can support managers and shape future studies.

According to the study, there was little evidence for the expected connection between corporate social responsibility (CSR) and brand image improvement. Although examples from prior research suggest that CSR helps a company's reputation, the results here do not show those effects. An explanation that has been given is the different ways CSR is viewed in China from place to place. It is often said that the CSR activities of multinational firms seem like they have been forced on people and are not well suited to the country (Shi & Qi, 2024). When local health requirements or cultural beliefs are not considered, stakeholders might see these initiatives as nothing more than show. As multiple Delphi panel experts shared, this interpretation makes sense since public legitimacy for CSR often depends on it being tailored to national priorities and responsibilities.

It also turned out that how managers work is not closely linked with decision-making efficiency. Even though experts thought that a large gap between headquarters and subsidiaries would reduce how quickly and effectively managers could decide, the evidence did not prove this theory. Some units inside MNCs in China have already been allowed more freedom, mainly where there are well-established local teams in larger companies. Even so, global priorities might still clash with local priorities, but problems are usually managed with appropriate rules for local teams or by coordination units. Besides, organizational agility might be limited more by slow regulations and existing institutions than by conflicts within the business, which suggests that relying only on internal data could be insufficient to determine agility.

Moreover, the predicted strong link between cultural adaptation and the success of entering a new market received only limited confirmation. It points out that cultural fit should be considered, though it may not make the most significant difference. Other institutional factors, including government partnerships, following regulations, and gaining approvals on pricing, may affect results more. In this environment, regulatory experience or political strength can help companies succeed, so cultural awareness may not be needed to reach favorable results.

Such differences in results suggest that considering context greatly matters in strategic management research. These authors explain that applying Western-made business frameworks in China often requires adjustments. According to these results, MNCs should go beyond general strategy formats and build real connections with local groups, customs, and partners. They warn against banking on approaches like CSR or adapting to the local culture, as outcomes are most likely influenced by how companies, governments, and the environment

interact. In short, the findings show that managing well in the Chinese pharmaceutical sector means doing more than just copying worldwide best practices. It calls for local responsiveness, close integration with host institutions, and dynamic action. Further research can improve this knowledge by combining methods and studying how institutions, stakeholder opinions, and policies evolve with time.

5.9 Sectoral comparison: pharmaceuticals vs. medical devices

Though this study focuses on the drug industry, a comparison with another regulated sector, medical devices, provides a helpful lens through which the unique challenges facing MNCs in China's drug market can be considered. Both industries lie under the regulatory jurisdiction of the National Medical Products Administration (NMPA), but they share differences in strategic and institutional characteristics as shown in Table A.7.

Medical device MNCs enjoy faster market entry and more straightforward regulatory adaptation (Hasan et al., 2024). These devices fall under general categories of risk levels and low-to-moderate risk devices, which avoid longer clinical approval processes. As a result, time-to-market efforts are simpler than drugs, where safety and effectiveness tests on humans must be conducted (Hasan et al., 2024).

Moreover, pricing structures also vary widely. Pharmaceuticals already face increasing levels of price negotiation at the national level via the NRDL, but commensurate pricing flexibility is constrained. Medical devices, in contrast, are often priced through hospital-level procurement systems, which allow greater levels of institutional-level negotiation flexibility.

This contrast highlights that:

Pharmaceutical multinationals face stronger institutional restraints and more extended payback time due to clinical obligations and price centralization (Hu et al., 2019).

Pharma localization initiatives are essential for production and regulatory compliance, innovation partnerships, and CSR (Hu et al., 2019).

These results also affirm the contention that pharma-specific approaches cannot be easily transferred from other regulated industries; the commitment of resources, regulatory alignment, and other stakeholders' involvement in pharma must be profound in China.

Chapter 6: Conclusion

The outcomes of this research, validated through the Delphi technique, provide clear and actionable strategies for MNCs to navigate the complex Chinese pharmaceutical market. Based on the consensus reached among the expert panel, the following recommendations are put forth:

6.1 Enhanced Corporate Social Responsibility (CSR) programs:

Delphi Consensus: Experts unanimously agreed that robust CSR initiatives significantly enhance a company's reputation and stakeholder relationships in China.

Recommendation: MNCs should integrate CSR activities that align with local community needs and regulatory expectations. Initiatives could include health education programs, community healthcare services, and environmental sustainability projects.

6.2 Sustainable development practices

Delphi Consensus: Sustainability is a critical factor for long-term success in the pharmaceutical sector.

Recommendation: MNCs should adopt sustainable practices in their operations and product development. This includes reducing environmental impact, improving energy efficiency, and using sustainable materials. Such practices not only meet regulatory requirements but also appeal to the increasing number of environmentally conscious consumers.

6.3 Innovative product development

Delphi Consensus: Continuous innovation in product development is essential to meet the evolving needs of the Chinese market.

Recommendation: MNCs should prioritize the development of innovative therapies, especially those addressing unmet medical needs. Collaboration with local research institutions and investment in R&D can expedite this process and improve the relevance of new products to the local market.

6.4 Adaptive regulatory strategies

Delphi Consensus: Navigating China's regulatory landscape requires a proactive and adaptive approach.

Recommendation: MNCs should establish strong, proactive relationships with Chinese regulatory authorities and maintain flexibility to adapt to policy changes. Regular updates and strategic alignment with regulatory developments are essential to ensure compliance and facilitate smoother product approvals.

6.5 Robust local partnerships

Delphi Consensus: Strategic alliances with local entities are vital for market penetration and operational efficiency.

Recommendation: MNCs should form partnerships with local companies to gain valuable market insights, enhance distribution networks, and better meet local preferences. Such alliances can also provide support in navigating the regulatory environment.

6.6 Effective market entry models

Delphi Consensus: Flexible and tailored market entry strategies are crucial for success in the diverse Chinese market.

Recommendation: MNCs should consider various market entry models such as joint ventures, partnerships, or localized production. Tailoring the approach to specific market conditions and competitive dynamics will enhance market penetration and competitiveness.

6.7 Integration with external opportunities

Delphi Consensus: Leveraging advancements in digital technology and biotechnology offers a significant competitive advantage.

Recommendation: MNCs should integrate digital and biotechnological advancements into their operations. This can include the use of big data for market analysis, digital marketing strategies, and biotechnological innovations in product development.

6.7.1 Theoretical and practical contributions

Theoretical contributions include integrating localization theories with established marketing paradigms, emphasizing CSR, concurrent innovation development, and sustainable management practices. Practically, the study underscores the financial considerations for market entry, the adaptation of strategies to local regulatory environments, and the importance of product diversification in sustaining competitive advantage.

6.7.2 Future lines of research

Future research should explore the evolving regulatory landscape in China's pharmaceutical industry and its implications for multinational corporations. Additionally, further investigation into enhancing R&D productivity through technological advancements and innovation strategies is recommended. Understanding the impact of digital transformation and green development initiatives on corporate strategies will also be crucial for future research endeavors. While Table 3.3 outlines eight hypotheses for theoretical completeness, only six (H1–H6) were empirically tested. H7 (Regulatory adaptability) and H8 (Localization strategy) were not included in the empirical analysis due to data constraints: the primary survey instruments and available secondary sources did not yield reliable or consistent measures for these constructs. As such, the empirical chapters focus on hypotheses for which robust, observable data were available, while H7 and H8 remain important directions for future research.

In summary, multinational pharmaceutical companies (MNCs) operating in China's biopharmaceutical sector navigate complex challenges influenced by theories integrating localization with established marketing paradigms, including corporate social responsibility (CSR), concurrent innovation development, sustained internal management practices, and integrative technologies (Müller & Wenninger, 2015). The industry's knowledge-intensive and interdisciplinary nature demands robust support from upstream and downstream knowledge networks, technological advancements, and favorable environmental conditions, emphasizing the need for product diversification to ensure future growth. MNC subsidiaries in China encounter specific hurdles related to evolving regulations and diverse health authority stipulations compared to traditional pharmaceutical enterprises, compounded by declining R&D productivity that questions the efficacy of conventional business models . A systematic review from 2010 to 2020 underscores financial considerations as pivotal for MNCs entering China's pharmaceutical market, alongside challenges in personnel management, product development, distribution strategies, and navigating policy and regulatory landscapes

(DiMaggio & Powell, 1991). Future research should validate themes such as CSR, innovation development, sustainable management practices, integrated supply chain management, and strategies for competitive advantage aligned with local and global dynamics. The shift in China's medical regulatory landscape between 2013 and 2015 signals ongoing transformations warranting continued investigation. Amidst globalization, biotechnological advancements, and digital innovation, pharmaceutical enterprises must pursue sustainable development and competitive advantage, focusing on sustainable green practices, adaptive strategies to external environments, and proactive management of emerging challenges (Cao & Song, 2018). As the global political and economic landscape evolves unpredictably, agile enterprise strategies must anticipate nonlinear complexities, necessitating a paradigm shift in management aligned with the digital age (Cao & Song, 2018). In conclusion, successfully navigating China's dynamic pharmaceutical market demands MNCs to craft adaptive strategies that align with evolving regulations and competitive dynamics, providing foundational insights for future research and strategic decision-making in this pivotal sector.

6.7.3 Limitations

This study acknowledges several limitations that may affect the interpretation and generalizability of findings. Firstly, the scope of this research is limited to multinational pharmaceutical companies (MNCs) operating within China's biopharmaceutical sector. Generalizing findings beyond this context should be done cautiously due to potential differences in regulatory frameworks, market dynamics, and organizational structures in other geographical locations.

6.7.4 Sample size

The sample size in this study was selected based on practical considerations and accessibility to data from multinational pharmaceutical companies operating in China. While efforts were made to include a diverse range of companies and perspectives, the sample size may not fully represent the entire population of MNCs in the biopharmaceutical sector. Future studies could benefit from larger sample sizes to enhance statistical power and robustness of findings.

6.7.5 Availability and reliability of data

Data availability and reliability pose inherent challenges in empirical research, particularly in accessing proprietary or sensitive information within corporate settings. This study relied on

publicly available data, industry reports, and academic literature to substantiate findings. While efforts were made to ensure data accuracy and reliability, limitations in data accessibility and completeness may have influenced certain analyses and interpretations.

6.7.6 Lack of previous research studies on the main topic

Despite the growing interest in corporate strategies of MNCs in the pharmaceutical sector, there remains a relative scarcity of comprehensive studies focusing specifically on biopharmaceutical enterprises operating in China. This study attempts to address this gap by synthesizing existing literature and empirical insights, yet acknowledges the need for further research to deepen understanding of the unique challenges and strategic imperatives facing MNCs in this dynamic market.

[This page is deliberately left blank.]

Bibliography

Abhari, K., Davidson, E. J., & Xiao, B. (2016, January 5-8). *Measuring the perceived functional affordances of collaborative innovation networks in social product development*. 49th Hawaii International Conference on System Sciences (HICSS-49), United State.

Agten, S., & Wu, B. (2024). *Biopharma in China: Innovation, trends and dealmaking*. Springer Nature.

Almasa, S., Fabian, J. F., Daniel, H. M. C., & Klaus, E. M. (2020). Entrepreneurial leadership and MNE subsidiary performance: The moderating role of subsidiary context. *International Business Review*, *29*(3), 101672

Baik, Y., Kim, H., & Park, Y. (2021). Environmental multi-dimensionality and staff localization in multinational enterprises: the case of Korean firms. *Canadian Journal of Administrative Sciences*, *38*(1), 68-79.

Barney, J. B. (2000). From Firm resources and sustained competitive advantage. In Joel, A. C. B. & Frank, D. (Eds), *Economics meets sociology in strategic management* (pp. 203-227). Emerald Group Publishing Limited.

Barney, J. (1991). Firm resources and sustained competitive advantage. *Journal of Management*, *17*(1), 99-120.

Bi, X. F. (2024). 数字化转型与跨国企业研发国际化投资模式 [Digital transformation and the international R&D investment model of multinational enterprises]. *R&D Management*, *3*, 45-57.

Buckley, P. J., & Casson, M. (1976). *The future of the multinational enterprise*. Macmillan Press.

Buckley, P. J., & Casson, M. (1985). *The economic theory of the multinational enterprise*. Macmillan Press.

Cao, Y., & Song, Y. J. (2018). 基于结构方程的基层医生工作满意度及离职意愿影响因素研究 [Studying on the doctors' job satisfaction and demission intention in grass-roots medical institutions and its influencing factors based on structural equation model]. *Chinese Health Service Management*, *35*(1), 24-26.

Cao, Z. J. (2023). *F跨国汽车公司在华采购成本优化研究* [Master's thesis]. Southeast University.

Chan, K., & Daim, T. (2018). Agile enterprise strategies and nonlinear complexities: A paradigm shift in management for the digital age. *Journal of Business Research*, *92*, 120-130.

Chen, H. M. (2019). *Research on the impact of employees, perception of payfairness on work performance and turnover intention in Laos state-owned enterprises* [Master's thesis]. South China University of Technology.

Chen, L. M., & Bu, X. L. (2021). 社会责任披露能否提升国际化企业绩效? [Can social responsibility disclosure improve the performance of internationalized enterprises?]. *Journal of Management*, *34*(3), 68-88.

Chen, W. X., & Hao, H. Y. (2024). ESG表现与企业"走出去"：路径机制与实证考察 [ESG performance and enterprises' "going global": Path mechanism and empirical investigation]. *World Economy Studies*, (3), 19-33.

Chen, W. H. (2006). 企业社会责任：中国企业跨国经营文化的核心 [Corporate social responsibility: The core of Chinese enterprises' transnational business culture].

International Business Research, (5), 51-53.

Choudhury, P. (2016). Return migration and geography of innovation in MNEs: A natural experiment of knowledge production by local workers reporting to return migrants. *Journal of Economic Geography*, *16*(3), 585-610.

Ciasullo, M. V., Montera, R., Cucari, N., & Polese, F. (2020). How an international ambidexterity strategy can address the paradox perspective on corporate sustainability: Evidence from Chinese emerging market multinationals. *Business Strategy and the Environment*, *29*(5), 2110-2129.

Cong, C., & Xu, C. W. (2011). 基于知识的跨国公司治理模式研究 [Research on the governance model of multinational corporations based on knowledge]. *Studies in Science of Science*, *29*(2), 252-256.

Corte, B. L. (2000). Evolving outsourcing landscape in pharma R&D: Different collaborative models and factors to consider when choosing a contract research organization. *Journal of Medicinal Chemistry*, *63*(20), 11362-11367.

Creswell, J. W., & Plano Clark, V. L. (2018). *Designing and conducting mixed methods research* (3rd ed.). SAGE Publications.

Cui, Q. L. (2015). 全球化视域下的本地化特征研究 [Research on localization characteristics from the perspective of globalization]. *Chinese Translators Journal*, *36*(04), 66-71.

Dachs, B., Amoroso, S., Castellani, D., Papanastassiou, M., & Von Zedtwitz, M. (2023). The internationalisation of R&D: Past, present and future. *International Business Review*, *33*(1), 102191.

DiMaggio, P. J., & Powell, W. W. (1991). *The new institutionalism in organizational analysis*. University of Chicago Press.

Greene, J. C., Caracelli, V. J., & Graham, W. F. (1989). Toward a conceptual framework for mixed-method evaluation designs. *Educational Evaluation and Policy Analysis*, *11*(3), 255-274.

Guan, Z. (2021). 数字化转型：壳牌、卡特彼勒、西斯科为什么国际领先 [Digital transformation: Why Shell, Caterpillar, and Sysco are internationally leading]. *State-Owned Enterprises*, (15), 20-22.

Guo, S. X. (2017). 在华跨国公司社会责任跨境异化的实证分析 [An empirical analysis of the cross-border alienation of corporate social responsibility of multinational companies in China]. *Friends of Accounting*, (5), 62-66.

Hadjikhani, A., Lee, J. W., & Park, S. (2016). Corporate social responsibility as a marketing strategy in foreign markets. *International Marketing Review*, *33*(4), 530-554.

Hao, C. X. (2021). 权变理论视角下跨国餐饮企业在中国本土化营销策略研究——以 肯德基为例 [Research on the localization marketing strategies of multinational catering enterprises in China from the perspective of contingency theory: A case study of KFC]. *Market Modernization*, (14), 53-55.

Hasan, M. M., Rayhan, Z., Mukta, R. T., & Faruq, O. (2024). Research on adapting marketing techniques to different culture economics and regulatory environment to entering new international markets. *Informatics Economics Management*, *3*(4), 257-277.

Hong, H. J., & Minbaeva, D. (2022). Multiculturals as strategic human capital resources in multinational enterprises. *Journal of International Business Studies*, *53*(1), 95-125.

Hu, L., Yu, Z., Yuan, Q., Hu, Y., & Ung, C. O. L. (2019). Opportunities and challenges of multinational pharmaceutical enterprises in transforming pharmaceutical market in China. *Therapeutic Innovation & Regulatory Science*, *53*(2), 207-214.

Huang, Y. (2022). 高管海外背景、进入模式与跨国企业海外子公司生存绩效 [Executives' overseas background, entry mode, and the survival performance of multinational

enterprises' overseas subsidiaries]. *Economic Theory and Business Management*, *42*(8), 88-100.

Li, P. P., Hofman, P. S., & Geraci, M. (2020). The Belt and Road Initiative for an intercontinental ecosystem: Strategic implications for multinational enterprises around the world. *Thunderbird International Business Review*, *62*(3), 239-248.

Jacob, J. (2020). Top management team international diversity and the performance of international R&D. *Global Strategy Journal*, *12*(1), 108-133.

Jamali, D., Makarem, Y., & Willi, A. (2019). From diffusion to translation: implementation of CSR practices in MNC subsidiaries. *Social Responsibility Journal*, *16*(3), 309-327.

Ji, H., & Miao, Z. (2020). Corporate social responsibility and collaborative innovation: The role of government support. *Journal of Cleaner Production*, *260*, 121028.

Jiang, L., Chang, Z., Yao, W., Huang, L., & Zhou, S. (2024). Transcend Local for G lobal: ESG as a legitimacy signal in the global expansion of emerging multinational enterprises. *Finance Research Letters*, *69*, 106174.

Johnson, R. B., & Onwuegbuzie, A. J. (2004). Mixed methods research: A research paradigm whose time has come. *Educational Researcher*, *33*(7), 14-26.

Khan, M., Lockhart, J., & Bathurst, R. (2020). A multi-level institutional perspective of corporate social responsibility reporting: A mixed-method study. *Journal of Cleaner Production*, *265*, 121739.

Kim, C., Kim, J., Marshall, R., & Afzali, H. (2018). Stakeholder influence, institutional duality, and CSR involvement of MNC subsidiaries. *Journal of Business Research*, *91*, 40-47.

Kim, M. (2023). How does multinational corporations' CSR influence purchase intention? The role of consumer ethnocentrism and consumer ambivalence. *Sustainability*, *15*(7), 5908.

Kitchell, S. (1995). Corporate culture, environmental adaptation, and innovation adoption: A qualitative / quantitative approach. *Journal of the Academy of Marketing Science*, *23*(3), 195-205.

Kley, D. (2020). Chinese companies' localization in Kyrgyzstan and Tajikistan. *Problems of Post-Communism*, *67*(3), 241-250.

Kodama, K. (2020). Impact of research and development strategy on sustainable growth in multinational pharmaceutical companies. *Sustainability*, *12*(13), 53-58.

Kremer, M. (2002). Pharmaceuticals and the developing world. *Journal of Economic Perspectives*, *16*(4), 67-90.

Lee, J. Y., Jimenez, A., & Bhandari, K. R. (2020). Subsidiary roles and dual knowledge flows between MNE subsidiaries and headquarters: The moderating effects of organizational governance types. *Journal of Business Research*, *108*, 188-200.

Lei, W. (2017). 中国企业跨国互动策略及其社会责任研究——基于对某中坦农场的工商人类学考察 [Research on the transnational interaction strategies and social responsibility of Chinese enterprises: Based on a business anthropology study of a Sino-Tanzanian farm]. *Journal of Southwest Minzu University (Humanities and Social Science Edition)*, *38*(5), 8-14.

Li, P. (2018). 跨国零售企业本土化策略影响因素的实证分析 [An empirical analysis of the influencing factors of localization strategies of multinational retail enterprises]. *Journal of Commercial Economics*, (17), 113-115.

Li, X. L. (2008). 强化跨国公司社会责任的意义和对策分析 [The significance and countermeasures of strengthening corporate social responsibility of multinational corporations]. *Modern Management Science*, (7), 77-78.

Liu, L. A. (2023). Culture fit and employee engagement in foreign subsidiaries: Evidence from Chinese multinational enterprises in the United States. *International Journal of Cross-Cultural Management*, *23*(3), 585-611.

Luo, X. Y., & Zhang, R. M. (2021). "一带一路"倡议下正式制度距离与海外投资企业社会

责任 [Formal institutional distance and corporate social responsibility of overseas investment enterprises under the Belt and Road Initiative]. *Journal of Hunan University of Science and Technology (Social Science Edition)*, *24*(4), 111-118.

Ma, J. (2023). 东道国员工视角下东南亚中资企业社会责任与民心相通 [Corporate social responsibility and people-to-people connectivity of Chinese enterprises in Southeast Asia from the perspective of host country employees]. *Southeast Asian Affairs*, (2), 90-105.

Ma, X. H., Wang, H. T., & Zhang, P. Y. (2022). 区域协同型跨境电商生态系统的构建、演化与优化路径 [Construction, evolution, and optimization path of regional collaborative cross-border e-commerce ecosystem]. *Journal of Commercial Economics*, (16), 92-97.

Matilde, M., Andrea, R., & Simone, G. (2020). Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research. *Journal of Cleaner Production*, *261*, 121204.

Meng, X. X. (2021). 国企业正当性影响因素研究——基于“一带一路”沿线企业的调查证据 [Research on the legitimacy factors of multinational enterprises: Evidence from enterprises along the “Belt and Road”]. *Jianghuai Forum*, (6), 41-47.

Milanesi, M., Runfola, A., & Guercini, S. (2020). Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research. *Journal of Cleaner Production*, *261*, 121204.

Morgan, D. L. (2007). Paradigms lost and pragmatism regained: Methodological implications of combining qualitative and quantitative methods. *Journal of Mixed Methods Research*, *1*(1), 48-76.

Motohashi, K., & Zhu, C. (2024). Technological competitiveness of China's internet p latformers: comparison of Google and Baidu by using patent text information. *Asia Pacific Journal of Innovation and Entrepreneurship*, *18*(3), 224-250.

Müller, R., & Wenninger, G. (2015). The changing landscape of Big Pharma: Strategi c reevaluation in response to market shifts. *Strategic Management Journal*, *36*(10), 1448-1467.

North, D. C. (1990). *Institutions, institutional change and economic performance*. Cambridge University Press.

Pang, W. Y. (2023). 跨国公司营销策略本土化研究——以肯德基为例 [Research on the localization of marketing strategies of multinational corporations: A case study of KFC]. *International Brand Observation*, (15), 34-43.

Peng, M. (2005). Act local, think global: Global strategies and local realities. *Global Business Review*, *6*(2), 123-145.

Porter, M. E. (2003). *竞争论* [On competition]. CITIC Press Group.

Powell, W. W. (1991). *The new institutionalism in organizational analysis*. University of Chicago Press.

Qiao, L. (2018). 企业社会责任与跨国并购的关系：研究综述与展望 [The relationship between corporate social responsibility and cross-border M&A: A review and prospects]. *Economic Management*, *40*(11), 191-208.

Rowe, G., & Wright, G. (1999). The Delphi technique as a forecasting tool: Issues and analysis. *International Journal of Forecasting*, *15*(4), 353-375.

Schmitt, L., Epler, R., Casenave, E., & Pallud, J. (2024). An inquiry into effective salesperson social media use in multinational versus local firms. *Journal of International Marketing*, *32*(1), 72-91.

Scott, W. R. (2001). *Institutions and organizations* (2nd ed.). Sage.

Shen, F., Li, Y., & Dong, L. L. (2004). 跨国制药企业研发国际化及对我国的启示 [The internationalization of R&D in multinational pharmaceutical enterprises and its implications for China]. *Chinese Journal of New Drugs*, *13*(12), 1078–1080.

Shen, Q., Jin, T., Zhao, D., & Du, Y. (2023). How can multinational enterprises effectively implement local consumer-oriented corporate social responsibility (CSR) strategies? A multi-perspective study on the differences in CSR response mechanisms between Chinese and Japanese consumers. *Sustainability*, *15*(21), 15433.

Shi, X. Y. (2024). 数字企业如何在新兴市场获得收益：弱制度、网络联结与数字产品特性的组态效应 [How digital enterprises gain profits in emerging markets: The configurational effects of weak institutions, network connections, and digital product characteristics]. *Research and Development Management*, *36*(3), 33-44.

Shi, Z. X., & Qi, H. X. (2024). Sino–US Competition: The Context for China's OFDI in BRI countries. *China: An International Journal*, *22*(3), 93-114.

Shirom, A. (2003). From Feeling vigorous at work? The construct of vigor and the study of positive affect in organizations. In Pamela, L. P., & Daniel, C. G., *Research in Occupational Stress and Well-Being* (pp. 135-164). Emerald Group Publishing Limited.

Tempest, S. (2010). Global pharmaceutical consumption: An analysis of market disparities. *International Journal of Health Policy and Management*, *5*(1), 23-34.

Teramae, F., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2020). Impact of research and Development Strategy on sustainable growth in multinational pharmaceutical companies. *Sustainability*, *12*(13), 5358.

Teramae, T., Yamamoto, S., & Takahashi, H. (2020). Corporate social responsibility and innovation development in the pharmaceutical industry. *Pharmaceutical Innovation Journal*, *25*(4), 301-316.

Vroom, V. H. (1964). *Work and motivation*. Wiley.

Wang, B. J., & Gao, K. L. (2023). 制度距离对中国跨国企业海外子公司绩效的影响 [The impact of institutional distance on the performance of overseas subsidiaries of Chinese multinational enterprises]. *The Journal of Quantitative & Technical Economics*, *40*(8), 111-130.

Wang, J., Liu, X., Wei, Y., & Wang, C. (2014). Cultural proximity and local firms' catch up with multinational enterprises. *World Development*, *60*, 1-13.

Wang, W., Pan, X. F., & Wang, Z. R. (2022). 研发投入对医药企业财务绩效影响的实证研究——基于数字技术投入的调节作用 [An empirical study on the impact of R&D investment on financial performance of pharmaceutical enterprises: The moderating role of digital technology investment]. *Enterprise Reform and Management*, (22), 153-157.

Wang, X. (2018). A game analysis of MNC CSR in China. *Cogent Business & Management*, *5*(1), 1409685.

Wang, X., Chang, H. C., Chen, J., & Yang, J. (2017). From Data analytics applied in CNKI databases search log: Understanding Chinese content users in North America. In Daniel, G. A., Jeff, A., & Suliman, H (Eds), *Knowledge discovery and data design innovation* (pp. 89-105). World Scientific Publishing Co., Inc.

Wang, Y., Han, Y., Ma, Y., Yang, Z., & Chen, T. (2024). From Analyzing new power system scholarly research trends based on CNKI via CiteSpace. In Kuang, Y. S., Zhu, L. X., Zhang X. Y., & Khan, I. A. (Eds), *Proceedings of the 2024 5th international conference on education, knowledge and information management* (pp. 607-616). Atlantis Press.

Wernerfelt, B. (1984). A resource-based view of the firm. *Strategic Management Journal*, *5*(2), 171-180.

Wirba, A. V. (2024). Corporate social responsibility (CSR): The role of government in promoting CSR. *Journal of the Knowledge Economy*, *15*(2), 7428-7454.

Wu, B. E. (1993). *组织行为学* [Organizational behavior]. Hua Tai Publishing.

Xiong, M. N., & Wang, T. (2020). 文化多样性会影响跨国企业的经营绩效吗?——基于动态能力理论的视角 [Does cultural diversity affect the operational performance of

multinational enterprises? From the perspective of dynamic capability theory]. *Economic Management*, *42*(6), 61-78.

Xu, L. Y., & Lan, Y. (2022). 生物医药行业研发支出与上市公司绩效的相关性分析 [Correlation analysis between R&D expenditure and performance of listed companies in the biopharmaceutical industry]. *Modern Marketing*, (10), 46-48.

Xu, L., Gao, H., Kaitin, K. I., & Shao, L. (2018). Reforming China's drug regulatory system. *Nature Reviews Drug Discovery*, *17*(12), 858-859.

Yu, G. S., Wu, Q. Q. & Dong, Z. R. (2021). 社会责任提升是否有助于我国跨国企业应对国际投资保护？——基于海外子公司视角的实证研究 [Does the improvement of social responsibility help Chinese multinational enterprises cope with international investment protection? An empirical study from the perspective of overseas subsidiaries]. *Journal of Finance and Economics*, *47*(7), 154-168.

Zhang, T., Liu, S. Y., & Bi, X. F. (2024). 数字化转型与跨国企业研发国际化投资模式 [Digital transformation and the international R&D investment model of multinational enterprises]. *R&D Management*, (03), 45-57.

Zhang, Z., Yang, Z., Gu, J., & Kim, M. (2023). How does multinational corporations' CSR influence purchase intention? The role of consumer ethnocentrism and consumer ambivalence. *Sustainability*, *15*(7), 5908.

Zhao, S., Tan, H., Papanastassiou, M., & Harzing, A. W. (2020). The internationalization of innovation towards the South: A historical case study of a global pharmaceutical corporation in China (1993-2017). *Asia Pacific Journal of Management*, *37*, 553-585.

Zhou, D. B., & Qin, Q. H. (2020). 差异化战略对跨境电商绩效的影响研究——基于企业能力理论视角 [Research on the impact of differentiation strategy on cross-border e-commerce performance: Based on the perspective of enterprise capability theory]. *Journal of Technical Economics & Management*, (03), 59-63.

Zhou, X., Ying, S. X., You, J., & Wu, H. (2023). Like parent, like child: MNCs' CSR and their foreign subsidiaries' environmental footprint. *Journal of Business Research*, *172*, 114413.

Zhou, Y., & Sun, F. (2022). Creating knowledge assets under biocapitalism: Analyzing China's biomedical industry and its patent networks. *Economic Geography*, *98*(5), 411-437.

Webliography

Clement, T. (2019, September 30). *Adopt-a-book activity.* OER Commons. Retrieved October 4, 2021, from https://www.oercommons.org/authoring/58499-adopt-a-book-activity/view

General Office of State Council. (2015, August 18). *The State Council opinion on the reform of pharmaceutical and medical devices regulator systems.* GOV.CN. Retrieved May 11, 2022, from http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm

MacGregor, R. K. (2021, October 7). *Pfizer Self-Presentation about sustainability and CSR – the message from its 2020 reports*. IMUP. Retrieved February 20, 2023, from https://www.imup.cz/data/files/IFRS2021-sbornik.pdf

[This page is deliberately left blank.]

Other References

Chinese Ministry of Health. (2017). *China health and family planning statistical yearbook* (Report No. 12).

[This page is deliberately left blank.]

Appendix: Tables

Table A.1 Results of regression analyses

variant	ratio	standard error	t-value	p-value	instructions
Investment in research and development	0.45	0.05	9.00	<0.001	significant positive correlation
Organizational process optimization score	0.30	0.03	10.00	<0.001	significant positive correlation
Level of technology introduction	0.25	0.04	6.25	<0.001	significant positive correlation
Cultural adaptability index	0.20	0.02	10.00	<0.001	significant positive correlation
Social responsibility fulfillment rate	0.15	0.03	5.00	<0.001	significant positive correlation

Table A.2 Factor analysis loadings

variant	Factor 1	Factor 2	Factor 3	instructions
Investment in research and development	0.75	0.20	-0.10	Mainly contained in factor 1
Organizational process optimization score	0.65	0.30	0.05	Mainly contained in factor 1
Level of technology introduction	0.10	0.80	0.10	Mainly contained in factor 2
Cultural adaptability index	0.20	0.10	0.70	Mainly contained in factor 3
Social responsibility fulfillment rate	0.30	0.60	0.10	Mainly contained in factor 2

Table A.3 Model validation results

Validation Methods	Descriptions	Outcome indicators	Interpretation of results
K-fold cross validation	The dataset is divided into K subsets for validation	accuracy	85 per cent
Bootstrap induction	Estimating confidence intervals for model parameters by resampling	confidence interval (math.)	[0.80,0.90]

Table A.4 Regulatory Milestones and Strategic Responses

Year	Regulatory Event	Observed MNC Strategic Shift

2015	China joins ICH (International Council for Harmonization)	Greater alignment with global R&D standards; increased clinical trials in China
2016	CFDA (now NMPA) announces accelerated drug approval reform	Surge in localization of regulatory affairs teams
2017	NRDL Reform: Centralized price negotiation introduced	Shift from independent pricing to co-development with local firms
2018	Implementation of MAH (Marketing Authorization Holder) system	MNCs begin local licensing collaborations to expedite launches
2020	Emphasis on domestic innovation in Healthy China 2030 Plan	Expansion of R&D investments and local innovation partnerships

Table A.5 Correspondence analysis and principal component analysis results

vocabulary	TF	vocabulary	TF	vocabulary	TF
innovation	21	build	2	result	2
pharmaceutical	11	change	2	risk	2
r&d	11	concept	2	role	2
research	11	cooperation	2	safety	2
management	10	create	2	such	2
technological	10	cultivation	2	support	2
strengthen	8	demand	2	systematic	2
resource	7	design	2	trend	2
enterprise	6	drive	2	ability	1
innovative	6	education	2	absorb	1
R&D	6	effectiveness	2	accelerate	1
system	6	efficiency	2	achieve	1
university	6	encourage	2	actively	1
establish	5	ensure	2	advantage	1
improve	5	entity	2	alliance	1
industry	5	etc	2	also	1
project	5	evaluation	2	attach	1
scientific	5	experience	2	avoid	1
technology	5	foreign	2	characteristic	1
activity	4	form	2	chinese	1
attention	4	give	2	collaboration	1
carry	4	impetus	2	commanding	1
development	4	implement	2	consider	1
drug	4	important	2	construction	1
market	4	incentive	2	continue	1
model	4	increase	2	continuous	1
open	4	institution	2	coordination	1
process	4	institutional	2	cultivate	1
promote	4	intellectual	2	device	1
user	4	international	2	different	1
allocation	3	introduction	2	do	1
control	3	it	2	duplication	1
force	3	learn	2	exchange	1
full	3	major	2	exploration	1
government	3	mechanism	2	extensive	1
institute	3	more	2	external	1
joint	3	necessary	2	feasible	1
make	3	network	2	field	1
medical	3	not	2	form	1
original	3	optimize	2	formulate	1
pay	3	orderly	2	fund	1

production	3	orientation	2	funding	1
sound	3	party	2	generic	1
standardized	3	performance	2	global	1
talent	3	personnel	2	good	1
use	3	platform	2	guarantee	1
various	3	play	2	guidance	1
adopt	2	product	2	height	1
advanced	2	provide	2	high-end	1
atmosphere	2	rely	2	imitation	1

Table A.6 Correspondence analysis and principal component analysis results

Dimension/Keyword	Management of discrepancies	Team conflict	prescription	social responsibility	brand image	market competition
Dimension 1 (%)	45	40	30	25	20	15
Dimension 2 (%)	30	35	40	20	25	30
Contribution (%)	20.5	18.2	16.4	15.3	14.1	12.9

Table A.7 Key Differences and Strategic Implications

Factor	**Pharmaceuticals**	**Medical Devices**
Regulatory Approval Time	Lengthy (4–6 years with clinical trials)	Shorter (6–18 months, based on risk class)
Pricing Regulation	Highly centralized (e.g., NRDL negotiations)	More decentralized; hospitals negotiate prices directly
R&D Localization Pressure	High – driven by innovation protection	Moderate –innovation; often policy and IP occurs post-market
IP Sensitivity	High (patents compounds, processes)	Lower (design protection, fewer exclusivity issues)
Strategic Mode	Entry **j**oint ventures, licensing deals, R&D partnerships	Distribution-focused, with fewer co-development models